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The novel Btk inhibitor ibrutinib has recently been introduced into the clinic for 
treatment of lymphoproliferative disorders (LPDs) where it is unexpectedly 
associated with major bleeding. It has been shown to block GPVI and CLEC-2-
mediated platelet function with the former correlating with bleeding. This 
contrasts with patients who are deficient in GPVI or Btk who experience 
minor/no bleeding respectively. Mice that lack CLEC-2 also have no bleeding 
diathesis but are protected from thromboinflammation. 
Aims 
This study aims to investigate the discrepancy between the bleeding seen with 
ibrutinib and those that lack Btk. It also aims to examine whether ibrutinib can 
block CLEC-2 signalling in mouse and human venous thrombosis. 
Results 
Ibrutinib blocks GPVI signalling due to off-target effects which occur because of 
the high clinical doses that are used. It blocks CLEC-2 signalling at ~50-fold 
lower concentrations and reduces venous thrombosis rates in patients taking it 
for LPD. 
Conclusions 
Lowering the dose of ibrutinib or developing a more specific Btk inhibitor would 
ameliorate the major bleeding that is seen with ibrutinib. Btk inhibitors are 
suitable for further study as inhibitors of CLEC-2 signalling in human venous 
thrombosis. 
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CHAPTER 1: GENERAL 
INTRODUCTION 
 
1.1 Introduction to platelets 
Platelets are small, anucleate, cell fragments that circulate in the blood with a 
normal level in humans of 150 - 450 x10
9
/l. They are involved in formation of a 
haemostatic plug to prevent excessive bleeding in response to vessel wall 
injury. They are also involved in preventing leakage from the vasculature at 
sites of inflammation (so called inflammatory haemostasis). Bleeding can occur 
if the platelet count is low, with its severity depending on the degree and cause 
of thrombocytopenia, and the need for a “second hit” e.g. an inflammatory 
insult. 
Platelets are only found in mammals. Their counterpart in other vertebrates is 
the nucleated thrombocyte. It is likely that they evolved from the haemocytes of 
marine invertebrates which have dual functions as cells that phagocytose 
pathogens and also aggregate together to prevent leakage of 
blood/haemolymph (Levin 2013; Martin et al. 2007). 
 
1.1.1 Platelet production 
Platelets are produced by bone marrow cells called megakaryocytes. These are 
large multinucleate cells with an average of 16 times the normal number of 
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chromosomes. They form thin projections of cytoplasm containing cell 
membrane called pro-platelets. Pro-platelets extend through sinusoidal 
epithelial cells to reach directly into the blood vessels which permeate 
throughout the bone marrow (Kaushansky 2005). Platelets are made directly 
from the megakaryocyte cytoplasm with surrounding cell membrane which 
forms buds and separates from these pro-platelet projections. Each 
megakaryocyte produces about 2000-3000 platelets and 1011 are produced 
every day (Harker et al. 2000). 
Platelet production is mainly regulated by the production and consumption of 
thrombopoetin (TPO). TPO is produced in the liver at a constant rate. In the 
normal physiological setting, most of this TPO binds to TPO receptors on 
platelets, whereupon it is internalised and degraded. This leaves any remaining 
TPO to act on the TPO receptor on megakaryocytes where, via the JAK-STAT 
pathway, it acts as to increase both the maturation and number of 
megakaryocytes leading to further platelet production (Kuter 2013). If the 
platelet count drops, then less TPO is bound up by the TPO receptors on 
platelets and more is available to stimulate megakaryocytes. The converse also 
applies if the platelet number increases.  
Once released by the megakaryocyte, each platelet circulates for up to 10 days 
before being taken up by the reticuloendothelial system in the spleen and liver 
(Josefsson et al. 2013). 
 
1.1.2 Platelet structure 
As previously stated, platelets are small and anucleate; measuring only 2-3 μm 
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in diameter. They are discoid in shape and are highly granular. This granularity 
results from a mixture of three main types of organelles; α-granules, dense 
granules and lysosomes. Platelets have an internal open canalicular system. At 
the surface of the platelet this serves to increase the surface area of the platelet 
membrane and act as a conduit for granule release. The dense tubular system 
is involved in storage and internal release of Ca2+. 
In addition, platelets have an actin cytoskeleton and microtubule system. Actin 
polymerisation occurs on platelet activation and causes a radical shape change 
from discoid to flat with multiple projections. This dramatically increases its 
surface area, increasing the structural stability of any developing thrombus 
(Hartwig 2013). 
 
1.1.3 Platelet function 
1.1.3.1 The role of platelets in haemostasis and thrombosis 
Haemostasis is defined as the prevention of bleeding through formation of a clot 
at the site of vessel injury whereas thrombosis is the pathological formation of 
such a clot. There are two main types of haemostasis; classical haemostasis 
and inflammatory haemostasis (sometimes known as vascular integrity), these 
are described in more detail below. There are also two main types of 
thrombosis; arterial and venous. The former involves platelets and the latter has 
been thought historically to not rely on platelet activation but there is increasing 
evidence to the contrary (see later). 
The importance of platelets in classical haemostasis is outlined by the severe 
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bleeding that occurs after injury in patients who are thrombocytopenic or those 
that have platelet function disorders such as Bernard Soulier Syndrome or 
Glanzmann’s Thrombasthaenia which are due to mutations in GPIb and integrin 
αIIbβ3, respectively. Their role in inflammatory haemostasis is seen in 
thrombocytopenic patients and animals who experience petechiae, bruising and 
endothelial thinning during inflammation or sepsis. 
Thrombosis is one of the leading causes of morbidity and mortality in the world. 
This is the case in high as well as low or middle-income countries. Arterial 
thrombosis, incorporating ischaemic heart disease (IHD) and stroke 
(cerebrovascular accident; CVA), is responsible for 25% of deaths worldwide. 
Venous thromboembolism (VTE), which incorporates deep vein thrombosis 
(DVT) and pulmonary embolism (PE) is a major source of morbidity and has a 
not-insignificant mortality. The world-wide incidence of VTE and PE has not 
been reported (Temgoua et al. 2017). But the annual incidence of VTE in 
western Europe is 100-700/100,000 with PE contributing 60/100,000 
(Belohlavek et al. 2013). PE has untreated and treated mortality rates of 30% 
and 8% respectively. VTE that results in hospitalisation is the leading cause of 
loss of disability adjusted life years (DALYs) in middle and low-income countries 
and the second highest cause of DALY loss in high income countries (Raskob 
et al. 2014). This is because 30% of patients who suffer from a deep vein 
thrombosis (DVT) will go on to develop post-thrombotic syndrome (PTS) 
(Belohlavek et al. 2013) and 4% of patients who develop a PE will go on to 
develop chronic thromboembolic pulmonary hypertension (CTEPH). Patients 
suffering from PTS have a chronically swollen and painful leg, sometimes with 
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associated skin ulceration. CTEPH is a chronic condition which is also 
associated with long term morbidity and mortality from right ventricular 
dysfunction (McNeil & Dunning 2007; Keeling et al. 2011). 
 
1.1.3.2 Functions of platelets outside haemostasis 
As well as what is considered to be their main function of prevention of bleeding 
at times of vascular injury platelets are integral to a number of other critical 
processes such as blood-lymphatic separation and inflammation. They also 
contribute to other non-thrombotic pathologies such as cancer progression. 
Blood-lymphatic separation occurs during embryonic development. During this 
process, platelets are activated by ligation of their C-type lectin receptor CLEC-
2 by podoplanin on lymphatic endothelial cells (LECs). Mice without CLEC-2 die 
in utero and post-mortem examination reveals extensively blood filled lymphatic 
vessels (S. P. Watson et al. 2010). 
As might be expected from the dual function of haemostasis and immunity of 
the haemocytes in some marine invertebrates, platelets have not completely 
lost their role in innate immunity in mammals despite their evolution to 
specialised haemostatic cells. Platelets can recognise pathogens and form a 
clot surrounding them to help prevent their local and systemic spread (Brühl et 
al. 2012). This process is called immunothrombosis. 
Much recent research has established that, through expression of platelet 
agonists, cancer cells are able to manipulate platelets to help them with the 
processes of tissue invasion, lymphatic and haematogenous spread as well as 
promoting growth in secondary sites. Some of these processes may involve 
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platelet CLEC-2 activation leading to cancer cells being coated with platelets 
(Astarita et al. 2012) and facilitating their survival in the circulation by making 
them resistant to shear stress and attack from Natural Killer (NK) cells (Leblanc 
& Peyruchaud 2016). Indeed, inhibition of CLEC-2’s interaction with podoplanin 
has been shown to suppress cancer metastasis in vitro (Chang et al. 2015) 
although there are a wealth of other ways in which platelets could enable 
cancer metastasis. 
 
1.1.4 Major platelet receptors and ligands 
In order to perform their various functions, platelets need to be activated. This 
occurs in three main steps: 
i) Agonists bind to their receptors on the platelet surface and early platelet 
activation signalling occurs. The various different signalling events of the 
different pathways downstream of each individual receptor converge on a 
common pathway. 
ii) This common pathway causes “inside-out” activation of integrin αIIbβ3 
(otherwise known as GPIIb/IIIa) and granule secretion. Granule secretion 
results in multiple positive feedback loops. 
iii) Subsequent “outside-in” activation of integrin αIIbβ3 by its ligands also 
acts as positive feedback. 
 
The two main types of receptors on the surface of platelets that facilitate this 
early platelet activation are G protein-coupled receptors (GPCRs) and those 
linked to an immunoreceptor-tyrosine-based-activation-motif (ITAM). These, as 
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well as the platelet adhesion receptors, are discussed below. 
 
1.1.4.1 GPCRs 
GPCRs are 7 transmembrane domain proteins that transmit their signals 
principally through membrane bound heterotrimeric G proteins, but also through 
arrestins and G-protein coupled receptor kinases. The major ligands that 
activate platelets via GPCRs are adenosine diphosphate (ADP), thromboxane 
A2 (TxA2) and thrombin. These bind to P2Y1 / P2Y12 for ADP, the thromboxane-
prostanoid receptors TPα and TPβ for TxA2 and the protease-activated 
receptors PAR1 and PAR4 for thrombin. Some GPCRs are regulated by rapid 
internalisation after activation. 
With the exception of thrombin and the protease-activated receptors (PARs), all 
of the GPCR ligands and receptors interact in the conventional way with ligand 
binding causing a conformational change of the receptor. The relevant coupled 
subunits for each receptor and their downstream signalling cascade is 
summarised in Figure 1.1. As a protease, thrombin cleaves the amino terminus 
of the PAR. The new N-terminus acts as a tethered ligand, binds to the receptor 
and activates it (K. J. Clemetson & J. M. Clemetson 2013). 
The importance of each of these receptors and their ligands is reflected in the 
phenotypes of those who lack the receptor and also their therapeutic use as 
drug targets. Patients who lack P2Y12 have a bleeding disorder and drugs which 
inhibit P2Y12 such as clopidogrel and ticagrelor are used clinically as a 
treatment for arterial thrombosis (Dorsam & Kunapuli 2004). Mice lacking TP 
are protected from atherosclerosis and aspirin is used widely in clinical practice 
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to inhibit TxA2 production and thus treat numerous diseases resulting from 
atheroma formation (Smyth 2010). Direct thrombin inhibitors are used in the 
treatment of VTE and have a side effect of bleeding. Mice lacking PAR4 have 
impaired haemostasis and are protected against thrombosis (Hamilton et al. 
2004). Drugs targeting PARs have been developed but have mostly failed to 
show sufficient efficacy in clinical trials when compared to aspirin for treatment 
of arterial thrombosis (Tricoci et al. 2012). 
 
1.1.4.2 ITAM receptors 
An ITAM is a conserved sequence of amino acids comprising two YxxL motifs 
separated by 6-12 amino acid residues and is denoted Yxx(L/I)x6-12Yxx(L/I). 
They are found in the intracellular region of receptors on many haematopoetic 
cells. In platelets they are found on FcɣRIIA, the FcRɣ chain which is linked non-
covalently to Glycoprotein VI (GPVI) and also in a truncated form (a so called 
hemITAM) on CLEC-2 (Boulaftali et al. 2014). Upon ligand binding in platelets, 
the receptors dimerise or cluster and the tyrosine residues in the ITAM are 
phosphorylated by Src family kinases (SFKs). This enables binding of spleen 
tyrosine kinase (Syk) to the ITAM and subsequent activation of a signalling 
cascade involving many adapter proteins, tyrosine kinases and enzymes such 
as linker for activation of T-cells (LAT), Bruton’s tyrosine kinase (Btk) and 
phospholipase Cɣ2 (PLCɣ2). The ultimate effector of this signalling cascade is 
internal mobilisation of Ca2+. The signalling of GPCRs and ITAM receptors is 
summarised in Figure 1.1. 
GPVI is the main platelet receptor for collagen. It is a type 1 transmembrane 
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receptor that is part of the immunoglobulin superfamily and is only expressed on 
megakaryocytes and platelets (Jandrot-Perrus et al. 2000). It associates non-
covalently with FcRɣ chain (S. P. Watson et al. 2010). There are approximately 
3-4000 copies of GPVI per human platelet (Burkhart et al. 2012) making it the 
most prevalent ITAM linked receptor on platelets. 
After initial activation, platelet adhesion to collagen is also supported by integrin 
α2β1. Activation of GPVI leads to shedding through the metalloproteinases 
ADAM10 and ADAM17. Patients lacking GPVI have a mild bleeding disorder. In 
addition to its well established role as the main collagen receptor it has also 
recently been identified as a receptor for fibrin and fibrinogen but the biological 
importance of this interaction is, as yet, unclear (Alshehri et al. 2015; 
Mammadova-Bach et al. 2015; Mangin et al. 2018). 
CLEC-2 is a C-type lectin-like type II transmembrane receptor. It has several 
exogenous ligands such as the snake venom rhodocytin and the polysaccharide 
fucoidan but podoplanin is the only known endogenous ligand. Under normal 
conditions podoplanin is not present in the vasculature and comes into contact 
with CLEC-2 during development or when there is damage or leakage in the 
vessel wall. Rather than two YxxL motifs it only contains a single YxxL which is 
downstream of a tri-acidic amino acid region (DEDG) (S. P. Watson et al. 2010). 
CLEC-2, therefore, exists as a homodimer so that two phosphorylated 
hemITAMs can still bind to the tandem Src Homology (SH)2 domains of Syk 
and activate downstream signalling. It is expressed in high numbers on 
megakaryocytes and platelets; 3700 copies per platelet in human platelets 
(Burkhart et al. 2012) and 40,000 in mouse platelets (Zeiler et al. 2014). The 
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reason for the markedly greater in expression in mouse platelets is not known. 
In mouse models it appears to play a minimal or no role in haemostasis but, as 
shall be explored later, it is essential in the pathogenesis of venous thrombosis. 
There is no known human condition where patients are deficient in CLEC-2. 
FcɣRIIA is a low affinity receptor for the Fc region of IgG. It plays a role in 
linking platelets to immunity as well as a pathological role in heparin-induced 
thrombocytopenia (Arman et al. 2014). 
 
1.1.4.3 Adhesion receptors 
GPIb-IX-V is a platelet surface receptor complex consisting of GPIbα, two 
GPIbβ subunits, GPIX and a loosely associated GPV subunit (R. Li & Emsley 
2013). Its primary function, for which no signalling is required, is to bind to von 
Willebrand’s factor (VWF) at high shear. The presence of the receptor is very 
important for haemostasis as evidenced by patients who lack it (Bernard Soulier 
Syndrome) who have a lifelong, often severe, bleeding disorder. No drugs 
against GPIb have yet been licensed. 
Integrin αIIbβ3 is a platelet receptor for fibrinogen and fibrin and several other 
extracellular matrix (ECM) proteins including VWF that, along with other 
integrins, is normally kept in a low affinity state. As shown in Figure 1.1, when 
activated by “inside-out” signalling from other receptors it undergoes 
conformational change to a high affinity conformation. Binding of the activated 
form to monomeric ligands does not induce signalling but results in adhesion. 
Multimeric ligands, by contrast, bind and activate “outside-in” intracellular 
signalling. The latter enables stable platelet adhesion and spreading, 
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aggregation, thrombus formation, clot retraction and further degranulation. This 
receptor is also of crucial importance to maintain haemostasis. Patients with 
Glanzmann’s thrombasthaenia lack this receptor and have a lifelong severe 
bleeding disorder. Drugs targeting this receptor such as abciximab and 
eptifibatide are used for treatment of myocardial infarction (MI) but their use is 
restricted to the hospital because of the risk of excessive bleeding. 
 
 
Figure 1.1: Schematic of platelet GPCR and ITAM receptor signalling. 
Platelets can be activated by many ligands via different GPCR and ITAM receptors. All 
pathways converge in Ca2+ release and PKC activation resulting in shape change and 
granule secretion. βɣ: Beta-gamma subunits of all heterotrimeric G-proteins. PI3K: 
phosphoinositide 3-kinase. AC: adenylate cyclase. RhoA: Ras homolog gene family, 
member A. IP3: inositol trisphosphate. DAG: 1,2-diacylglycerol. PKC: protein kinase C. 
PKG: protein kinase G. Adapted from Li et al. 2010) 
 
1.2 Haemostasis 
1.2.1 Classical Haemostasis 
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In the classical descriptions of haemostasis, the process is separated into 
primary and secondary haemostasis with primary haemostasis involving the 
formation of the initial platelet plug and secondary haemostasis being the 
activation and addition of coagulation cascade proteins (also known as clotting 
factors) to strengthen it. In reality, the two processes occur simultaneously, but 
the division is useful for descriptive purposes. 
Primary haemostasis: Within the vasculature platelets are marginalised to the 
outer aspects of the blood vessels by the red blood cells. During normal 
conditions platelets are kept in an inactive state through numerous mechanisms 
such as the endothelial release of nitric oxide (NO) and prostacyclin (PGI2). But 
when there is a breach in the blood vessel lining platelets are activated. 
Vascular injury exposes the subendothelial collagen to the flowing blood. Free 
VWF in the blood is captured by the collagen. This is then able to bind to 
platelets under the high shear rates present in the arteries and arterioles by 
binding to the GPIb-V-IX receptor complex on the platelet surface. The fast 
on/off interaction between VWF and GPIb causes platelets to roll at low speeds 
over the area of damage (Andrews & Berndt 2013). This is called rolling 
adhesion. The reduced speed of platelets then enables collagen to bind directly 
to GPVI on the platelet surface (Z. Li et al. 2010). This activates GPVI and 
results in Ca2+ mobilisation within the platelet. This causes platelet shape 
change, granule release and activation of surface integrins. Inside-out activation 
of integrin α2β1 and αIIbβ3 results in much more stable binding of platelets to 
collagen and other platelets/fibrin/VWF respectively. The degranulation of 
platelets releases numerous proteins and small molecules which promote 
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platelet further platelet recruitment, activation and thrombus growth. 
Secondary Haemostasis: Tissue Factor released from damaged endothelium as 
well as negatively charged phospholipids inserted into the platelet surface 
membrane during degranulation activate clotting factors and provide a scaffold 
for assembly of these clotting factors into complexes. Via a tightly regulated 
sequence of activation steps and feedback loops the clotting factors converge 
on and activate Factor X and thrombin which ultimately cleaves fibrinogen into 
fibrin and it is cross-linked fibrin that provides the major source of structural 
support for the clot. 
GPVI, therefore, is critical for initial platelet activation on contact with collagen. 
The recent discovery that it is also a ligand for fibrin could indicate an additional 
role in thrombus growth and stability (Bender et al. 2017). This important role is 
also evidenced by patients with congenital or acquired GPVI deficiency who 
have been described in the literature, all of whom have mild bleeding symptoms 
(Arthur et al. 2007; Onselaer et al. 2017). 
Consistent with only having a single endogenous ligand which is not present in 
the vasculature under normal conditions, CLEC-2 does not appear to play any 
significant role in haemostasis. Studies examining the role of CLEC-2 in 
maintaining haemostasis either show no effect of CLEC-2 deficiency / inhibition 
or merely a minor contribution (Hughes et al. 2010; Suzuki-Inoue et al. 2010; 
May et al. 2009; Bender et al. 2013). 
 
1.2.2 Inflammatory haemostasis 
Vascular integrity is the prevention of leakage of blood from vessels during 
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circumstances other than vascular injury. The leakage occurs through sites of 
breach in the vessel wall caused by immune cell transmigration. This process 
increases markedly during inflammation. This gives rise to the term 
inflammatory haemostasis. It has shown to occur in mice in multiple studies 
(Boulaftali et al. 2018) and also occurs in humans where it is recognised that 
platelet transfusion thresholds need to be higher in thrombocytopenic patients 
with concomitant inflammation (Estcourt et al. 2016). This form of haemostasis 
occurs independently of most major platelet receptors including integrin αIIbβ3. 
It does, however, depend heavily on GPVI and, to a lesser extent, CLEC-2 
activation. 
 
1.3 Platelets in thrombosis and 
thromboinflammation 
1.3.1 Arterial thrombosis 
Arterial thrombosis occurs in areas where there is diseased vessel wall 
(plaque). The plaque ruptures, exposing its contents to the flowing blood. 
Platelets then adhere and activate rapidly. These thrombi have a high platelet 
content and are white in colour. Because of the well known role of platelets in 
the pathophysiology of arterial thrombosis there are numerous strategies used 
to inhibit platelets to treat this disease. Inhibition of production of TxA2 is 
performed with aspirin. P2Y12 is blocked with clopidogrel, prasugrel or 
ticagrelor. Phosphodiesterase (PDE) induced breakdown of cyclic adenosine 
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monophosphate (cAMP) is inhibited with dipyridamole. Integrin αIIbβ3 activation 
is blocked with eptifibatide, abciximab or tirofiban. All of these carry the 
common side effect of causing both major and minor bleeding. There are also 
numerous other antiplatelet agents in development such as GPVI inhibitors as 
well as PAR inhibitors. It is hoped that these will be able to treat arterial 
thrombosis without giving rise to major bleeding. 
 
1.3.2 Venous thrombosis 
Venous clots typically form as a DVT behind the venous valves of the iliac, 
femoral, popliteal and calf veins with the latter being the most common 
(Yoshimura et al. 2012). These clots cause painful swelling of the affected area 
due to localised inflammation and pressure build up within the vessel. There is 
also often tenderness and erythema of the overlying skin.  
They are classically thought to occur in areas where there is disturbance to 
blood flow, blood contents or the vessel wall (known as Virchow’s triad). If 
unstable thrombus from the clot is dislodged it travels through the venous 
system and the right side of the heart and can settle in the pulmonary 
vasculature. If this occurs in a small vessel then it may merely cause some 
pulmonary ischaemia resulting in a small amount of chest pain and dyspnoea. If 
it lodges in a large vessel, however, then a large part of the lung can lose its 
blood supply and become infarcted. Furthermore, if the embolised thrombus 
lodges at the bifurcation of the pulmonary artery (a so-called saddle embolus) 
then this can result in sudden death because all blood flow in the body travels 
through this single point. 
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Traditionally VTE is treated with medications that inhibit proteins in the 
coagulation cascade. Historically treatment of a venous thrombosis was done 
with oral vitamin K antagonists (VKAs) such as warfarin for somewhere 
between 6 weeks and lifelong depending on the circumstances of the clot 
(Keeling et al. 2011). 
Because they do not directly inhibit the action of the clotting factors, but rather 
prevent their production, they have a slow onset of action, often of several days. 
If more acute manipulation of the patient’s coagulation system is required (e.g. if 
a patient on a VKA needed to undergo surgery) then they would be admitted to 
hospital and infused intravenously with the short acting anticoagulant 
unfractionated heparin (UFH). This can be stopped and the patient’s 
coagulation activity will return to normal rapidly to enable surgery to take place 
(Keeling et al. 2016). 
In the 1990s derivatives of UFH have been developed in the form of low 
molecular weight heparins (LMWHs). These can be dosed subcutaneously, 
have a rapid onset and have a more predictable therapeutic activity when 
compared to UFH as well as a longer half-life. They are used in acute venous 
thrombosis to rapidly anticoagulate patients whilst VKA levels are up-titrated 
and in patients who are unable to tolerate the frequent blood monitoring 
required for VKA treatment (Keeling et al. 2011). In some settings they have 
been shown to have superior efficacy to VKAs such as VTE associated with 
cancer (H. G. Watson et al. 2015). They are also used in lower, prophylactic, 
doses in patients deemed to be at high risk for VTE. These are typically those in 
hospital undergoing surgery, with significantly reduced mobility, with cancer or 
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other inflammatory conditions (Schulman et al. 2017). 
Even more recently oral drugs which directly inhibit coagulation cascade 
proteins have been introduced into clinical use. These are termed Direct-acting 
Oral Anticoagulants (DOACs). For some instances of venous thrombosis 
treatment and prophylaxis they have replaced the older medications as 
standard of care due to superior efficacy and/or an improved side effect profile 
(Keeling et al. 2011; National Institute for Health and Care Excellence 2018c). 
It is important to note, however, that all of these agents have a side effect of 
bleeding. 3% of patients on warfarin will experience a major or fatal bleeding 
event each year and this compares with a rate of about 1.5-2% for patients on 
DOACs (Crowther & Warkentin 2008). If a patient on medication experiences 
major bleeding this is significant life event for them. Not only does a major bleed 
itself carry with it a significant risk of death of 8-11% (Chai-Adisaksopha et al. 
2015), but it also results in a subsequent cessation of the causative drug and an 
increased rate of post bleed thrombosis. It carries a significant cost to the 
healthcare service in terms of the expense of any admission for bleeding as well 
as a chronic cost associated with any long term physical disability that results 
from it (particularly with intracerebral haemorrhage). It also causes a lot of 
psychological harm to patients (Hutter & Kreitschmann-Andermahr 2014; 
Fumagalli et al. 2014). The bleeding rates are such that, despite the improved 
safety of the DOACs over VKAs, anticoagulants are still contraindicated in some 
patients with a history or high risk of bleeding. Presently these patients have no 
adequate treatment strategy. 
Platelets have not historically been thought to be involved in the 
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pathophysiology of VTE. The age-old dichotomy states that venous thrombi are 
made up of red cells and fibrin and are platelet poor, whereas arterial thrombi 
are platelet rich. But antiplatelet agents are, in fact, used for VTE prophylaxis in 
some patient groups. They protect against VTE but have a lower bleeding risk 
than anticoagulants (Castellucci et al. 2013). There are an increasing number of 
studies showing a benefit when using antiplatelet agents as part of the 
management strategy for treating patients with VTE. Aspirin has been shown to 
reduce VTE recurrence if used as a long term maintenance therapy after 
anticoagulation treatment had been discontinued (Becattini et al. 2012; Brighton 
et al. 2012). Indeed, in order to look for specific VTE scenarios where 
antiplatelets might be as efficacious as anticoagulants;  a Cochrane review is 
being performed to compare them as treatment for VTE (Flumignan et al. 2016). 
 
1.3.3 Immunothrombosis and thromboinflammation 
Immunothrombosis is the process by which platelets contribute to the function 
of the innate immune system by forming thrombi in vessels which catch / wall 
off bacteria. Thromboinflammation is the pathological formation of venous 
thrombi in response to inflammatory stimuli. They are terms that are unfamiliar 
to most clinicians. But despite this it is well known that inflammation is 
associated with increased rates of VTE. They have been shown to occur in 
numerous animal models. 
Immunothrombosis most frequently occurs in the microvasculature, particularly 
the hepatic and splenic sinusoids (Engelmann & Massberg 2012). Here, 
neutrophils, monocytes, fibrin and platelets recognise pathogens and form a 
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small clot surrounding them which helps to prevent their local and systemic 
spread (Brühl et al. 2012; Engelmann & Massberg 2012). These clots in the 
microvasculature do not cause disturbance of blood flow because of the large 
volume of collateral flow that goes on the liver and spleen. It is, however, when 
this process occurs in larger veins or the non-hepatosplenic microvasculature 
that it can initiate over-activation of platelets and the coagulation cascade and 
ultimately cause pathological thromboinflammation (Wakefield et al. 2008). 
There are no human diseases where thromboinflammation is known definitively 
to occur. It is, however, suspected to play a role in the development of 
disseminated intravascular coagulation (DIC), arterial atherothrombosis and 
venous thrombosis (Engelmann & Massberg 2012). It is not yet known whether 
it plays a role in all types of VTE or merely some distinct subtypes that are yet 
to be identified (Engelmann & Massberg 2012). It is compelling, however, that 
VTE rates are increased in patients who have inflammatory disease. Indeed, 
the incidence of VTE in patients with inflammatory bowel disease is 3-fold 
higher than in the general population (Papa et al. 2014). It is also possible that 
all DVT has a hitherto undiscovered inflammatory component. 
 
1.3.4 ITAM receptors as new targets in thrombosis and 
thromboinflammation 
Given that ITAM receptors play an important role in inflammatory haemostasis, 
it may not come as a surprise to learn that they are also important in 
thromboinflammation. In a mouse model of hepatic vein thrombosis induced by 
S typhimurium there is up-regulation of the CLEC-2 ligand podoplanin in the 
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liver. In particular this occurs at the site of vascular breach and it is here that 
platelets interact with podoplanin expressed on inflammatory macrophages and 
this triggers the inflammation-driven occlusive thrombosis. Indeed, the venous 
thrombosis is markedly reduced in the absence of platelet CLEC-2 or in the 
absence of macrophages (Hitchcock et al. 2015). Furthermore, in a mouse 
model of DVT induced by inferior vena cava (IVC) stenosis podoplanin is 
upregulated in the IVC wall. Platelets penetrate the damaged vessel wall and 
are activated by podoplanin which leads to further platelet recruitment and 
thrombus growth. The thrombus size is dramatically reduced in the absence of 
platelet CLEC-2 and in the presence of an anti-podoplanin antibody (Payne et 
al. 2017). 
Together these data show that up-regulation of podoplanin in the vessel wall 
interacts with platelet CLEC-2 and triggers venous thrombosis in the setting of 
thromboinflammation in mice. This may represent a novel anti-thrombotic target 
but studies showing podoplanin up-regulation in the vasculature in human 
venous thrombosis are lacking. 
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1.4 Bruton’s tyrosine kinase (Btk) and its 
inhibitors 
1.4.1 Btk 
Btk is a member of the Tec family of cytosolic tyrosine kinases and mediates 
phosphorylation and activation of PLCɣ2 downstream of many receptors in 
haematopoetic cells. It was initially identified in 1993 as the non-functional 
protein in the immunodeficiency syndrome X-linked agammaglobulinaemia 
(XLA) which was first described by Colonel Ogden Bruton in 1952 (Tsukada et 
al. 1993; Vetrie et al. 1993). Its predominant role is in B-cells where it acts 
downstream of the B-cell receptor (BCR) to promote differentiation and 
maturation (Akinleye et al. 2013). It is expressed in myeloid and erythroid 
progenitors at lower levels (Weers et al. 1993). It is also present in platelets 
where it is phosphorylated downstream of the ITAM receptors GPVI, FcɣRIIA 
(Quek et al. 1998; Oda et al. 2000) and CLEC-2 (Manne et al. 2015) and the 
adhesion receptors GPIb-IX-V and integrin αIIbβ3 (Suzuki-Inoue et al. 2004; 
Atkinson et al. 2003). 
 
1.4.1.1 Structure 
Btk is one of the five members of the Tec family of kinases which also includes 
Tec, Itk, Bmx and Txk (also known as Rlk). All except Txk share the same 
structure with a Plekstrin Homology (PH) domain, adjacent Tec Homology (TH) 
domain, Src Homology (SH) 3 and SH2 domains as well as a kinase domain at 
22 
the C-terminus of the protein (Kawakami et al. 1999). The Tec kinases are one 
of the largest family of cytoplasmic tyrosine kinases alongside SFKs (Akinleye 
et al. 2013). 
The structure of Btk is shown in Figure 1.2. The N-terminal PH domain is critical 
for trafficking of Btk to the inner aspect of the cell membrane because it 
mediates its interaction with phosphatidylinositol 3,4,5-trisphosphate (PIP3) 
(Varnai et al. 1999). The TH domain is adjacent (Vihinen et al. 1994). Its N-
terminal end contains the zinc finger Btk motif and the proline rich region at its 
C-terminal end which serves a point of interaction with other proteins such as 
Protein Kinase C β (PKCβ) (Kang et al. 2001). Initial activation occurs by 
phosphorylation at tyrosine (Y) 551. This is situated in the activation loop in the 
kinase domain (Wahl et al. 1997). The adenosine triphosphate (ATP) binding 
site, catalytic apparatus and allosteric inhibitory segments are located in this 
domain as well (Oppermann et al. 2009). Full activation requires 
autophosphorylation at Y223 in the SH3 domain (Wahl et al. 1997). It is not 
clear, however, whether this is a result of dimerisation and phosphorylation by 
another Btk molecule or true self phosphorylation (Mohamed et al. 1999). Y223 
is in a YxxM motif that is common to all the Tec family kinases except Tec and 
its phosphorylation means that it becomes a docking site for SH2 domains on 
other kinases and adapters such as phosphoinositide 3-kinase (PI3K). Like 
other kinases and adapters, the SH2 domain is important for interactions with 




Figure 1.2: The Structure of Btk. 
The non-receptor tyrosine kinase Btk has 659 amino acids. It consists of PH, TH, SH3, 
SH2 and kinase domains. The latter incorporates the transphosphorylation site Y551 
and ATP binding loop which contains C481. 
 
1.4.1.2 Signalling and interactions with other kinases and adapters 
In resting conditions, Btk is cytosolic, unphosphorylated and catalytically 
inactive. Btk activation is a complex process which is summarised in Figure 1.3. 
The first step is translocation to the lipid rafts of the plasma membrane (Varnai 
et al. 1999). This occurs when PI3K generates PIP3 from membrane bound 
phosphatidylinositol 4,5-bisphosphate (PIP2). Btk can then bind to PIP3 on the 
inner surface of the plasma membrane via its PH domain. During this 
translocation process the PH/TH domain associates with phosphatidylinositol-4-
phosphate 5-kinase (PIP5K) and brings this to the plasma membrane as well 
(Salto et al. 2003).This makes more PIP2 which allows PI3K to produce more 
PIP3 and enables further Btk recruitment (Salto et al. 2003). Tec can also 
associate with PIP5K and bring it to the plasma membrane (Salto et al. 2003). 
 In platelets, LAT and SH2 domain containing leukocyte protein of 76 kDa 
(SLP76) are phosphorylated by Syk and this enables them to associate with the 
SH2 domain on Btk. Btk is phosphorylated at Y551 by the SFK Lyn and also by 
Syk (Yang & Desiderio 1997). Along with LAT and SLP76, Btk forms a 
signalling complex with Syk itself and other kinases and adapters called the 
LAT signalosome (Boulaftali et al. 2014; Zhou et al. 2013; Judd et al. 2002). Btk 
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then undergoes autophosphorylation at Y223 and becomes catalytically active 
(Park et al. 1996). 
Phosphorylated tyrosine residues in the LAT signalosome form docking sites for 
the SH2 domain of PLCɣ2 (Watanabe et al. 2001). PLCɣ2 is then 
phosphorylated and activated by Btk and Syk (Rodriguez et al. 2001). Following 
this it produces inositol 1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG) 
leading to the activation of many downstream effectors including internal Ca2+ 
mobilisation. PLCɣ2 has four phosphorylation sites, two in the SH2-SH3 linker 
(Y753 and Y759) and two in the C-terminal region (Y1197 and Y1217). The 
degree to which each of these phosphorylation sites contributes to PLCɣ2 
activation and indeed which tyrosine residues are phosphorylated by Syk and 
which by Btk is contentious. A summary of the findings of the available literature 
on phosphorylation of PLCɣ2 by Btk and Syk is shown in Table 1.1. 
One of the principal mechanisms of regulation of Btk activation is through 
phosphorylation of Serine (S) 180 in the TH domain by PKCβ. This causes Btk 
to move back to the cytoplasmic compartment from the membrane, thus 




Figure 1.3: Mechanism of Btk activation and its subsequent activation of PLCɣ2.  
(1) PI3K catalyses PIP2 to PIP3. The PH domain of Btk binds to PIP3 enabling Btk 
translocation from cytosol to lipid rafts of the plasma membrane (Varnai et al. 1999). 
The SH3 domain of Btk associates with PI3K (2) PH/TH domain associates with PIP5K 
and brings it to the membrane with Btk. This produces more PIP2 substrate for PI3K 
which is then able to recruit more Btk. (3) Btk associates with phosphorylated LAT, 
SLP76 and Syk via its SH2 domain and forms the LAT signalosome (4) Btk is 
phosphorylated at Y551 by the SFK Lyn and also by Syk. (5) Btk autophosphorylates at 
Y223 and becomes catalytically active. (6) SH2 domain of PLCɣ2 binds to 
phosphorylated LAT. (7) PLCɣ2 is activated by a mixture of Syk and Btk mediated 
phosphorylation and through a phosphorylation independent interaction with Btk, likely 









pY753 + pY759 (SH2-SH3 linker region) pY1197 + pY1217 (C-terminal region) 




Phosphorylated? Required for 
activation? 
TK responsible for pY 
Watanabe et al. 
2001 DT40 BCR Anti-IgM Yes Partially 
Mainly Btk. Syk 
partially. Yes Yes Btk  






BCR Pervanadate Yes Partially Mainly Btk Yes Partially Not Btk  




BCR Anti-IgM Yes Yes - No No - Basal pY753 present 
Kim et al. 2004 Jurkat CD3 OKT-3 mAb Yes - - No - - Basal pY753 present 
Kim et al. 2004 Platelets GPVI Convulxin Yes - - No - - No basal pY753  
Kim et al. 2004 Fibroblasts PDGFR PDGF No - - No - -  
 
Table 1.1: Existing studies and their findings regarding Btk and Syk mediated PLCɣ2 phosphorylation.  
There have been multiple studies investigating the kinases responsible for PLCɣ2 phosphorylation at specific tyrosine residues and how 
these phosphorylation events relate to PLCɣ2 kinase activity. Their results are summarised here. PDGF = Platelet Derived Growth Factor. 
PDGFR = PDGF Receptor. 
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1.4.1.3 Role of Btk in B cells 
XLA is an X-linked immunodeficiency syndrome caused by a congenital 
dysfunction or lack of Btk. It results in a complete lack of mature B-cells due to a 
block in B-cell development at the Pro-B to Pre-B-cell transition and a resultant 
susceptibility to bacterial infections which can be life threatening. Historically 
most affected individuals with this condition would die from one of these 
infections in childhood or adolescence. After introduction of prophylactic 
treatment with intravenous pooled immunoglobulin, however, life expectancy is 
fairly normal. 
The Btk gene is located on the X chromosome. There are many different 
mutations that result in XLA. Patients with PH domain mutations and those 
which result in a heavily truncated protein get a “classical” XLA manifestation 
with no mature B cells (Vihinen et al. 1995; Vihinen et al. 1997). Mutations in 
the kinase domain that result in the expression of a normal protein with no 
autophosphorylation activity cause a less severe phenotype (Gaspar et al. 
1998) although it is not often possible to predict the severity of the 
immunodeficiency from the particular mutation that the patient has (Holinski-
Feder et al. 1998). All of the mutations are held in a registry for mutations 
associated with XLA called BTKbase (Vihinen 1995). 
X-linked Immunodeficiency (XID) is a murine immunodeficiency syndrome 
caused by a specific point mutation in the PH domain of the Btk gene that 
prevents the resultant protein’s association with PIP3 (Rawlings et al. 1993). 
There is also a knockout mouse with a complete homozygous deficiency of Btk 
(Btk-/-). Both of these mice have reduced populations of B cells but the 
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phenotype is less severe than for humans (Kerner et al. 1995; W. N. Khan et al. 
1995). This difference in phenotype is attributed to a much higher amount of 
Tec in murine B cells than in human B cells. Double knock out mice lacking both 
Btk and Tec have a complete lack of mature B-cells resembling human XLA 
(Ellmeier et al. 2000). 
Its role in the development of B-cell lymphoproliferative disorders (LPDs) has 
been extensively studied. Inappropriate activation of Btk-dependent pathways 
have been implicated in maintaining a malignant phenotype in a wide variety of 
cancers. Survival and progression of LPDs is promoted by dysregulated Btk 
activity (Vassilev et al. 1998; Kuppers 2005; Buggy & Elias 2012). Indeed it 
seems that constitutive Btk activation enhances the development of leukaemia 
in mouse models and is a necessary step in the series of events leading to 
development of chronic lymphocytic leukaemia (CLL) in patients (Kil et al. 
2013). There are also other cancers with gain of function mutations in Btk such 
as chronic myeloid leukaemia (CML), colorectal cancer and acute lymphoblastic 
leukaemia (ALL) (Akinleye et al. 2013). 
Because of the prevalence of upregulated Btk in LPDs several pharmaceutical 
and bio-technology companies have targeted Btk in these disorders. In the last 
4-5 years, Btk inhibitors have entered clinical practice for the treatment of LPDs 
such as CLL, small cell lymphoma (SLL) and mantle cell lymphoma (MCL) 




1.4.1.4 Role of Btk in platelet ITAM signalling 
There is only a small amount of literature on the role of Btk in platelets. Most of 
the understanding of the function and signalling has been gained from studies in 
B-cells with assumptions made that it performs a similar role in platelets. 
Platelets from patients with XLA have normal thrombin responses but partial 
inhibition of GPVI-mediated platelet function which can be overcome at higher 
concentrations of agonist (Quek et al. 1998). No patients with XLA are reported 
to have any symptoms or signs of excessive bleeding, be that spontaneous or 
as a result of trauma. 
Biochemical studies have shown that Btk is phosphorylated downstream of 
GPVI, FcɣRIIA, CLEC-2, integrin αIIbβ3 and GPIb-IX-V (Oda et al. 2000; 
Suzuki-Inoue et al. 2004; Manne et al. 2015; Atkinson et al. 2003). It has also 
been shown to be phosphorylated in response to thrombin-mediated platelet 
activation in one study (Quek et al. 1998) but not in another (Oda et al. 2000). 
Tec has also been shown to be phosphorylated downstream of GPVI, integrin 
αIIbβ3 and GPIb-IX-V (Suzuki-Inoue et al. 2004; Atkinson et al. 2003).  
Of note, however are the subtle differences in the role of Btk in the different 
signalling cascades. GPVI stimulation results in Syk autophosphorylation, Btk 
phosphorylation at Y551 and Y223 and PLCɣ2 phosphorylation at Y753 and 
Y759 (with other PLCɣ2 phosphorylation sites not studied) (Suzuki-Inoue et al. 
2004). CLEC-2 stimulation results in Syk and Btk autophosphorylation as well 
as PLCɣ2 phosphorylation at Y759 but treatment with the Btk inhibitor ibrutinib, 
even at very low concentrations (10 nM), unexpectedly causes loss of Syk as 
well as Btk and PLCɣ2 phosphorylation. This has led to the proposal that Btk 
lies upstream of Syk in CLEC-2 signalling (Manne et al. 2015) (see Figure 1.4) 
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whereas it is clear it lies downstream of Syk in GPVI signalling (Atkinson et al. 
2003) (see Figure. 1.1). 
 
Figure 1.4: Model for Btk regulating Syk activation downstream of CLEC-2.  
After CLEC-2 ligation SFKs phosphorylate the HemITAM which binds Syk and 
activates PI3K. PI3K then generates PIP3 which binds Btk and recruits it to the plasma 
membrane. Btk then, once phosphorylated by SFKs, phosphorylates and activates Syk. 
Adapted from Manne et al (Manne et al. 2015). 
 
Studies in mice again highlight the extra signalling redundancy provided by Tec 
in mouse platelets as Btk-/- mice have almost normal aggregation in response 
to GPVI ligation whereas Btk and Tec double knockout mice have completely 
impaired functional and biochemical responses (Atkinson et al. 2003). 
Spreading on fibrinogen is unaffected, even in the double knockout mice, 
showing that Btk and Tec do not play a functional role in integrin αIIbβ3 outside-
in signalling even though they are phosphorylated downstream of integrin 
activation (Atkinson et al. 2003). 
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1.4.2 Btk inhibitors 
Btk inhibitors are a novel class of oral tyrosine kinase inhibitor that have only 
recently been introduced into clinical practice for treatment of B-cell LPDs. Early 
trial data showed an unexpected side effect of major haemorrhage and this was 
attributed in early reports to inhibition of platelet activation by GPVI. This is 
obviously at odds with the existing literature on Btk and bleeding where patients 
with XLA do not suffer from any bleeding but this has yet to be explored further. 
Btk inhibitors were first developed in 2009 (Honigberg et al. 2010) but were not 
licensed until 2014 in the US and 2017 in the UK (Liang et al. 2018; National 
Institute for Health and Care Excellence 2018a). They are broadly separated 
into two types; those that bind covalently to Cys481 in the ATP binding site in 
the kinase domain and thus prevent kinase activity and those that reversibly 
associate to the SH3 domain when Btk is in its inactive conformation and 
prevent change to the active conformation (Liang et al. 2018). The irreversible 
inhibitors share a core structural element but are linked to different side chains 
but the same is not said of the reversible inhibitors (Liang et al. 2018). 
Of the many Btk inhibitors in development, three, so far, have been approved in 
the US. These are ibrutinib and acalabrutinib, which are currently only used for 
the treatment of haematological malignancies and PRN-1008 which is licensed 
for the treatment of the autoimmune skin condition pemphigus vulgaris (Liang et 
al. 2018). The only one licensed in the UK is ibrutinib. 
Ibrutinib (PCI-32765, imbruvica) is an irreversible Btk inhibitor and was the first 
Btk inhibitor to be developed. It has an IC50 for Btk of 0.5-1.5 nM in vitro and for 
the other relevant kinases in platelets (C-src terminal kinase (Csk), Tec, Fyn, 
Src, and Lyn) it has an IC50 of 2.3, 10, 96, 171 and 200 nM respectively 
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(Honigberg et al. 2010; Barf et al. 2017). It does not inhibit Syk directly. 
In the US it is approved for use in the treatment of relapsed CLL, MCL, 
Waldenström’s macroglobulinaemia (WM) and marginal zone lymphoma (MZL) 
and has very recently been licensed for the treatment of chronic graft-vs-host-
disease (cGVHD) after allogeneic stem cell transplant. In the UK it only has 
approval from NICE for use in relapsed or del17p / TP53 mutated CLL and also 
in MCL in patients who have relapsed or are unsuitable for chemo-
immunotherapy (National Institute for Health and Care Excellence 2018a; 
National Institute for Health and Care Excellence 2018b). It can also be used for 
treating relapsed WM if Cancer Drugs Fund (CDF) funding is approved 
(National Institute for Health and Care Excellence 2017). For treatment of 
CLL/SLL, WM and cGVHD it is used at a dose of 420 mg once daily (roughly 
equivalent to 6 mg/kg) and for MCL and MZL 560 mg (~8 mg/kg) once daily is 
used. 
It is much more tolerable than conventional chemotherapy agents. But it still has 
some significant side effects. These are atrial fibrillation (AF), bleeding and 
diarrhoea. The former is mediated by effects on the Btk regulated PI3K/Akt 
pathway or possibly off-target effects on other tyrosine kinases (Wiczer et al. 
2017; McMullen et al. 2014). The latter two are reported to be due to off-target 
effects of the drug downstream of platelet GPVI and on the epidermal growth 
factor receptor (EGFR) in the gastrointestinal mucosa respectively (Wu et al. 
2016; Byrd et al. 2016). Because of these side effects the use of ibrutinib in 
autoimmune conditions has not been approved. Reversible inhibitors may have 
a more tolerable side effect profile but none of these have come to market yet 
(Liang et al. 2018). 
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Acalabrutinib (ACP-196, calquence) is structurally related to ibrutinib and is also 
an irreversible inhibitor. Compared to ibrutinib it has a lower potency for 
inhibiting Btk (it has an IC50 for Btk that is 5-fold higher (5 nM)) but it has a 
higher selectivity over other tyrosine kinases. Its IC50 for Tec is 126 nM and it 
has been shown that it does not inhibit Fyn, Lyn and Src (Barf et al. 2017). For 
this reason it is claimed that it has a more tolerable side effect profile. In the 
only reported phase II clinical trial it did not cause atrial fibrillation or major 
bleeding (Byrd et al. 2016), but it does still caused some unpleasant 
gastrointestinal side effects (Liang et al. 2018). 
It was granted FDA approval for treatment of relapsed MCL in 2017 but is yet to 
be approved in the UK or Europe and so its use is limited to clinical trials 
outside the USA. It is used at a single dose of 100 mg (~1.5 mg/kg) twice daily. 
Because of the improved side effect profile it is being trialled in autoimmune 
conditions such as rheumatoid arthritis (RA) as well as in some solid organ 
cancers and various other haematological malignancies. 
PRN-1008 is a reversible covalent Btk inhibitor (Langrish et al. 2017). It has an 
IC50 for Btk of 1.3 nM in vitro (Liang et al. 2018). It has undergone phase II trials 
in immune thrombocytopenia (ITP) and the autoimmune skin condition 
Pemphigus vulgaris. It has been granted orphan drug status for the treatment of 
the latter (Principia Biopharma 2017). Other drugs reportedly showing promise 
for the treatment of LPDs and/or autoimmune diseases include CC-292 
(Spebrutinib), ONO/GS-4059 (Tirabrutinib) and BGB-3111 (Zanubrutinib) (Liang 
et al. 2018). All of these bind covalently to Cys481. 
 
1.5 Aims of the Thesis 
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It is clear from the above information that further prophylaxis/treatments for VTE 
/ thromboinflammation that do not cause bleeding are required and that 
inhibition of platelet CLEC-2 is a hitherto unexplored drug target with a critical 
role in both of these conditions, as shown in mice, but apparent lack of 
involvement in classical haemostasis. Btk inhibitors may be an ideal class of 
drug to use for this purpose because they are oral, they have been shown to 
potently inhibit CLEC-2 signalling at very low concentrations and most are 
irreversible and thus would inhibit Btk for the lifetime of the platelet in an 
analogous way to aspirin. 
Several questions need to be answered, however, before this hypothesis can 
be taken forward to clinical trials. Firstly, the current explanation that ibrutinib 
causes bleeding through inhibition of GPVI needs further exploration as, 
although GPVI inhibition is associated with bleeding, absence of Btk in patients 
with XLA is not (most likely because of the presence of Tec). The bleeding is 
therefore likely to be due to an off-target effect of the drug. Secondly, if Btk 
blockade is to be used as a means of blocking CLEC-2 then understanding 
Btk’s role downstream of CLEC-2 activation is crucial. The controversial model 
of Btk lying upstream of Syk in this setting as proposed by Manne et al. needs 
further investigation. Finally, despite CLEC-2 clearly being critical for mouse 
thrombosis, this same role has not been shown in humans. Evidence supporting 
this role of CLEC-2 in human thrombosis is essential. 
 
The aims of this thesis therefore are to: 
i) Determine whether the bleeding seen with ibrutinib is due to off-target 
effects downstream of GPVI rather than being mediated through inhibition of 
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Btk. 
ii) Explore the role that Btk plays downstream of CLEC-2. 








2.1.1 Antibodies and reagents 
The α-phosphotyrosine (4G10) monoclonal antibody (mAb) was from Millipore 
(Abingdon, UK). The HRP-conjugated Goat α-rat IgG (SC 2032) and α-Syk pAb 
(SC-1077) were from Santa Cruz Biotechnology (Dallas, USA). The α-Btk pAb 
(SAB3500372) was from Sigma-Aldrich (Poole, UK). The α-LAT pAb (06-807) 
was from Merck Millipore (Burlingon, MA). Phosphospecific pAbs against Syk 
pY525/6, PLCɣ2 pY759 and pY1217 were from Cell Signalling Technology 
(Hitchin, UK), against LAT pY200, SLP76 pY145, PLCɣ2 pY753 and pY1197, 
Btk pY223 and pY551 were from Abcam (Cambridge, UK) and against Src 
pY418 was from Life Technologies (Carlsbad, CA). The α-Tec pAbs (BL17 and 
BL19) were a gift from Michael G Tomlinson (Birmingham, UK) and have been 
described previously (Tomlinson et al. 1999). The anti-human podoplanin mAb 
(NZ-1) was from eBioscience (Waltham, MA). The mouse α-human CLEC-2 
antibody AYP1 was made in house and has been previously described (Gitz et 
al. 2014). (Ibrutinib (PCI-32765) and acalabrutinib (ACP-196) were from 
Selleckchem (Munich, Germany). Eptifibatide was from GSK (Brentford, UK). 
The FITC-conjugated rat α-mouse CD41 mAb was from BD Biosciences (San 
Jose, CA). Alexa Fluor 488-conjugated Phalloidin, the PE-conjugated rat α-
mouse mAb against CD41 and FITC-conjugated IgG1 and IgG2b negative 
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control mAbs as well as the AF 647 conjugated goat α-mouse secondary pAb 
were from ThermoFisher (Waltham, MA). The FITC-conjugated rat α-mouse P-
selectin mAb and PE-conjugated rat α-mouse integrin αIIbβ3 mAb were from 
Emfret Analytics (Eibelstadt, Germany). The FITC-conjugated rat α-mouse, 
HRP-conjugated α-mouse and α-rabbit secondary pAbs and Hyperfilm 
enhanced chemiluminescence (ECL) autoradiography film were from 
Amersham Biosciences (GE Healthcare, Bucks, UK). Glucose, pH 7 and pH 10 
buffer solutions, Bolt running buffer, Bolt antioxidant, ECL reagent and the Ca2+ 
sensitive reporter precursor dye Fura-2-AM were from ThermoFisher (Waltham, 
MA). Heparin was from LEO Laboratories Ltd (Hurley, UK). Collagen related 
peptide (CRP) was from Richard Farndale (Cambridge, UK). Collagen was 
made from equine tendon and sourced from Takeda (Linz, Austria). Rhodocytin 
was provided as a gift from Johannes A Eble (Münster, Germany). PAR1 
peptide was from Severn Biotech (Kidderminster, UK). PAR4 peptide was from 
Alta Biosciences (Birmingham, UK) Podoplanin-Fc was made in house in HEK 
293T-cells and has been previously described (Navarro-Núñez et al. 2015). 
Non-fatty acid free Bovine Serum Albumin (BSA) was from First Link (UK) ltd 
(Birmingham, UK). ChronoLume® and ATP standard were from ChronoLog 
Corporation (Havertown, PA). Methanol and ethanol were from VWR Chemicals 
(Lutterworth, UK). Transblot Turbo western blotting buffer and the Rat IgG2b 
negative control pAb (SDS 10303) were from Bio-Rad (Kidlington, UK). Histo-
Clear (d-limonene) was from National Diagnostics (Atlanta, GA). ImmPACT 
DAB peroxide reagent was from Vector Labs (Burlingame, CA). Uti-Lyse 
erythrocyte lysing reagent was from Dako North America Inc (Carpinteria, CA). 
All other reagents were purchased from Sigma-Aldrich (Poole, UK). 
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2.1.2 Chemical analysis of inhibitors 
Purity assessment of individual batches of ibrutinib and acalabrutinib was 
performed by High Performance Liquid Chromatography and Liquid 
Chromatography Mass Spectrometry. Individual batches of inhibitor were 
compared to each other using lumiaggregometry to CRP in washed platelets as 
a bioassay. Concentration calculations for each batch of inhibitor were adjusted 
to reflect their differences in potency in this bioassay when compared to the 
measured chemical concentration. 
 
2.2 Blood collection and preparation 
2.2.1 Blood collection 
Blood was taken from consenting patients or healthy, drug-free volunteers, into 
4% sodium citrate. Blood from patients with CLL, who were not taking 
concomitant antiplatelet medication, was taken at 2-3 hours after the ingestion 
of Btk inhibitor on the final day of a treatment cycle. If patients were not being 
treated with Btk inhibitors but instead were receiving standard chemotherapy 
with Fludarabine, Cyclophosphamide and Rituximab (FCR) then citrated blood 
was taken immediately before any pre-medication was given prior to the first 
day of a chemotherapy cycle. 
Mice were culled by CO2 asphyxiation following isofluorane anaesthesia. 900 μl 
of whole blood was removed from the IVC using a 25 gauge needle with a 1 ml 
syringe containing 100 μl of heparin (100 units/ml) or 100 μl Acid Citrate 
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Dextrose (ACD) depending on whether platelets were to be prepared as platelet 
rich plasma (PRP) or washed platelets respectively. The anticoagulated blood 
was then immediately combined with 200 μl of heparin (10 units/ml) or 200 μl 
modified Tyrode’s-HEPES buffer for PRP or washed platelets respectively. 
For analysis of platelet activation in whole blood by flow cytometry mice were 
bled via saphenous vein puncture with a 26 gauge needle followed by collection 
of 30 μl of blood into a Sarstedt Microvette 300 lithium heparin (LH) capillary 
tube (Sarstedt AG & Co. KG, Nümbrecht, Germany) that was pre-coated with 
heparin. No more than 200 μl of blood was taken by this method from a single 
mouse over the course of an experiment. 
 
2.2.2 Human platelet preparation 
For preparation of PRP, whole blood was centrifuged at 200 g for 20 minutes at 
room temperature. The supernatant PRP was removed and the remaining red 
cells were centrifuged at 1,000 g for 10 minutes to yield a supernatant of 
platelet poor plasma (PPP) to act as a blank. 
 
For preparation of washed platelets 10% volume of ACD was added to the 
whole blood before centrifugation at 200 g for 20 minutes at room temperature. 
Washed platelets were obtained by centrifugation of the supernatant PRP at 
1,000 g for 10 minutes in the presence of 0.2 μg/ml PGI2. The supernatant was 
discarded and the platelet pellet resuspended in 24 ml modified-Tyrode’s-
HEPES buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM 
NaHCO3, 20 mM HEPES, 5 mM glucose, 1 mM MgCl2; pH 7.3) and 3 ml ACD, 
re-centrifuged at 1,000 g for a further 10 minutes in the presence of 0.2 μg / ml 
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PGI2 and resuspended in modified-Tyrode’s-HEPES buffer to a concentration of 
4×108/ml for aggregation and biochemistry unless otherwise stated. Platelets 
were rested for 30 minutes prior to use in any experiments. 
For preparation of ADP-sensitive washed platelets 10% volume of ACD was 
added to the whole blood before centrifugation at 100 g for 20 minutes at room 
temperature. PRP supernatant was removed and re-centrifuged at 300 g for 20 
minutes. The resultant platelet pellet was then resuspended in modified-
Tyrode’s-HEPES buffer to 4x108/ml. 
 
2.2.3 Mouse platelet preparation 
For preparation of murine PRP, whole blood anticoagulated with heparin was 
centrifuged at 2,000 rpm for 5 minutes using a MicroCentaur bench top 
centrifuge (Sanyo Electric Co. Ltd, Osaka, Japan). The PRP and a third of the 
rest of the blood was then centrifuged at 200 g for 6 minutes in a swinging 
bucket centrifuge to pellet erythrocytes. The PRP was removed and transferred 
to another 1.5 ml tube. 200 μl of modified-Tyrode’s-HEPES buffer was added to 
the remaining erythrocytes and re-centrifuged at 200 g in the swinging bucked 
centrifuge for another 6 minutes. The PRP from this spin was collected and 
pooled with existing the PRP. If needed, the remaining erythrocytes were 
centrifuged at 1,000 g for 10 minutes to create a supernatant of PPP to use as a 
blank tube for light transmission aggregometry (LTA). Platelet concentration in 
PRP was measured but not adjusted. 
For preparation of murine washed platelets the same process as for PRP was 
followed except whole blood anticoagulated with ACD was used and, following 
pooling of PRP, the total volume of PRP was brought up to 1 ml using modified-
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Tyrode’s-HEPES buffer. 1 μl of PGI2 (1 mg/ml) was added before platelets were 
pelleted by centrifugation at 1,000 g for 6 minutes. Supernatant was then 
aspirated and the platelet pellet was resuspended in 400 μl modified-Tyrode’s-
HEPES buffer. Platelets were then made up to 4x108/ml unless otherwise 
stated. At this point, platelets were rested for 30 minutes before performing an 
experiment. 
 
2.2.4 Full blood counts 
For analysis of total white cell and platelet counts in whole blood, blood was 
taken into 3.2-4% citrate or ethylenediaminetetraacetic acid (EDTA) at 1.8 
mg/ml and analysed using a UniCel DxH 800 Haematology Analyser(Beckman 
Coulter, Brea, CA) or a Sysmex XN-1000 Haematology Analyser (Sysmex, 
Kobe, Japan). 
 
2.3 Platelet function testing 
2.3.1 Light transmission aggregometry (LTA) 
300 μl of washed platelets or PRP was added to glass vials and warmed to 
37°C in a Model 700 aggregometer (ChonoLog, Havertown, PA) for 5 minutes 
prior to stimulation. 3 μl of 100X agonist was added under stirring conditions 
(1200 rpm) followed by measurement of aggregation for 3-5 minutes. If 
inhibitors were being used, they were incubated for 5 minutes in stirring 
conditions after the platelets had been warmed unless otherwise stated. The 
blank vial was either filled with 300 μl of PPP or modified-Tyrode’s-HEPES 
buffer depending on whether the experiment was being performed on PRP or 
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washed platelets respectively. Inhibitors used were ibrutinib (17 nM - 70 μM), 
acalabrutinib (50 nM - 200 μM) or vehicle (dimethyl sulfoxide, DMSO). Results 
are displayed as final % aggregation. 
 
2.3.2 Dense granule release 
During LTA, 5 μL ChronoLume® (a commercial reagent containing a D-luciferin- 
luciferase mixture) was added 1 minute prior to insertion of glass vials into the 
measurement chamber of the aggregometer. Light production by luciferase was 
measured by the Model 700 aggregometer. Calibration was performed by 
adding 5 μl of 2 μM (i.e. 2 nmol) ATP standard at the end of the experiment. 
 
2.3.3 Measurement of [Ca2+]i 
Platelets were loaded with the Ca2+ sensitive dye Fura-2-AM by incubation of 
PRP with 2 μM Fura-2-AM for 1 hour at 30°C. Platelets were then washed by 
centrifugation at 300 g for 20 min and resuspended in modified-Tyrode’s-
HEPES buffer. Fura-2-loaded platelets were incubated with inhibitors or vehicle 
for 5 minutes at 37°C prior to addition of agonists. Fluorescence measurements 
with excitation at 340 and 380 nm and emission at 510 nm were recorded over 
a period of 5 minutes using a NOVOstar plate reader (BMG Labtech GmbH, 
Ortenberg, Germany) for experiments with ibrutinib or a FlexStation (Molecular 
Devices LLC, San Jose, CA) for experiments with acalabrutinib. [Ca2+]i was 
calculated using the ratio of the 340 and 380 nm excitation signals according to 
the method of Grynkiewicz et al (Grynkiewicz et al. 2001). 
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2.3.4 Flow cytometry 
5 μl of heparinised whole blood was diluted to 45 μl using phosphate buffered 
saline (PBS) in the presence or absence of fluorophore conjugated antibody 
before being stimulated with 5 μl of 10X agonist. This was then incubated with 
the stated antibodies for 30 minutes at room temperature in the dark. Following 
this, erythrocytes were lysed using 50 μl of Uti-Lyse erythrocyte lysing reagent 
A (Dako North America Inc. Carpinteria, CA) for 10 minutes and fixed using 500 
μl of Uti-Lyse erythrocyte lysing reagent B (Dako North America Inc. 
Carpinteria, CA) for 10 minutes. Samples were then analysed using an Accuri 
C6 Flow Cytometer (BD Biosciences, San Jose, CA). 
 
2.3.5 Platelet adhesion under flow 
Micro-capillaries on Cellix Vena8 Fluoro+ Biochips (Cellix Limited, Dublin, 
Ireland) were pre-incubated with 100 μl of 50 μg/ml collagen or 100 μg/ml 
podoplanin-Fc overnight at 4°C. Excess unbound agonist was then removed 
and capillaries were flushed with 5 mg/ml fatty acid free heat-denatured BSA 
and left to block for 1 hour at room temperature. Micro-capillaries were then 
flushed with PBS and kept for up to 24 hours before being used for flow 
adhesion assays. 
For experiments investigating the effect of in vitro addition of inhibitor; 200 μl 
washed platelets at 10x108/ml were incubated with inhibitor/vehicle for 5 
minutes. Platelets were added back to non-ACD treated autologous red blood 
cells (250 μl) and PPP (50 μl) to a final concentration of 4x108/ml. Blood was 
incubated with 4 μM of the lipid dye 3,3’-dihexyloxocarbocyanine iodide (DiOC6) 
for 5 minutes immediately prior to flow to aid visualisation. Micro-capillaries 
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were flushed through with modified-Tyrode’s-HEPES buffer for 3 minutes and 
then blood for 3-5 minutes at the stated shear rates followed by modified-
Tyrode’s-HEPES buffer for a further 3 minutes. Micro-capillaries were 
subsequently fixed with 10% neutral buffered formalin solution and platelet 
adhesion was viewed using a Zeiss Axio Observer 7 microscope (Carl Zeiss 
AG, Oberkocken, Germany) at 20X magnification using fluorescence intensity 
emitted at 520 nm. Platelet surface coverage on flow adhesion micro-capillary 
images were measured using ImageJ 1.5 (National Institutes of Health, USA). 
For the in vitro experiments analysing flow over podoplanin-Fc, and also 
experiments using ex vivo inhibitors and blood from patients with XLA, adhesion 
of platelets was performed under direct vision during flow with images taken 
every second using the same microscope and objective. For these experiments 
where adhesion was visualised in real-time platelet surface coverage and 
cluster size was analysed using the KNIME 3.4 analytics platform (KNIME.com 
AG, Konstanz, Germany) with Ilastik 1.1.2 machine learning software 
(University of Heidelberg, Germany) used to automatically and reproducibly 
identify platelets. 
 
2.3.6 Platelet spreading 
Glass coverslips were coated with 10 μg/ml collagen or podoplanin-Fc at 4°C 
overnight before excess agonist was aspirated and coverslips were blocked 
with 5mg/ml fatty acid free heat-denatured BSA for 1 hour at room temperature. 
Coverslips were then washed using PBS. 300 μl washed platelets at 2x107/ml 
was added onto the coverslip and left to spread for 45 minutes at 37°C before 
non-adherent platelets were removed by aspiration and remaining platelets 
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were fixed using 10% neutral buffered formalin solution for 10 minutes. 
Coverslips were then washed three times using PBS to remove the fixative. For 
in vitro experiments platelets were either pre-treated with inhibitor or vehicle or 
had these added 30 minutes after spreading had started. Platelets were probed 
using Alexa Fluor 488-conjugated phalloidin before imaging using a Zeiss Axio 
Observer 7 microscope (Carl Zeiss AG, Oberkocken, Germany) at 63X 
magnification using fluorescence intensity emitted at 520 nm. Information on 
average spread platelet size and number of adherent platelets was analysed 
using the KNIME 3.4 analytics platform (KNIME.com AG, Konstanz, Germany) 
with Ilastik 1.1.2 machine learning software (University of Heidelberg, Germany) 




2.3.7 Platelet receptor clustering 
50 μl washed platelets at 2x107/ml were added to Glass bottomed dishes 
(MatTek Corporation, Ashland, MA) coated with 10 μg/ml collagen or 
podoplanin-Fc at 4°C and left to spread for 45 minutes at 37°C before removal 
of non-adherent platelets and subsequent fixation using 10% neutral buffered 
formalin. For in vitro experiments platelets were either pre-treated with inhibitor 
or vehicle or had these added 30 minutes after spreading had started. Platelets 
were probed using the mouse anti-CLEC-2 antibody AYP1 and a goat anti-
mouse secondary antibody conjugated to Alexa Fluor 647 as well as Alexa 
Fluor 488-conjugated phalloidin. Super-resolution imaging was performed in 
switching buffer using an Eclipse Ti-E N-STORM microscope (Nikon 
Corporation, Tokyo, Japan) in (Direct Stochastic Optical Reconstruction 
Microscopy (dSTORM) mode as described by Poulter et al (Poulter et al. 2017). 
Images were reconstructed using the ThunderSTORM plugin in ImageJ 1.5 as 
described by Khan et al (A. O. Khan et al. 2017). Cluster analysis was then 
performed on the reconstructed images using persistence based clustering as 
has been recently described by Pike et al (Pike et al. 2018).The clustering was 
examined using the open-source software KNIME 3.4 (KNIME.com AG, 
Konstanz, Germany) and the R package ‘RMSLM’. The local neighbourhood 
radius was set to 20nm, and the persistence threshold to 10 detections. Cluster 
area was calculated by placing a circle of radius 30 nm over every detection in a 
cluster and calculating the union of these circles. This was estimated using a 
grid with pixel size 5 nm and image based dilation. Clusters with less than 20 
detection were discarded. 
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2.4 Biochemical and histological analysis 
2.4.1 Protein phosphorylation 
Washed platelets were pre-treated with 9 μM eptifibatide to block integrin αIIbβ3 
activation. Agonists were added while stirring at 1200 rpm in an aggregometer 
at 37°C for 180 seconds unless stated otherwise. Stimulations were performed 
in the presence of ibrutinib (17 nM - 7 μM), acalabrutinib (50 nM – 200 μM) or 
vehicle (DMSO). For whole cell lysate experiments; activation was terminated 
with 5X SDS reducing sample buffer. For immunoprecipitation; 8x108/ml 
platelets were used and reactions were terminated by addition of 2X ice-cold 
Nonidet P-40 lysis buffer containing the protease inhibitors sodium 
orthovanadate (5 mM), leupeptin (10 μg/ml), AEBSF (200 μg/ml), aprotinin (10 
μg/ml) and pepstatin (1 μg/ml). Platelet lysates were pre-cleared, and 
detergent-insoluble debris was discarded. An aliquot was dissolved with SDS 
sample buffer for detection of total tyrosine phosphorylation. Lysates were 
incubated with either the indicated antibodies and protein A- or protein G-
Sepharose. Lysates were separated by SDS-PAGE, electro-transferred, and 
Western blotted. Western blots were probed with the stated antibodies and 
imaged using ECL autoradiography film. For analysis of levels of 
phosphorylation, Western blot films were scanned and band intensity measured 




Paraffin embedded histological sections were de waxed and dehydrated with d-
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limonene and ethanol respectively. Antigen retrieval was performed with citrate 
buffer. Endogenous peroxide was blocked with 3% hydrogen peroxide. Slides 
were probed with stated antibodies and imaged using a Zeiss Axio Scan Z1 
slide scanner (Carl Zeiss AG, Oberkocken, Germany). 
 
2.5 Animal experimentation and the IVC stenosis model 
All mouse experiments were performed using wild type (WT) mice on a C57/Bl6 
genetic background which were sourced from Charles River Laboratories Inc. 
(Wilmington, MA). For ex vivo platelet function assays and in vivo thrombosis 
assays 8 week old C57/Bl6 WT male mice were dosed by intraperitoneal (IP) 
injection with 35 mg/kg ibrutinib or vehicle (5% DMSO, 30% Polyethylene 
glycols (PEG) 300, 5% Tween 20, 60% deionised water) once daily for the 
stated number of days. Blood was taken at the stated times and platelet 
function analysis was performed as described above. 
The IVC stenosis model was performed by Alex Brill as described by Payne et 
al. (Payne et al. 2017). In brief, mice were anaesthetised using isofluorane and 
then a laparotomy was performed. Side branches of the IVC were identified and 
tied off before the IVC itself was stenosed with a ligature, using a 30-gauge 
spacer to maintain a small degree of vessel patency. The incision was then 
closed and mice were allowed to recover from surgery. Buprenorphine was 
used pre- and post-operatively for analgesia. Mice were then culled 48 hours 




2.6 Approvals and ethics 
Ethical approval for collecting blood from patients with CLL and healthy 
volunteers was granted by the National Research Ethics Service (10/H1206/58) 
and Birmingham University Internal Ethical Review (ERN_11-0175) 
respectively. Work on patients with XLA and venous thrombosis tissue had 
ethical approval via the University of Birmingham Human Biomaterial Resource 
Centre (HBRC); Project 16-251 Amendment 1. Mouse work was conducted 
under the Home Office project licence P0E98D513 for in vitro and ex vivo 
analysis of platelet function and biochemistry and PPL 40/3745 for the in vivo 
thrombosis assay. 
 
2.7 Statistical analysis 
All data are presented as mean ± standard error of the mean (SEM) with 
statistical significance taken as p < 0.05 unless otherwise stated. Dose 
response curves were plotted and IC50 values were calculated using GraphPad 
Prism 7 (GraphPad Software Inc. La Jolla, Ca). Correlation of aggregation and 
tyrosine phosphorylation was assessed using Pearson’s correlation coefficient. 
Statistical analysis was performed using one or two-way ANOVA with 
corrections for multiple comparisons as stated. Statistical analysis of the IC50 
values was performed using Welch’s t-test. Statistical analysis of the results of 
randomised controlled trials (RCTs) using ibrutinib and dasatinib were 
performed using a Cox regression analysis with a stratified cohort approach (as 
described by Giganti et al. (Giganti et al. 2015)) in the open source statistical 
package R 3.5.1. All other statistical analyses were performed using GraphPad 




CHAPTER 3: THE EFFECT OF 




As alluded to previously there is a discrepancy in the literature when the 
information on the role GPVI plays in haemostasis is put together with what is 
known about the role of Btk downstream of GPVI and the observations of the 
haemostatic effects of Btk inhibitors. More specifically; GPVI deficient patients 
have a mild bleeding phenotype, patients with Btk mutations (XLA) have 
impaired GPVI-mediated platelet function but do not bleed and patients treated 
with Btk inhibitors (ibrutinib) have an increased rate of both mild and life-
threatening bleeding and this is reported to be due to blockade of GPVI-
mediated platelet function. 
What follows is a discussion of the evidence underlying the role of Btk in GPVI 
signalling as elucidated from the use of Btk deficient patients and mice, the 
bleeding phenotype experienced by GPVI deficient patients and also of the anti-
haemostatic and anti-platelet effects of the Btk inhibitor ibrutinib. 
 
3.1.1 The effect of Btk deficiency on platelet GPVI function 
Downstream of GPVI Btk activates PLCɣ2 with resultant production of the 
second messengers IP3 and DAG. It has been shown in other cell types that it 
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does this by phosphorylating some or all of PLCɣ2’s four tyrosine residues in 
the SH3-SH2 linker and C-terminal regions. 
Consistent with this; patients with XLA and Btk knockout mice have blocked 
GPVI-mediated functional platelet responses but these can be overcome when 
high concentrations of agonist are used (Quek et al. 1998; Atkinson et al. 2003). 
Likewise overall PLCɣ2 phosphorylation is significantly reduced but not lost 
entirely (Quek et al. 1998). The explanation for this incomplete blockade is that 
the other Tec family kinase in platelets, Tec, can substitute for Btk in its 
absence but because it is present in ~10-fold lower amounts than Btk (Burkhart 
et al. 2012; Zeiler et al. 2014), the lack of Btk still manifests in a defect at 
modest concentrations of agonist. It is also possible that the residual 
phosphorylation of PLCɣ2 is mediated by Syk instead of/as well as Tec. 
 
3.1.2 The bleeding phenotype of GPVI deficient patients 
Patients with congenital or acquired defects in GPVI or its downstream 
signalling are rare, but a total of 17 patients have been described (Sugiyama et 
al. 1987; Moroi et al. 1989; Ryo et al. 1991; Arai et al. 1994; Tsuji et al. 1997; 
Takahashi & Moroi 2001; Boylan et al. 2004; Nurden et al. 2004; Bellucci et al. 
2004; Kojima et al. 2006; Dunkley et al. 2007; Hermans et al. 2009; Dumont et 
al. 2009; Matus et al. 2013). The common symptoms, signs and investigation 
findings they all share are typical mild “platelet-type” bleeding (including 
ecchymoses, petechiae, menorrhagia and prolonged post-injury/surgical 
bleeding as well as bleeding peripartum), normal “coagulation screens”, 
prolonged bleeding times and reduced aggregation responses on LTA to 
collagen, CRP or convulxin. 
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It has been stated in previous reviews on this topic that the fact that the patients 
described had additional complications, such as thrombocytopenia, made it 
unclear as to whether the bleeding was due partially or completely to the defect 
in collagen response (S. P. Watson et al. 2010). Whilst this is true of 8 of the 
patients described (three had moderate/severe thrombocytopenia associated 
with immune thrombocytopenia, ITP) (Sugiyama et al. 1987; Takahashi & Moroi 
2001; Kojima et al. 2006), one had unexplained mild thrombocytopenia (Boylan 
et al. 2004), three had concurrent haematological malignancies but normal or 
low-normal platelet counts (Bellucci et al. 2004; Dunkley et al. 2007), and one 
had concurrent grey platelet syndrome (Nurden et al. 2004)), there are 9 
patients who have no other complicating factors (i.e. they had normal platelet 
counts and no other medical conditions). All of these 9 patients had a suspected 
or proven congenital deficiency in GPVI or its downstream signalling and 
suffered from mild lifelong bleeding symptoms as described above (Ryo et al. 
1991; Arai et al. 1994; Tsuji et al. 1997; Hermans et al. 2009; Dumont et al. 
2009; Matus et al. 2013). Of particular note is that in the patients with ITP, the 
mild bleeding symptoms persisted in all of them after normalisation of their 
platelet count and in one of the patients with haematological malignancy, the 
bleeding symptoms had persisted since childhood, a long time before her 
lymphoma diagnosis at age 60. 
It is certainly important to state, however, that case reports of mild bleeding in 
17 patients still represents quite a paucity of information and it may well be that 
positive reporting bias is playing a role here; i.e. there could be many more 
GPVI deficient people in the population who have not been diagnosed because 
they lack any bleeding symptoms. It is also important to compare the relatively 
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mild symptoms of the small number of patients described here with the much 
more severe bleeding and the wealth of information surrounding deficiencies in 
other platelet receptors such as GPIb and integrin αIIbβ3. 
 
3.1.3 The anti-haemostatic effects of ibrutinib 
During the first trials of ibrutinib in MCL and CLL safety concerns were raised 
about its effect on bleeding (Byrd et al. 2013; Wang et al. 2015). Of the 196 
patients studied 5% suffered from severe bleeding events such as subdural 
haematomas and haemorrhages following invasive procedures. Minor bleeding 
events occurred in ~16% of patients. Further information was published 
claiming concomitant anticoagulants or other underlying reasons for each of the 
patients suffering a major haemorrhage (Jones et al. 2017; Jones et al. 2014) 
and, as such, a recommendation was made that ibrutinib should not be co-
administered with VKAs (Byrd et al. 2014; Janssen 2015; Burger et al. 2016; 
Chanan-Khan et al. 2016) and to withhold ibrutinib for 3-7 days before and after 
invasive procedures (Treon et al. 2015; Janssen 2015). 
Further information was given showing “clotting screen” data from 25 patients. 
Platelet counts, Factor VIII levels, VWF antigen and activity levels were normal. 
Platelet Function Analyser (PFA) testing, however showed that 22 had 
prolonged closure times when tested with the epinephrine cartridges prior to 
starting treatment and a further 19 patients developed a transient defect during 
ibrutinib treatment. ADP closure times were normal (Lipsky et al. 2015). 
Results from a subsequent trial where the use of warfarin was contraindicated 
was also published showing that the major bleeding rate had reduced to 1% 
(Jones et al. 2017; Jones et al. 2014). Further studies, however, have shown 
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ongoing minor bleeding rates of 28% in patients not on concomitant 
anticoagulant or antiplatelet treatment (Wang et al. 2015) and a systematic 
review that included RCTs showed a statistically significant 3-fold higher rate of 
bleeding of any grade in ibrutinib treated patients (Yun et al. 2017). Although it 
has been argued that, because bleeding events occur mostly in the first 6 
months of treatment, the LPD itself, as well as the ibrutinib, may be contributing 
to the bleeding side effect (Jones et al. 2017). 
 
3.1.4 The anti-platelet effects of ibrutinib 
The first study looking at the effect of ibrutinib on platelet function showed 
reduced collagen-induced whole blood multiplate aggregation in 22 MCL/CLL 
patients whose blood had been treated in vitro with ibrutinib. It argued that, 
because Btk was involved downstream of many platelet receptors, ibrutinib may 
cause bleeding of its own accord and the bleeding seen in the trials should not 
just be dismissed as caused by VKAs (Rushworth et al. 2013). 
Further studies then followed which showed that ibrutinib had no effect, in PRP 
ex vivo, on ADP mediated platelet responses but that it inhibited GPVI-mediated 
platelet aggregation at low and high concentrations of agonist and adhesion to 
fixed VWF at arterial shear. Importantly mild bleeding in these patients 
correlated with the degree of inhibition of platelet aggregation to high 
concentrations of GPVI agonist and adhesion to VWF (Kamel et al. 2015; 
Levade et al. 2014). 
In vitro work included in one of these publications showed that ibrutinib at 
pharmacologically achieved concentrations inhibits GPVI-mediated platelet 
function in washed platelets and PRP and that this does also blocks Btk pY223 
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and downstream PLCɣ2 phosphorylation. Surprisingly they also showed that the 
same concentration inhibits whole cell tyrosine phosphorylation and Src 
phosphorylation at Y418 (Levade et al. 2014). In further in vitro work they 
showed that pharmacologically achieved concentrations of ibrutinib inhibit firm 
but not rolling adhesion to VWF and interpreted this as blocking inside-out 
signalling downstream of GPIb-IX-V (Levade et al. 2014). 
Another group looked at the effect of in vitro ibrutinib on GPVI function with 
immobilised ligands as well as looking at its effects on integrin αIIbβ3 outside-in 
signalling. Using a fixed and supra-therapeutic concentration of ibrutinib that 
reduced Src pY418 (1 μM) they showed inhibited spreading and abrogated Ca2+ 
mobilisation on CRP, collagen and fibrinogen and reduced adhesion to CRP 
and fibrinogen but not collagen. Under arterial shear conditions they showed 
that 1 μM ibrutinib treatment had no effect on overall platelet surface coverage 
but that aggregate size started to tail off after 3 minutes of flow over collagen 
(presumably also reflecting an inhibition of inside-out signalling). Clot retraction 
in whole blood was also impaired by 1 μM ibrutinib (Bye et al. 2015). 
In similar studies, but with two structurally related Btk inhibitors rather than 
ibrutinib itself, another group showed that, at concentrations where both 
inhibitors blocked Btk pY223 but one of the inhibitors also inhibited Src pY418, 
CRP induced P-selectin expression was blocked by both inhibitors but CRP, 
fibrinogen and collagen induced platelet spreading was only blocked by the 
inhibitor that blocked Src pY418. They also showed that both inhibitors reduced 
the surface coverage of platelets binding to collagen under arterial shear (Rigg 
et al. 2016). Interestingly dosing of these inhibitors to primates caused loss of 
ex vivo platelet aggregation to low concentration CRP but did not cause any 
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prolongation of their bleeding times (Rigg et al. 2016).  
As well as studies looking at platelet function in classical haemostasis, another 
group looked at how the maintenance of inflammatory haemostasis was 
affected by ibrutinib. Unlike the studies discussed above, they used mouse 
platelets to perform their assays. They found that, while pharmacologically 
relevant concentrations of in vitro ibrutinib blocked aggregation to low 
concentrations of collagen, very high concentrations of ibrutinib (5 μM) were 
required to inhibit aggregation responses to high concentrations of collagen and 
in flow cytometry assays using activated integrin αIIbβ3, rather than P-selectin 
expression, as a marker of activation. They also found that this high 
concentration of ibrutinib was ineffective at blocking platelet aggregation when 
PRP was studied rather than washed platelets. Interestingly, in two models of 
inflammation induced vascular damage they found that, while thrombocytopenic 
mice had skin and alveolar haemorrhage in response to skin inflammation and 
lung injury respectively, even in vitro ibrutinib treated platelets could prevent 
haemorrhage when transfused into the mice. Though what they found when 
they re-tested the aggregation responses of the platelets at the end of the assay 
was that a small amount of platelet response had returned despite complete 
inhibition being demonstrated at the beginning of the experiment (Lee et al. 
2017). Consistent with the lack of bleeding time results in the ibrutinib-analogue 
dosed Baboons used by Rigg et al. Lee et al. also found that when mice were 
treated with intraperitoneal (IP) ibrutinib at 6.25-12.5 mg/kg, this had no effect 
on saphenous vein thrombus formation or haemorrhage in response to laser 
injury or complete transection of the vein unless the mice also had an additional 
genetic knock-out of the P2Y12 receptor (Lee et al. 2017). 
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In the studies outlined above there are a number of unexplained findings and 
also some discrepant results: 
i) In the experiments by Levade et al. the same concentration of ibrutinib 
(0.5 μM) blocks aggregation in response to GPVI ligation in washed 
platelets and in PRP despite the drug being 97% plasma protein bound 
(Honigberg et al. 2010). Moreover, in dose response studies, they show 
that the minimum ibrutinib concentration that blocks Btk pY223 is 0.5 μM 
but that at this same concentration whole cell tyrosine phosphorylation is 
also lost, implying an upstream and downstream blockade as well as the 
on-target effect on Btk (Levade et al. 2014). They also show that 
adhesion to VWF under flow is inhibited by ibrutinib at 0.5 μM. They 
interpret this result as showing a blockade of Btk in GPIb mediated 
inside-out activation of integrin αIIbβ3. They do not reflect on the 
possibility of an off-target effect nor do they consider the results of 
Suzuki-Inoue et al. who show that this process is independent of PLCɣ2 
phosphorylation, and therefore presumably also independent of Btk 
(Suzuki-Inoue et al. 2004). 
ii) In the studies done by Bye et al. they use a single concentration of 
ibrutinib (1 μM) that they themselves show has some off-target effects on 
Src pY418. They use this concentration regardless of whether they are 
treating platelets or whole blood. They do not seem to consider that the 
dosing requirements may change if plasma proteins, which bind ibrutinib 
heavily, are introduced into the assay. This may be why, in contrast to 
the results of Rigg et al, they fail to show any change in surface coverage 
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in their flow adhesion assays (Bye et al. 2015). An alternative 
explanation is offered by the results of an identical assay performed by 
Busygina et al. where both in vitro and ex vivo ibrutinib is used. They 
show that adhesion in this assay is critically dependent on integrin α2β1 
and on GP1b (neither of which require signalling for adhesion). Like Rigg 
et al, they make no comment on overall aggregate sizes however 
(Busygina et al. 2018). 
iii) The results of the assays involving fibrinogen are interesting. Studies by 
Atkinson et al. in Tec kinase deficient mice have previously shown that 
neither Btk nor Tec are required for integrin αIIbβ3 outside-in signalling 
(Atkinson et al. 2003). This contrasts with the results obtained by Bye et 
al. and Rigg et al. where platelet spreading on fibrinogen is inhibited 
(Rigg et al. 2016). Perhaps the explanation for these discrepant results 
is, again, off-target effects of ibrutinib, particularly when it is seen that the 
ibrutinib analogue that has no effect on Src pY418 does not block 
fibrinogen binding but the ibrutinib analogue that inhibits Src pY418 does 
(Rigg et al. 2016). 
 
Because of the known redundancy that exists between Tec kinases, it has been 
suggested that off-target inhibition of Tec as well as Btk by ibrutinib is 
responsible for many of the findings seen above (Shatzel et al. 2015). Indeed 
this is the rationale behind the development of acalabrutinib, which is much 
more Btk-specific (Byrd et al. 2016). Despite this, early reports from the trials 
using acalabrutinib still have low grade bleeding of up to 18%, not at all 
dissimilar to rates reported with ibrutinib (Shatzel et al. 2015). In addition, if the 
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effects on platelets were mediated through Tec inhibition, then these effects 
should be irreversible. The results from the studies in mice where some 
recovery in platelet function was seen would, therefore, argue against this (Lee 
et al. 2017). 
So while it is clear from these studies that ibrutinib, at currently used clinical 
doses, does inhibit multiple aspects of platelet function and that these correlate 
with the increase in bleeding seen with its use, it is not clear at all which effects 
are mediated through the inhibition of Btk and which are caused by off-target 
effects. It is not clear, even, which other tyrosine kinases might be responsible 





3.2.1 Ibrutinib dose-dependently inhibits GPVI-
mediated platelet function 
3.2.1.1 Ibrutinib inhibits GPVI-mediated platelet aggregation in PRP 
Given the >10-fold differences in concentrations of ibrutinib that inhibit GPVI-
mediated platelet aggregation in PRP between different studies (Levade et al. 
2014; Lee et al. 2017) LTA was performed by adding ibrutinib in vitro to 
healthy donor PRP. Ibrutinib caused a dose-dependent inhibition of 
aggregation (see Figure 3.1A) with complete blockade of aggregation at 
70 μM and an IC50 of 25 μM (see Table 3.2). This is considerably higher 
than the inhibitory concentration used by Levade et al. (Levade et al. 
2014) but the delay in aggregation seen at 7 μM is similar to the results 
of Lee et al (Lee et al. 2017). 
 
3.2.1.2 Ibrutinib inhibits GPVI-mediated platelet aggregation in 
washed platelets 
Because some studies showed that the concentrations of ibrutinib required to 
block GPVI-mediated platelet aggregation in washed platelets were the same 
as in PRP (Levade et al. 2014), and some studies showed a >10-fold difference 
in concentration (Lee et al. 2017) LTA was extended to include the addition of 
ibrutinib to washed platelets. Washed platelets were isolated from 
citrated blood of healthy donor volunteers and incubated with ibrutinib for 
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5 minutes as for the PRP experiments. As in PRP, ibrutinib inhibited 
GPVI-mediated platelet aggregation in washed platelets in a dose-
dependent manner (see Figure 3.1B). But in contrast to PRP, the dose 
response curve was left-shifted approximately 20-fold with complete 
blockade at 1.7 μM and an IC50 at 1.2 μM (see Table 3.2). It was noted 
that at very low concentrations of ibrutinib (70 nM) there was a delay in 





Figure 3.1: Ibrutinib dose-dependently inhibits GPVI-mediated platelet 
aggregation in PRP and washed platelets.  
PRP (A) or washed platelets at 4x108/ml (B) isolated from healthy donors was 
stimulated with CRP 10 μg/ml for 3 minutes after incubation with ibrutinib or vehicle at 
the stated concentrations for 5 minutes. Representative traces of LTA with (Ai) PRP 
and (Bi) washed platelets of three and six identical experiments respectively. Dose 
response curves for (Aii) PRP and (Bii) washed platelets (n=3 and n=6 respectively). 
The curve from Aii is shown as a dotted line in Bii to enable easy comparison. Results 




The washed platelet dose response curve was slightly right-shifted when 
compared to the results of previous studies with similar experimental conditions 
(Levade et al. 2014; Bye et al. 2015). One possible explanation was the use of 
different agonists in these studies, so the same experiment was performed 
using the physiological agonist (collagen) instead of CRP. The results were 
similar regardless of the agonist used (see Figure 3.2A). 
 
3.2.1.3 Inhibition of GPVI-mediated platelet aggregation by ibrutinib 
is not affected by the presence BSA 
Another possible reason for the discrepancy between these results and those of 
Levade et al (Levade et al. 2014) and Bye et al (Bye et al. 2015) was the 
possibility that ibrutinib was becoming adsorbed to the sides of the 
aggregometer tube with less drug available for binding to the platelets. In order 
to investigate if this was happening, 0.3% BSA was added to the washed 
platelets and the same GPVI-mediated LTA in the presence of ibrutinib was 
performed. The results showed a small, but not statistically significant, reduction 
in aggregation in those aggregations performed with BSA in the vehicle and 





Figure 3.2: Ibrutinib dose-dependently inhibits aggregation stimulated by 
collagen or CRP, this is not enhanced by the presence of BSA but is made more 
potent by lowering the agonist concentration. 
Healthy donor washed platelets at 4 x 108/ml were incubated with ibrutinib or vehicle for 
5 minutes. (A) Dose response curve for ibrutinib inhibited aggregation when stimulated 
with CRP 10 μg/ml or collagen 10 μg/ml for 3 minutes (n=3). (B) The ibrutinib or vehicle 
was also incubated in the presence or absence of 0.3% BSA (Fatty acid free, boiled). 
They were then stimulated with CRP 10 μg/ml for 3 minutes (n=6). (C) Separately, 
without 0.3% BSA, the washed platelets were also stimulated with CRP at (i) 10 μg/ml 
(ii) 3 μg/ml or (iii) 1 μg/ml (n=1). All mean results shown ± SEM. Statistical analysis was 
with one way ANOVA. ns = non-significant. 
 
3.2.1.4 The sensitivity to blockade by ibrutinib of GPVI-mediated 
platelet aggregation is dependent on concentration of agonist used 
As well as different agonists, different concentrations of agonist might contribute 
to the slight right shift of the dose response curve when compared to previous 
studies. In fact, in the Levade et al. study there were a range of different agonist 
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concentrations used for each assay without comment on how these might have 
affected the results (Levade et al. 2014). 
An experiment was performed, therefore, to include lower concentrations of 
CRP and this showed that GPVI-mediated platelet activation was more 
sensitive to inhibition by ibrutinib at lower concentrations of agonist (see Figure 
3.2C). Of note, the concentration of ibrutinib (70 nM) at which delay to 
aggregation is seen with high concentrations of CRP (10 μg/ml) results in 
almost complete blockade of aggregation at low concentrations (1 μg/ml). 
Because there is no consensus on what is a physiologically relevant 
concentration of CRP and because the previous studies that showed a 
correlation between inhibition of GPVI-mediated platelet function and bleeding 
used high concentrations of agonist, further experiments proceeded using CRP 
10 μg/ml as the agonist. Washed platelets were used for all further in vitro 
experiments because of the high degree of drug protein binding in PRP. BSA 
was not added to these platelets because of the lack of effect seen in Figure 
3.2. 
 
3.2.1.5 Ibrutinib inhibits GPVI-mediated platelet granule release 
Platelet granule secretion plays a key role in platelet activation and so the effect 
of ibrutinib on GPVI-mediated granule secretion was also studied. 
Chronolume® treated washed platelets were stimulated with CRP in the 
presence or absence of ibrutinib in the same conditions as for LTA. As with 
LTA, ibrutinib dose-dependently inhibited platelet granule release (see Figure 
3.3A) but the dose response curve was left-shifted when compared to the 




3.2.1.6 Ibrutinib inhibits GPVI-mediated Ca2+ mobilisation 
Ca2+ mobilisation is another crucial step in platelet activation. Thus experiments 
measuring Ca2+ mobilisation using exactly the same conditions as for LTA were 
attempted but these failed. If platelets were prepared with gentler spin steps, 
however (see Chapter 2), then it was possible to measure Ca2+ mobilisation in a 
96 well plate using the Ca2+ sensitive dye Fura-2 AM. 
This showed that ibrutinib also dose-dependently inhibited GPVI-mediated 
platelet Ca2+ mobilisation with a similar IC50 to that for aggregation (see Figure 





Figure 3.3: Ibrutinib dose-dependently inhibits GPVI-mediated granule release 
and Ca2+ mobilisation. 
Healthy donor washed platelets at 4x108/ml were treated with (A) Chronolume®, (B) 
the Ca2+ sensitive dye Fura-2 AM (C) nothing or (D) indomethacin (10 μM) then 
incubated with ibrutinib or vehicle for 5 minutes before being stimulated with CRP (10 
μg/ml). Platelets from (B) and (C) were prepared using the ADP-sensitive method. (Ai) 
Representative ATP secretion trace from 3 identical experiments. (Aii) Dose response 
curve for granule release (n=3). (Bi) Representative luminescence trace from three 
identical experiments. (Bii) Dose response curve for Ca2+ mobilisation (n=3). (C) Dose 
response curve for aggregation for platelets prepared by ADP-sensitive or insensitive 
methods (n=3). (D) Dose response curve for aggregation for normally prepared 
platelets in the presence or absence of indomethacin (n=3). For A-C the dose response 
curve for LTA with ibrutinib treated normally prepared platelets is shown to enable 
comparison. All mean data is shown ± SEM. 
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3.2.1.7 ADP-sensitive human platelets display the same sensitivity to 
ibrutinib at inhibiting GPVI-mediated platelet aggregation as ADP-
insensitive platelets 
The method of platelet preparation used for the Ca2+ mobilisation experiments 
means that the platelets are able to be stimulated by ADP. It has previously 
been shown that traditional washed platelet preparation down-regulates the 
P2Y1 receptor and this is what renders them insensitive to stimulation with ADP 
(Koessler et al. 2016). 
Because of the different method of platelet preparation for the LTA and Ca2+ 
mobilisation assays. It needed to be established if this was introducing 
variability into the data. Therefore LTA using washed platelets prepared by the 
traditional and also the ADP-sensitive methods in the presence or absence of 
ibrutinib was performed using CRP 10 μg/ml as an agonist. This showed there 
was no difference in the sensitivity of GPVI-mediated platelet aggregation to 
ibrutinib regardless of which preparation method was used (see Figure 3.3C). 
 
3.2.1.8 GPVI-mediated platelet aggregation in wild type mouse 
platelets has the same sensitivity to blockade by ibrutinib as human 
healthy donor platelets 
Because of the discrepancy seen between the human platelet results of Levade 
et al and those of Lee et al. for mouse platelets, LTA using washed mouse 
platelets was performed in exactly the same conditions as for human platelets. 
Results in Figure 3.4 show that, like human platelets, ibrutinib also dose-
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dependently inhibits mouse GPVI-mediated platelet function with a similar IC50 




Figure 3.4: Ibrutinib dose-dependently inhibits GPVI-mediated mouse platelet 
aggregation with the same potency as for human platelets. 
WT mouse washed platelets at 4x108/ml were incubated with ibrutinib or vehicle for 5 
minutes prior to being stimulated with CRP 10 μg/ml for 3 minutes. (A) Trace 
representative of 3 identical experiments. (B) Dose response curve for mouse 
aggregation (n=3). Curve for human platelet aggregation is shown as a dotted line for 
comparison. Results shown are mean ± SEM. 
 
3.2.2 The inhibition of GPVI-mediated platelet 
function is reversible 
The blockade of GPVI-mediated platelet function by ibrutinib has been 
postulated to be due to inhibition of Btk along with inhibition of the related non-
receptor tyrosine kinase Tec (Byrd et al. 2016). If this was the case then the 
inhibition of GPVI-mediated platelet function by ibrutinib would be irreversible as 
Tec shares a conserved Cysteine in its ATP binding loop, equivalent to the 
Cys481 of Btk, which ibrutinib binds to irreversibly. (Brown et al. 2004) One 
existing study hints that inhibition of GPVI-mediated platelet function might not 
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be irreversible (Lee et al. 2017). Another suggests it is irreversible on the basis 
of mixing studies (Levade et al. 2014). Irreversible inhibition is characterised by 
being time-dependent and not able to be reversed despite washing out of 
excess drug. 
 
3.2.2.1 Complete blockade of GPVI-mediated platelet aggregation is 
not time-dependent 
To investigate whether the inhibition of GPVI-mediated platelet function by 
ibrutinib was time-dependent, platelets were incubated with ibrutinib or vehicle 
for increasing periods of time before stimulating with CRP. High concentrations 
of ibrutinib were able to inhibit GPVI-mediated platelet function after only a very 
short incubation (30 seconds) (see Figure 3.5Ai). The prolonged lag time seen 
with low concentrations of ibrutinib (70 nM) was only present after 5 minutes of 
incubation and the extent of the delay increased with lengthening incubation 
time but the overall aggregation percentage did not decrease with time (see 
Figure 3.5Aii-iv). This is consistent with the full blockade of aggregation, seen 
with high concentrations of ibrutinib, being due to a reversible action, but the 




Figure 3.5: Complete blockade of GPVI-mediated platelet aggregation by ibrutinib 
is reversible and not time-dependent. 
Human healthy donor washed platelets at 4x108/ml were incubated with ibrutinib or 
vehicle for 30 seconds - 60 minutes before being stimulated with CRP 10 μg/ml. (Ai-iii) 
Representative aggregation traces from one of the three identical experiments. (iv) 
Mean data showing the effect of ibrutinib incubation time on the lag time between 
addition of agonist and beginning of aggregation (n=3). (Bi) Platelets were also 
incubated with ibrutinib or vehicle for 5 minutes before being stimulated with CRP 10 
μg/ml. (ii) Alongside, washed platelets treated identically with either ibrutinib or vehicle 
were washed twice in modified-Tyrode’s-HEPES buffer and resuspended back to 
4x108/ml. Platelets were then stimulated with CRP 10 μg/ml. (iii) Mean data (n=3). All 




3.2.2.2 Complete blockade of GPVI-mediated platelet aggregation is 
reversible 
To directly test the reversibility of ibrutinib’s effects on GPVI function; washed 
platelets were incubated with high concentrations of ibrutinib for 5 minutes 
before stimulation with CRP to ensure that full blockade had been achieved 
(see Figure 3.5Bi). Platelets incubated for 5 minutes with this same 
concentration of ibrutinib were then washed twice in modified Tyrode’s-HEPES 
buffer in order to wash off the excess drug and then they too were stimulated 
with CRP. Strikingly, and in disagreement to results by Levade et al. which 
suggested that Btk inhibition was sufficient to block GPVI-mediated activation, 
the platelets where the excess ibrutinib had been washed out were able to 
aggregate fully to CRP  (see Figure 3.5Bii-iii). The slight delay that had been 
noted in other aggregation experiments persisted, however, and was not able to 




3.2.3 Ibrutinib dose-dependently inhibits 
phosphorylation events downstream of the GPVI 
receptor 
In order to investigate the effects of ibrutinib on the phosphorylation events 
downstream of the platelet GPVI receptor, and to see how changes in individual 
phosphorylation events influence the functional response of platelets to 
stimulation of the GPVI-receptor, platelet lysates were prepared. Ideally, these 
would be prepared using conditions that were identical to those used for the 
functional studies. 
 
3.2.3.1 Pattern of inhibition of GPVI-mediated tyrosine 
phosphorylation is not affected by presence or absence of the 
integrin αIIbβ3 inhibitor eptifibatide 
Normal practice for preparing platelet lysates with which to make western blots 
is to add reducing sample buffer under stirring but non-aggregating conditions 
by using the integrin αIIbβ3 inhibitor eptifibatide at a concentration of 9 μM. This 
is considered necessary to ensure there is no interference from signalling 
downstream of integrin αIIbβ3 which might alter the phosphorylation events 
downstream of GPVI. 
To study whether or not the relevant signalling events changed in the absence 
of eptifibatide lysates were made in exactly the same conditions as for 
aggregations in the presence or absence of 9 μM eptifibatide. Results showed 
that pan-phosphorylation events were enhanced in the presence of eptifibatide 
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(see Figure 3.6A). This was particularly the case for proteins with a molecular 
weight > 100 kDa or those < 55 kDa. In order to study individual 
phosphorylation events phosphospecific antibodies were used and showed that 
it was possible to detect ibrutinib’s inhibition of Btk pY223 in both conditions but 
downstream phosphorylation of the large molecular weight protein PLCɣ2 at 
Y1217 was much easier to detect in the presence of eptifibatide (see Figure 
3.6A). Because it was crucial that the assay was sensitive enough to detect 
blockade of PLCɣ2 phosphorylation, further experiments were performed in the 
presence of 9 μM eptifibatide. 
 
3.2.3.2 Level of phosphorylation post stimulation of the GPVI 
receptor is time-dependent 
The next step taken to optimise conditions for making platelet lysates was to 
determine the optimum time point after stimulation to lyse the platelets. 
Therefore, as 70 nM ibrutinib was sufficient to block Btk pY223, platelets were 
incubated with either 70 nM ibrutinib or vehicle for 5 minutes prior to stimulation 
with CRP 10μg/ml and then reducing sample buffer was added at 20, 45, 90 
and 180 seconds. The resultant lysates were then probed with the pan-
phosphotyrosine antibody 4G10 as well as phosphospecific antibodies for pY 
residues upstream and downstream of Btk pY223. 
For all samples peak phosphorylation levels were seen at 180 seconds with 
some, such as LAT pY200, being achieved more quickly than this (see Figure 
3.6B). No loss of intensity following peak phosphorylation was seen at any 
point. As for aggregation experiments, these results led to the decision to use 
the time point of 180 seconds following stimulation with CRP to lyse platelets for 
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all future experiments. 
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Figure 3.6: The level of phosphorylation of tyrosine residues on kinases and 
adapter proteins downstream of the GPVI receptor rises after stimulation and 
does not decrease up to 180 seconds. The pattern of inhibition of this 
phosphorylation by ibrutinib is not affected by treatment with eptifibatide or 
agonist concentration. 
Healthy donor washed human platelets at 4x108/ml were incubated with ibrutinib or 
vehicle for 5 minutes prior to stimulation. Platelets were then lysed with 5X reducing 
sample buffer after addition of agonist. Whole cell lysates were then separated by 
SDS-PAGE and Western blots were probed for whole cell phosphorylation or kinase 
phosphorylation with the stated antibodies downstream of the platelet GPVI receptor. 
(A) Representative blot of platelets incubated with ibrutinib or vehicle in the presence or 
absence of eptifibatide 9 μM and lysed 3 minutes after addition of CRP 10 μg/ml. 
Result shown is from two similar experiments. (B) Platelets incubated with ibrutinib or 
vehicle in the presence of eptifibatide 9 μM, stimulated with CRP 10 μg/ml and then 
lysed at the stated times. (i) Representative blot of three identical experiments. (ii, iii) 
Mean phosphorylation levels ± SEM for the vehicle and ibrutinib treated platelets were 
calculated by comparing band intensity to that of the 180 second stimulated vehicle 
control band (n=3). (C) Platelets were stimulated with (i) CRP 3 μg/ml or (ii) collagen 10 
μg/ml 5 minutes before lysis. Blots are representative of a single experiment with CRP 
and three identical experiments with collagen. 
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3.2.3.3 Pattern of inhibition of GPVI-mediated tyrosine 
phosphorylation is not affected by the GPVI agonist used or its 
concentration 
Biochemical studies are traditionally done with high concentrations of agonists 
in order to maximise the level of protein phosphorylation. Hitherto, all tests to 
optimise conditions for biochemical studies had been done using 10 μg/ml CRP 
as the agonist. Given that lowering the concentration of agonist increased the 
sensitivity of the platelets to inhibition by ibrutinib it was necessary to investigate 
whether lowering of the agonist concentration changed the concentration at 
which Btk pY223 was inhibited. Platelets were incubated with ibrutinib or vehicle 
and lysed 180 seconds after stimulation with 3 μg/ml CRP and probed with the 
pan-phosphotyrosine antibody 4G10 as well as the phosphospecific antibodies 
for Btk pY223 and PLCɣ2 pY1217. This showed that the pattern of inhibition of 
overall tyrosine phosphorylation as well as PLCɣ2 pY1217 was similar to that for 
platelets stimulated with 10 μg/ml CRP (see Figure 3.6Ci). Probing for Btk 
pY223 failed in this assay. 
It has been shown above that ibrutinib’s dose-dependent inhibition of GPVI-
mediated platelet aggregation is unchanged whether collagen or CRP is used 
as the agonist. It was important to establish whether this interchangeability 
extended to biochemical studies. Thus platelets lysed 180 seconds after 
stimulation with collagen 10 μg/ml in the presence or absence of ibrutinib were 
probed with 4G10. The pattern of inhibition of whole cell phosphorylation was 
identical to that of platelets stimulated with CRP 10μg/ml (see Figure 3.6Cii). 
For this reason, and to maintain consistency between different assays, further 




3.2.3.4 Ibrutinib inhibits autophosphorylation of Btk Y223 and 
downstream PLCɣ2 phosphorylation at a lower IC50 than it inhibits 
aggregation. Inhibition of Src pY418 occurs at a higher IC50. 
It has been shown above that CRP induces robust whole cell tyrosine 
phosphorylation in platelets and that this is dose-dependently inhibited by 
ibrutinib. A detailed analysis of the dose response to ibrutinib on a wide range of 
proteins downstream of the GPVI receptor was investigated using 
phosphospecific antibodies. 
Autophosphorylation of Btk at Y223 and downstream phosphorylation of PLCɣ2 
at Y753, Y759, Y1197 and Y1217 was reduced to basal levels by a low 
concentration of ibrutinib (70 nM) (see Figure 3.7Ai-ii). In contrast, 
phosphorylation of Btk on Y551, which is mediated by Src family kinases (Wahl 
et al. 1997), and proteins that lie upstream of Btk, namely Src Y418, Syk 
Y525/6, SLP76 Y145 and LAT Y200, was not altered (see Figure 3.7Ai,iii-iv). 
Inhibition of phosphorylation of Src on its activation site, Y418, was observed at 
a tenfold higher concentration of ibrutinib and shown to correlate with inhibition 
of aggregation (Pearson’s correlation coefficient 0.959) (see Figure 3.7Ai,iv). 
Inhibition of whole cell phosphorylation and phosphorylation of Syk Y525/6, 
SLP76 Y145, Btk Y551 and LAT Y200 was seen at 7 μM ibrutinib which is 
tenfold higher than the maximal concentration in patients (see Figure 3.7Ai,iii-
iv). Where analysable the IC50 values for each phosphorylation event are 
included in Table 3.2. Despite having a single good quality blot for inclusion in 
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the images seen in Figure 3.7Ai, the PLCɣ2 pY1197 antibody generally gave 





Figure 3.7: Ibrutinib inhibits Btk pY223 and downstream PLCɣ2 phosphorylation 
at a lower concentrations than that which inhibits aggregation. 
(A) Eptifibatide (9 μM) treated washed human platelets at 4×108/ml were incubated with 
ibrutinib or vehicle for 5 minutes followed by stimulation with CRP 10 μg/ml for 3 
minutes. Samples were lysed with 5X SDS reducing sample buffer after 3 minutes. 
Whole cell lysates were then separated by SDS-PAGE and underwent Western blot 
with the stated antibodies for whole cell phosphorylation, kinases and proteins 
downstream of GPVI. (i) Blots are representative of four identical experiments. (ii-iv) 
Percentage tyrosine phosphorylation as compared to vehicle platelets was measured 
and is represented as the means ± SEM (n=4). The dose response curve for inhibition 
of washed platelet aggregation is shown as a dotted line to enable comparison. (B) 
Eptifibatide (9 μM) treated washed human platelets at 8×108/ml were stimulated with 
CRP 10 μg/ml after incubation with ibrutinib or vehicle for 5 minutes. After 3 minutes 
platelets were lysed with 2X ice cold lysis sample buffer. Lysates were pre-cleared and 
Tec was immunoprecipitated before addition of SDS reducing sample buffer and 
separation by SDS-PAGE and underwent Western blot with the anti-pY antibody 4G10. 
Membranes were stripped and then re-probed with the pan-Tec antibody. (i) Blots are 
representative of three identical experiments. (ii) The percentage of tyrosine 
phosphorylation as compared to vehicle treated platelets was measured and is 
represented as the means ± SEM (n=3). 
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3.2.3.5 Ibrutinib inhibits Tec phosphorylation at a higher 
concentration than for Btk pY223 but lower than that which inhibits 
aggregation 
Tec is the only other Tec family kinase expressed in platelets (Burkhart et al. 
2012). Ibrutinib is known to irreversibly inhibit Tec with an IC50 about 150 fold 
higher than that with which it inhibits Btk. (Honigberg et al. 2010). Due to the 
absence of phosphospecific antibodies for Tec, the effect of ibrutinib on Tec 
phosphorylation was investigated following immunoprecipitation and re-probing 
with the antiphosphotyrosine mAb 4G10. The effect of ibrutinib on Tec 
phosphorylation was biphasic with partial blockade at 170 nM and full blockade 
observed at 7 μM (see Figure 3.7B) consistent with there being two 
phosphorylation sites on Tec analogous to those on Btk. The IC50 of ibrutinib for 
Tec was unable to be calculated because of the biphasic nature of the dose 
response curve. 
 
3.2.3.6 Blockade of GPVI-mediated platelet aggregation by ibrutinib 
is not affected by indomethacin 
Given that it is generally accepted that PLCɣ2 activation is required for Ca2+ 
mobilisation and subsequent activation of platelets, it was surprising that GPVI-
mediated platelet aggregation and Ca2+ mobilisation were able to occur in the 
absence of any detectable PLCɣ2 phosphorylation. This could be due to PLCɣ2 
activation occurring in the absence of phosphorylation, or it could be that the 
other major PLC isoform in platelets, PLCβ, is responsible for the Ca2+ 
mobilisation. The major route of PLCβ stimulation following GPVI activation is 
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via TP receptor stimulation with TxA2. Production of TxA2 can be blocked by 
indomethacin. 
To test whether PLCβ was responsible for the Ca2+ mobilisation, platelets were 
stimulated by CRP 10 μg/ml in the presence or absence of indomethacin 10 μM 
for 3 minutes after being incubated with ibrutinib or vehicle for 5 minutes. There 
was no difference in the sensitivity of platelets to ibrutinib whether or not 
indomethacin was present (see Figure 3.3). This implies that PLCβ mediated 
Ca2+ mobilisation does not account for the difference seen between Ca2+ 
mobilisation and PLCɣ2 phosphorylation when platelets are inhibited with low 
concentrations of ibrutinib. 
 
3.2.3.7 Ibrutinib's inhibition of Btk Y223 autophosphorylation and 
downstream PLCɣ2 phosphorylation is irreversible but upstream 
inhibition of Src Y418 is reversible. 
To further investigate whether blockade of GPVI-mediated platelet activation by 
ibrutinib is secondary to its inhibition of Btk or an off-target effect the washout 
experiment described for the LTA experiments was repeated but with lysis of 
platelets at 3 minutes following stimulation with CRP 10 μg/ml. 
The results showed that, consistent with ibrutinib’s known irreversible binding to 
Btk, the effect of ibrutinib on Btk pY223 and downstream PLCɣ2 
phosphorylation was irreversible (see Figure 3.8). They also reveal that, like 
aggregation, ibrutinib’s inhibition of Src pY418 was fully reversible along with 
variable and less consistent effects on other phosphorylation events such as 




Figure 3.8: Phosphorylation of Btk at Y223 and PLCɣ2 at Y753 and Y1217 is 
irreversible whereas Src pY418 is reversible. 
Eptifibatide (9 μM) treated human healthy donor washed platelets at 4x108/ml were 
incubated with ibrutinib or vehicle for 5 minutes. They were then stimulated with CRP 
10 μg/ml for 3 minutes prior to addition of 5X SDS reducing sample buffer. Alongside, 
platelets treated with ibrutinib or vehicle in the same way were washed twice in 
modified-Tyrode’s-HEPES buffer before being stimulated with CRP 10 μg/ml. After 3 
minutes these platelets too were lysed with 5X SDS reducing sample buffer. Whole cell 
lysates were then separated by SDS-PAGE and Western blot with the stated 
antibodies for whole cell phosphorylation, kinases and proteins downstream of GPVI. 
(A) Blots are representative of three identical experiments. (B) Percentage tyrosine 
phosphorylation as compared to non-washed vehicle platelets was measured and is 
represented as the means ± SEM (n=3). Results were analysed statistically using a 
paired two-tailed t-test* P<0.05, ns = non-significant. 
 
3.2.3.8 Ibrutinib's inhibition of tyrosine phosphorylation downstream 
of mouse GPVI mimics human GPVI. 
The inhibitory effect of ibrutinib on tyrosine phosphorylation downstream of the 
platelet GPVI receptor in mice was also studied using exactly the same 
conditions as used for the experiments on human platelets. Representative 
blots of whole cell phosphorylation and specific phosphorylation events as well 
as quantification data is shown in Figure 3.9. Like the results in human platelets, 
ibrutinib inhibited Btk pY223 and downstream PLCɣ2 phosphorylation at lower 
concentrations than it inhibited aggregation, but these concentrations were not 
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quite as low as for human platelets (see Table 3.2). It also inhibited Src pY418 
with an IC50 of 350 nM (but with very wide confidence intervals). Also like in 
human platelets, ibrutinib only inhibited whole cell phosphorylation and 
upstream phosphorylation at high concentrations (7 μM). 
 
 
Figure 3.9: Ibrutinib dose-dependently inhibits GPVI-mediated Btk and 
downstream PLCɣ2 phosphorylation in WT mouse platelets at lower 
concentrations than it inhibits aggregation in washed platelets. 
Eptifibatide (9 μM) treated WT mouse platelets at 4x108/ml were incubated with 
ibrutinib or vehicle for 5 minutes prior to stimulation with CRP 10 μg/ml. After 
stimulation for 3 minutes, platelets were lysed with 5X SDS reducing sample buffer. 
Whole cell lysates were then separated by SDS-PAGE and Western blot with the 
stated antibodies for whole cell phosphorylation, kinases and proteins downstream of 
GPVI. (A) Blots are representative of four similar experiments. Percentage tyrosine 
phosphorylation as compared to vehicle treated platelets was measured and is 
represented as the means ± SEM (n=3) for proteins downstream (B) and upstream (C) 
of Btk autophosphorylation as well as for Src pY418 (D). The dose response curve for 
inhibition of LTA is included as a dotted line to enable comparison. 
 
3.2.4 Btk-specific concentrations of ibrutinib only have a very small 
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effect on spreading of platelets on immobilised collagen 
Another important measure of platelet function is their ability to spread on a 
fixed ligand. The effect of ibrutinib on platelet spreading on immobilised 
collagen was assessed using washed platelets isolated from healthy donors. 
These were allowed to spread on collagen coated coverslips for 45 minutes 
prior to fixation, antibody staining and imaging. Platelets were treated with 
ibrutinib 170 nM or vehicle either for 5 minutes prior to spreading or for 15 
minutes, after spreading had been ongoing for 30 minutes (see Figure 3.10). 
Confirmation of the expected effect on aggregation was confirmed prior to 
commencing the spreading experiment (not shown). 
There was a statistically significant, but very small, reduction of platelet 
spreading area when ibrutinib was added to the platelets before spreading took 
place. There was also a statistically significant, but even smaller, increase in 
platelet spread area when ibrutinib was added after spreading had commenced 
(see Figure 3.10B). 
There was no effect of adding ibrutinib on number of adherent platelets 




Figure 3.10: Btk-specific concentrations of ibrutinib only have a very small effect 
on spreading of platelets on immobilised collagen. 
Human healthy donor washed platelets at 2x107/ml were incubated with ibrutinib (170 
nM) or vehicle for 5 minutes before spreading on collagen coated coverslips at 37°C for 
45 minutes. Simultaneously, untreated platelets were spread on collagen coated 
coverslips at 37°C for 30 minutes before ibrutinib (170 nM) or vehicle was added and 
incubated for 15 minutes at 37°C. Coverslips were then washed to remove non-
adherent platelets before fixation with formalin and staining with Phalloidin-488. (A) 
Representative images of three identical experiments. Ilastik machine learning software 
was used to automatically and reproducibly identify platelets. Data on platelet number 
and surface area was measured using the KNIME analytics platform. (B) Mean data ± 
SEM (n=3). Statistical analysis performed using two-tailed Welch’s t-test. (C) Mean 
data ± SEM (n=3). Statistical analysis performed using a one-way ANOVA with Tukey’s 
correction for multiple comparisons. 
 
3.2.5 Acalabrutinib dose-dependently inhibits 
GPVI-mediated platelet function and tyrosine 
phosphorylation 
In order to further corroborate which effects of ibrutinib are mediated by its 
effects on Btk and which by off-target effects the second generation, more Btk-




3.2.5.1 Acalabrutinib dose-dependently inhibits GPVI-mediated 
platelet aggregation 
Like ibrutinib, acalabrutinib added to washed platelets prior to stimulation with 
CRP 10 μg/ml also inhibited GPVI-mediated platelet aggregation in a dose-
dependent manner. This is shown in Figure 3.11A-B. This was similar to the 
effect of ibrutinib but it occurred at higher concentrations. The IC50 for 
acalabrutinib’s inhibition of aggregation was ~20-fold higher than that for 
ibrutinib (see Table 3.2). Also like the results seen with ibrutinib, there was a 
delay in aggregation at 2 uM acalabrutinib (not quantified). 
 
3.2.5.2 Acalabrutinib dose-dependently inhibits GPVI-mediated 
granule release 
The effects of acalabrutinib on platelet function were extended to look at 
granule secretion. As for aggregation and like that seen with ibrutinib, 
acalabrutinib inhibited GPVI-induced granule secretion in a dose-dependent 
manner but with the dose response curve slightly left-shifted (see Figure 3.11C-




3.2.5.3 Acalabrutinib dose-dependently inhibits GPVI-mediated Ca2+ 
mobilisation 
Acalabrutinib’s effects on platelet function were further extended to look at Ca2+ 
mobilisation. Again, as for aggregation and granule secretion, acalabrutinib 
inhibited GPVI-induced Ca2+ mobilisation in a dose-dependent manner over a 
similar concentration range with a similar IC50 to that for inhibition of granule 
release (ie slightly left-shifted when compared with aggregation) (see Figure 





Figure 3.11: Acalabrutinib inhibits GPVI-mediated platelet function in a dose-
dependent manner. 
Human healthy donor washed platelets at 4x108/ml were incubated with acalabrutinib 
or vehicle for 5 minutes before stimulation with 10 μg/ml CRP. (A) LTA trace 
representative of six identical experiments and (B) dose response curve (n=6) is shown 
as mean ± SEM. (C) Representative trace and (D) dose response curve for granule 
release from 3 identical experiments. The equivalent curve for LTA is shown as a 
dotted line to allow comparison. Results shown are mean ± SEM. (E) Representative 
trace from three identical experiments and (F) dose response curve (n=3) for Ca2+ 
mobilisation. Results shown are mean ± SEM. 
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3.2.5.4 Acalabrutinib inhibits Btk Y223 and downstream PLCɣ2 
phosphorylation with a lower IC50 than its inhibition of aggregation 
but leaves upstream phosphorylation unaffected 
As for ibrutinib, functional experiments with acalabrutinib were expanded by 
looking further into the biochemical signalling pathway using Western blot with 
the same phosphospecific antibodies. This showed similar overall inhibition of 
pan-phosphotyrosine levels, Btk Y223 and downstream phosphorylation of 
PLCɣ2 (see Figure 3.12Ai-ii). It also showed a similar lack of inhibition of 
phosphorylation upstream of Btk Y223 (see Figure 3.12Aiii). Notably however, 
unlike inhibition with ibrutinib, Src pY418 was unaffected by even very large 
concentrations of acalabrutinib (see Figure 3.12Aiv). Like ibrutinib, acalabrutinib 
inhibited Tec phosphorylation in a biphasic dose-dependent manner (see Figure 
3.12B) over a lower concentration range than that which inhibited aggregation. 
The IC50 for the inhibition of Tec phosphorylation could not be calculated 
because of the biphasic nature of the curve. 
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Figure 3.12: Acalabrutinib inhibits Btk pY223 and downstream PLCɣ2 
phosphorylation at a lower concentration than that which inhibits aggregation. 
(A) Eptifibatide (9 μM) treated washed human platelets at 4×108/ml were incubated with 
acalabrutinib or vehicle for 5 minutes followed by stimulation with CRP 10 μg/ml for 3 
minutes. Samples were lysed with 5X SDS reducing sample buffer after 3 minutes. 
Whole cell lysates were then separated by SDS-PAGE and underwent Western blot 
with the stated antibodies for whole cell phosphorylation, kinases and proteins 
downstream of GPVI. (i) Blots are representative of three identical experiments. (ii-iv) 
Percentage tyrosine phosphorylation as compared to vehicle platelets was measured 
and is represented as the means ± SEM (n=3). The dose response curve for inhibition 
of washed platelet aggregation is shown as a dotted line to enable comparison. (B) 
Eptifibatide (9 μM) treated washed human platelets at 8×108/ml were stimulated with 
CRP 10 μg/ml after incubation with acalabrutinib or vehicle for 5 minutes. After 3 
minutes platelets were lysed with 2X ice cold lysis sample buffer. Lysates were pre-
cleared and Tec was immunoprecipitated before addition of SDS reducing sample 
buffer and separation by SDS-PAGE and underwent Western blot with the anti-pY 
antibody 4G10. Membranes were stripped and then re-probed with the pan-Tec 
antibody. (i) Blots are representative of three identical experiments. (ii) The percentage 
of tyrosine phosphorylation as compared to vehicle treated platelets was measured and 
is represented as the means ± SEM (n=3). 
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3.2.6 Btk-specific concentrations of ibrutinib have no effect on 
adhesion or aggregation to collagen in whole blood under flow 
conditions at arterial shear 
Btk-specific concentrations of ibrutinib fail to inhibit GPVI-mediated platelet 
aggregation, granule release and Ca
2+
 mobilisation stimulated with high 
concentrations of CRP but can block at low concentrations of CRP. The 
significance of this observation was investigated by using the more 
physiological flow adhesion assay in whole blood. To circumvent the issue of 
ibrutinib’s high level of plasma protein binding and so achieve a known degree 
of Btk inhibition washed platelets were isolated from citrated healthy donor 
whole blood and incubated with 70 nM ibrutinib for 5 minutes before being 
reconstituted with autologous platelet poor plasma and red cells to a final 
platelet concentration of 400 x10
9
/l. To confirm Btk inhibition, the expected 
effect of delayed platelet aggregation to CRP was verified before reconstitution 
(see Figure 3.13A). The reconstituted blood was then flowed through a collagen 
coated glass capillary at arterial shear rates for 3 minutes before being fixed, 
after which 5 images were taken, equally spaced along the capillary. Platelet 





Figure 3.13: In vitro low concentration ibrutinib has no effect on adhesion to 
collagen under flow. 
Human healthy donor washed platelets at 10x108/ml were incubated with ibrutinib or 
vehicle for 5 minutes. (A) A 300 μl aliquot of these platelets was stimulated with CRP 
10 μg/ml to measure LTA. (i) Representative trace of three identical experiments and 
(ii) results shown as mean ± SEM (n=3). The remainder of the platelets were 
reconstituted with autologous red cells and PPP to a final platelet concentration of 
400x109/l and incubated with DiOC6 dye for 5 minutes before being flowed over 
collagen at 1000 s-1 for 3 minutes. Flow capillaries were then flushed with modified-
Tyrode’s-HEPES buffer and fixed with formalin before being imaged in DIC and 
Fluorescent channels on a Zeiss Axio inverted microscope at 20X magnification. 
Representative images are shown in (B). ImageJ was used to analyse platelet surface 
coverage. Results are shown in (C) as mean ± SEM (n=3). Statistical analyses by 
paired t-tests. *P<0.05, ns = non significant. 
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3.2.7 Platelets taken ex vivo from patients on Btk 
inhibitors 
3.2.7.1 Platelets taken from untreated patients with CLL have 
partially inhibited GPVI-mediated platelet aggregation 
In order to study the effects of Btk inhibitors ex vivo it was necessary to use 
patients with B-cell lymphoproliferative disorders as these were the only 
patients prescribed these drugs. There have been reports that patients with CLL 
with high white cell counts have reduced whole blood platelet aggregation in 
response to stimulation with ADP because of excess activity of leukocyte ecto-
nucleotidase (Glenn et al. 2009). It was important to establish if a similar 
reduction occurs in response to GPVI ligation. 
Initial studies were done, therefore, on untreated patients with CLL as well as 
those same patients after treatment with a single cycle of a “standard” 
chemotherapy regimen containing the purine analogue fludarabine, the 
alkylating agent cyclophosphamide and the anti-CD20 antibody rituximab 
(FCR). These showed that, in untreated patients with CLL, there was a non-
statistically significant trend to reduced platelet aggregation in PRP to all 
concentrations of CRP, the thrombin receptor agonist PAR1-peptide and ADP 
and a significant reduction in platelet aggregation in response to medium and 
high concentrations of collagen (see Figure 3.14A). There was no significant 
increase in platelet count following the chemotherapy to explain the improved 
aggregation but the white cell count (WCC) did decrease, although this was not 
statistically significant because of the large variation in WCCs in CLL patients 
prior to starting treatment (see Figure 3.14Biii). These results confirmed that it 
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was necessary to include pre-treatment platelet function testing when 





Figure 3.14: Patients with CLL who have received chemotherapy have increased 
platelet aggregation responses to collagen but aggregation in response to CRP, 
PAR1 peptide and ADP are unchanged. 
PRP was isolated from the blood of four patients with CLL immediately prior to 
treatment with FCR chemotherapy and then again from the same patients immediately 
prior to their second cycle of chemotherapy. (A) Optical density of PRP was measured 
over 3 minutes following stimulation with (i) CRP 0.3 - 10 μg/ml, (ii) collagen 0.3 - 10 
μg/ml, (iii) PAR1 peptide 100 μM and ADP 10 μM. Results shown are mean ± SEM of 
four identical experiments. Statistical analysis was performed with a 2-way ANOVA 
with Sidak’s multiple comparison test. (B) White cell and platelet counts in whole blood 
as well as platelet counts in the isolated PRP were measured and are shown as mean 
± SEM with statistical analysis performed using a two tailed paired t-test (n=4). 
*P<0.05, ns = non-significant. 
 
3.2.7.2 Platelets from patients on ibrutinib show reduced platelet 
aggregation in response to GPVI activation 
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Studies were extended to include patients before and after taking ibrutinib 420 
mg once daily as a single agent or in combination with rituximab 375 mg/m2 
once monthly. Because of the relative difficulty in identifying and acquiring blood 
pre-treatment, not all patients on treatment were able to have platelet function 
analysis pre-treatment as well as post-treatment. 
Results showed a significant reduction in GPVI-mediated platelet aggregation to 
low (CRP), medium and high (CRP and collagen) concentrations of agonist in 
the patients taking ibrutinib (see Figure 3.15Ai-ii). There was no difference, 
however, in the response to stimulation by GPCR agonists PAR1 peptide or 
ADP (see Figure 3.15Aiii). There was no difference in the whole blood or PRP 
platelet count between treatment groups (see Figure 3.15Bi-ii) and, similar to 
the results on chemotherapy treated patients, there was no difference in the 
whole blood WCC (see Figure 3.15Biii). Although, again, this probably merely 
reflects the highly variable nature of pre-treatment white cell counts in patients 




Figure 3.15: Ibrutinib inhibits GPVI-mediated platelet function ex vivo.  
PRP was isolated from the blood of patients with CLL immediately prior to and 
following treatment with FCR or ibrutinib based chemotherapy regimens. (A) Optical 
density of PRP was measured over 3 minutes following stimulation with (i) CRP 0.3 - 
10 μg/ml, (ii) collagen 0.3 - 10 μg/ml, (iii) PAR1 peptide 100 μM and ADP 10 μM. 
Results shown are mean ± SEM (Pre-treatment n=9, Post-FCR n=5, Post-ibrutinib 
n=12). Statistical analysis was performed with a 2-way ANOVA with Tukey’s multiple 
comparison test. (B) White cell and platelet counts in whole blood as well as platelet 
counts in the isolated PRP were measured and are shown as mean ± SEM with 
statistical analysis performed using a 1-way ANOVA with Tukey’s multiple comparison 




3.2.7.3 Platelets taken from patients on acalabrutinib have delayed 
but normal magnitude of GPVI-mediated platelet aggregation 
To match the in vitro studies, experiments were extended to include patients 
with CLL taking the second generation Btk inhibitor acalabrutinib at 100mg 
twice daily. At the time of performing this work this drug was only available to 
patients through being involved in clinical trials and hence there were not many 
patients available for analysis. This meant that only three patients taking 
acalabrutinib were able to be sampled. 
Patients taking acalabrutinib had a reduced magnitude of platelet aggregation in 
response to low and medium concentrations of GPVI agonists collagen and 
CRP but normal responses to high concentrations when compared to ibrutinib 
treated patients (see Figure 3.16Bi-ii). Like the in vitro platelets treated with 
acalabrutinib or low concentration ibrutinib however, this aggregation to high 
concentration agonist was delayed (see Figure 3.16A). There was no difference 
in the platelet aggregation response to GPCR agonists PAR1 peptide and ADP 
(see Figure 3.16Biii). There was no difference in the whole blood platelet count 
or WCC or the PRP platelet count in acalabrutinib and ibrutinib treated patients 
(see Figure 3.16C). 
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Figure 3.16: Acalabrutinib does not inhibit GPVI-mediated platelet function ex 
vivo. 
PRP was isolated from the blood of three patients with CLL following treatment with 
acalabrutinib 100 mg twice daily. Data from Figure 3.15 is included to enable 
comparison. Optical density of PRP was measured over 3 minutes following stimulation 
with CRP 10 μg/ml (A) Representative LTA traces of PRP. (B) Mean optical densities ± 
SEM (n=3) following 3 minutes of stimulation with (i) CRP 0.3 - 10 μg/ml, (ii) collagen 
0.3 - 10 μg/ml, (iii) PAR1 peptide 100 μM and ADP 10 μM. Statistical analysis was 
performed with a 2-way ANOVA with Tukey’s multiple comparison test. (C) White cell 
and platelet counts in whole blood as well as platelet counts in the isolated PRP were 
measured and are shown as mean ± SEM with statistical analysis performed using a 1-
way ANOVA with Tukey’s multiple comparison test. *P<0.05, ns = non-significant. 
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3.2.7.4 Platelets taken from patients on ibrutinib and acalabrutinib 
have inhibited Btk Y223 and downstream PLCɣ2 phosphorylation 
Ex vivo experiments were extended to include studies looking at the 
phosphorylation events downstream of the GPVI receptor. Because of the 
limited volumes of blood available from these patients with leukaemia, 
phosphorylation studies had to be limited and did not include examination of 
Syk pY525/6 or SLP76 pY145. Like the in vitro results, whole cell tyrosine 
phosphorylation was generally intact but closer inspection revealed a missing 
band at ~ 145 kDa in both ibrutinib and acalabrutinib treated patients (see 
Figure 3.17A). Further analysis using phosphospecific antibodies showed that 
Btk Y223 and downstream PLCɣ2 phosphorylation at Y753, Y759 and Y1217 
was reduced in the Btk inhibitor treated patients but upstream phosphorylation 
at Btk Y551 and LAT Y200 was unaffected. Interestingly, and unlike the in vitro 
studies, there was no inhibition of Src pY418 in any patients treated with Btk 





Figure 3.17: Patients treated with Btk inhibitors have reduced Btk Y223 and 
downstream PLCɣ2 phosphorylation. 
Eptifibatide (9 μM) treated washed human platelets at 4×108/ml from patients with CLL 
treated with FCR, ibrutinib or acalabrutinib were stimulated with CRP 10 μg/ml. 
Samples were lysed with 5X SDS reducing sample buffer after 3 minutes. Whole cell 
lysates were then separated by SDS-PAGE and underwent Western blot with the 
stated antibodies for whole cell phosphorylation, kinases and proteins downstream of 
GPVI. (A) Blots are representative of similar blots from twelve patients; four treated 
with FCR, five with ibrutinib and three with acalabrutinib. (B) Percentage tyrosine 
phosphorylation as compared to healthy donor platelets was measured and is 
represented as the means ± SEM (FCR n=4, ibrutinib n=5, acalabrutinib n=3). 
Statistical analysis was performed with a two way ANOVA with Tukey’s multiple 
comparison test. 
 
3.2.7.5 Platelets taken from patients on Btk inhibitors spread 
normally on collagen 
The effect of Btk inhibition in platelet spreading on immobilised collagen was 
also assessed by washed platelets isolated from healthy donors and those 
taking ibrutinib 420 mg once daily and 100 mg acalabrutinib twice daily and 
allowing them to spread on collagen coated coverslips for 45 minutes prior to 
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fixation, antibody staining and imaging. No pre-treatment or FCR treated 
patients were used for this study because of a lack of availability at the time of 
performing the spreading experiments. 
The results shown in Figure 3.18 indicate that Btk inhibition has very little effect, 
with the only statistically significant finding being that the spread platelet area of 
patients taking ibrutinib was more than those taking acalabrutinib or the healthy 




Figure 3.18: Patients on Btk inhibitors or those with XLA have minimally changed 
platelet adhesion and spreading when bound to immobilised collagen. 
Washed platelets at 2x107/ml from healthy human donors, patients taking ibrutinib or 
acalabrutinib and those with XLA were incubated on collagen coated coverslips at 37°C 
for 45 minutes. Coverslips were then washed to remove non-adherent platelets before 
fixation with formalin and staining with Phalloidin-488. (A) Representative images. 
Ilastik machine learning software was used to automatically and reproducibly identify 
platelets and data on platelet number and surface area was measured using the 
KNIME analytics platform. (B) and (C) Data shown as Mean ± SEM for healthy donors 
(n=5), ibrutinib (n=4), acalabrutinib (n=2) and XLA patients (n=2). Statistical analysis 
performed using a one-way ANOVA with Tukey’s correction for multiple comparisons. 
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3.2.7.6 Platelets taken from patients on Btk inhibitors have normal 
adhesion to collagen under flow conditions at arterial shear 
The effect of pharmacological Btk inhibition with ibrutinib and acalabrutinib was 
tested in a more physiological ex vivo flow adhesion assay. Whole blood from 
healthy donors and patients treated with ibrutinib or acalabrutinib was flowed 
over immobilised collagen at arterial shear. Rather than merely measuring the 
percentage surface coverage with platelets after three minutes of flow, the 
experimental method was further optimised to include fluorescence microscopy 
during flow. This enabled the study of change in surface coverage and 
aggregate size over time. Analysis methods were also developed so that they 
were automated and thus more reproducible. This enabled the measurement of 
mean aggregate size as well as total area covered. At the time of performing 
this assay, there were no patients taking FCR or pre-treatment Btk inhibitor 
patients available for inclusion. 
Interestingly, as shown in Figure 3.19A, C and E, there was no difference in the 
platelet coverage or aggregate size over time when using blood from ibrutinib 
treated patients when compared to healthy controls. The same appears to be 
true for patients treated with acalabrutinib (Figure 3.19 Bi, D and F) but, 
because only two acalabrutinib patients were available for this assay, statistical 
analysis is inappropriate. 
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Figure 3.19: Ex vivo Btk inhibition has no effect on adhesion to collagen under 
conditions of arterial flow. 
Whole blood from healthy donors, patients treated with ibrutinib or acalabrutinib or 
those with XLA was incubated with DiOC6 dye for 5 minutes before being flowed across 
a capillary coated with collagen 100 μg/ml at 1000 s-1 for 3 minutes. Images were taken 
every second using fluorescent channels on a Zeiss Axio inverted microscope at 20X 
magnification. (A) Representative images from (i) healthy donors, patients treated with 
(ii) ibrutinib 420 mg once daily, (iii) acalabrutinib 100 mg twice daily or (iv) patients with 
XLA. Ilastik 1.1.2 machine learning software was used to automatically and 
reproducibly identify platelets. Data on platelet surface area coverage and cluster size 
was measured using the KNIME 3.4 analytics platform. Mean data ± SEM showing 
increase in total platelet aggregate area over time of (C) healthy donors (n=4) and 
ibrutinib treated patients (n=5) and (D) acalabrutinib treated patients (n=2) and those 
with XLA (n=2). Mean data ± SEM showing increase in mean aggregate size over time 
of (E) healthy donors and ibrutinib treated patients and (F) acalabrutinib treated 
patients and those with XLA, the results from ibrutinib treated patients is included for 
comparison. (G) Platelet counts from donors and patients. Statistical analysis was 
performed with two-way ANOVA (C and E) or one-way ANOVA (G). ns=non significant. 
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3.2.8 Platelets taken ex vivo from patients with 
XLA 
Given there are differences seen in the GPVI-mediated platelet responses 
between the healthy donor platelets and patients treated with ibrutinib and 
acalabrutinib a useful way of establishing whether these effects were due to the 
specific actions on Btk or off-target effects was to acquire platelets from patients 
with XLA. 
 
3.2.8.1 Sampled XLA patients do not express Btk 
There are multiple different mutations in patients with XLA that result in the 
same phenotype of lacking mature B-cells. Some mutations result in complete 
loss of protein expression whereas some produce a non-functioning protein. Six 
patients with XLA were recruited and had their platelets studied. These patients 
were all unrelated. Information on their individual mutations was already 
available from the west midlands regional genetics laboratory (see Table 3.1). 
All except one of the of the patients had previously described mutations and the 
single patient with a previously non-described mutation (patient 5) was 
predicted to to abolish the 5’ donor splice site of exon 12. Some mutations, 
despite only changing the protein structure subtly, still result in absence of Btk 
because of problems in protein trafficking from the rough endoplasmic reticulum 
to the cytosol. In order to test this lysed platelets were probed with an antibody 
to the N-terminus of the Btk protein and this failed to detect Btk in any of the 
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sampled patients thus confirming lack of Btk expression (see Figure 3.20A). 
 
Patient Mutation Predicted effect 
1 c.1750+1G>A 5’ donor splice site of exon 17 abolished  
(K. W. Chan et al. 2006) 
2 c.700C>T Stop codon at Gln234 (Tani et al. 2002) 
3 c.710del Frameshift with premature termination  (Jo et al. 2001) 
4 c.1820C>A Mutation likely to affect the kinase domain (Bradley et al. 1994) 





Duplication of exons 6-18 resulting in frameshift with premature termination 
(Endo et al. 2011) 
 
 
Table 3.1: Btk mutations and their predicted effects. 
DNA sequencing of the Btk gene was performed by the West Midlands Regional 
Genetics Service and this information on the genetic mutations present in the sampled 
patients with XLA was provided by Dr Aarnoud Huissoon from Birmingham Heartlands 
Hospital. 
3.2.8.2 Platelets from patients with XLA have delayed GPVI-mediated 
platelet aggregation but a normal amplitude of response when 
compared with healthy donors 
In order to look at the functional effects of the absence of Btk, PRP was isolated 
from the patients with XLA and then stimulated with GPVI agonists and GPCR 
agonists with optical density measured over the course of 3 minutes. As 
expected, the results showed that there was low level / no aggregation at low 
concentrations of GPVI agonist but normal aggregation percentages with high 
concentrations of CRP and collagen when compared to healthy donor washed 
platelets (see Figure 3.20B). Like for the patients taking acalabrutinib and the in 
vitro experiments where healthy donor washed platelets were treated with 
acalabrutinib or low concentration ibrutinib there was delayed GPVI-mediated 
aggregation in the platelets from patients with XLA treated with high 
concentration GPVI agonists (see Figure 3.20Cii-iii). There was no statistically 
significant difference in platelet count between the patients with XLA and 
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healthy donors (but there was a trend to a higher platelet count in the patients 
with XLA) (see Figure 3.20Ci). This is probably accounted for by the higher 
haematocrit and consequential lower PRP volume with higher platelet 
concentration in the patients with XLA as they were all male whereas the 
healthy donors included males and females. There is no evidence in the 




Figure 3.20: Patients with XLA lack Btk expression and have normal but delayed 
aggregation in response to high concentrations of GPVI agonist. 
(A) Eptifibatide (9 μM) treated unstimulated platelets at 4x108/ml from 6 patients with 
XLA and 3 healthy donors were lysed with 5X SDS reducing sample buffer. Whole cell 
lysates were then separated by SDS-PAGE and underwent Western blot with the anti-
Btk antibody SAB3500372. (i) Representative blot, (ii) quantification of band intensity 
compared to mean healthy donor. Results shown are mean ± SEM. Statistical analysis 
by unpaired t-test. *P<0.05, ns = non-significant. (B) PRP from patients with XLA was 
stimulated with increasing concentrations of (i) CRP and (ii) collagen and optical 
density was measured for 3 minutes. (iii) Aggregation responses after stimulation with 
PAR1 peptide 100 μM, ADP 10 μM, CRP 10 μg/ml and collagen 10 μg/ml were 
compared to those from healthy donors. Results shown are mean ± SEM for four 
patients with XLA and six healthy donors. Statistical analysis was performed using a 
two way ANOVA with Sidak’s correction for multiple comparisons. (C) (i) Platelet 
counts in PRP from the same patients/donors were measured and are shown as mean 
± SEM. (ii) Representative trace and (iii) mean data ± SEM of aggregation from 
patients with XLA or donors stimulated with CRP 10 μg/ml (n=5). Statistical analysis 
was performed with a two tailed unpaired t-test. *P>0.05, ns = non-significant. 
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3.2.8.3 Platelets from patients with XLA are more sensitive to 
inhibition by ibrutinib 
Given the difference in results between platelets ibrutinib treated patients and 
those with XLA when stimulated with GPVI agonists the next step was to see if 
addition of ibrutinib to platelets from XLA patients had any additional effect. 
Surprisingly, even at low concentrations that were previously shown to inhibit 
Btk pY223 (70 nM) without any other off-target effect, ibrutinib completely 
inhibited GPVI-mediated platelet aggregation to high concentrations of CRP (10 
μg/ml) (see Figure 3.21A). This occurred at a similar IC50 (86 nM) to that at 
which ibrutinib inhibited Btk pY223 in healthy donor platelets (see Table 3.2). 
 
3.2.8.4 Platelets from patients with XLA have normal PLCɣ2 
phosphorylation and ibrutinib inhibits this at concentrations 
previously thought to be Btk-specific 
In order to investigate this difference between healthy donors and patients with 
XLA further, phosphorylation events downstream of the GPVI receptor in the 
patients with XLA were studied. These confirmed lack of Btk pY223 but, 
consistent with previous publications that examined total PLCɣ2 
phosphorylation, they showed that PLCɣ2 phosphorylation in patients with XLA 
looked preserved (albeit with slightly lower intensities) at tyrosines in the SH2-
SH3 linker and the C-terminal region (see Figure 3.21B-C). Indeed, in contrast 
to the results seen with healthy donor washed platelets, the dose response 
curve for inhibition of aggregation and PLCɣ2 phosphorylation by ibrutinib 




Figure 3.21: Platelets from patients with XLA are more sensitive to inhibition of 
GPVI-mediated platelet aggregation by ibrutinib than healthy donor platelets. 
Washed platelets from patients with XLA at 4x108/ml incubated with ibrutinib or vehicle 
for 5 minutes before being stimulated with CRP 10 μg/ml. Optical density was 
measured for a further 3 minutes. (A) Representative trace. The same platelets were 
treated in the same way but in the presence of eptifibatide (9 μM) before being lysed 
with 5X SDS reducing sample buffer after 3 minutes. Whole cell lysates were then 
separated by SDS-PAGE and underwent Western blot with the stated antibodies for 
whole cell phosphorylation, and kinases  downstream of GPVI. (B) (i) Blots are 
representative of similar blots from four patients. (ii) Percentage tyrosine 
phosphorylation as compared to vehicle treated platelets as well as aggregation 
percentage was measured and is represented as the means ± SEM (n=4). (C - D). 
Dose response curves of platelets from patients with XLA treated with 
ibrutinib/acalabrutinib or vehicle. Equivalent dose response curves from healthy donor 
experiments are included as dotted lines for comparison. 
 
3.2.8.5 Platelets from patients with XLA have a normal sensitivity to 
blockade with acalabrutinib 
Because of the difference in the sensitivity to ibrutinib of platelets from healthy 
donors and platelets from patients with XLA further studies were done with 
acalabrutinib. Acalabrutinib was added in vitro to platelets taken from patients 
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with XLA. 
In stark contrast to the results when ibrutinib was used, the sensitivity of 
platelets from patients with XLA to the inhibitory effects of acalabrutinib was 
similar as for platelets from healthy donors (see Figure 3.21D and Table 3.2). 
 
3.2.8.6 Platelets from patients with XLA have normal spreading on 
collagen 
Platelet spreading experiments using blood from patients with XLA was also 
performed. As shown in Figure 3.18, platelets from patients with XLA have 
normal spreading and adhesion characteristics on immobilised collagen. The 
results from patients with XLA are identical to those from healthy donors. 
 
3.2.8.7 Platelets taken from patients with XLA have normal adhesion 
to collagen under flow conditions at arterial shear 
For a more physiological assessment of the effect of Btk inhibition on platelet 
function ex vivo, blood from patients with XLA was flowed over collagen at 
arterial shear. Blood from only two patients was sourced and so statistical 
analysis is inappropriate but, consistent with the results for in vitro Btk inhibition 
with low concentration ibrutinib, there appears to be no difference in overall 
platelet coverage or aggregate size between healthy donors and patients with 
XLA (Figure 3.19:Bii, D and F). 
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Ibrutinib containing figures Name of Curve IC50 (μM) 95% C.I. (μM) 
3.1 HD PRP Aggregation 25.14 16.79 — 39.48 
3.1 HD Aggregation 1.19 0.730 — 1.950 
3.3 HD Secretion 0.25 0.121 — 0.548 
3.3 HD Ca2+ Mobilisation 1.88 0.445 — 22.18 
3.4 WT Mouse Aggregation 2.804 1.503 — 5.663 
3.7 HD Btk pY223 0.023 0.14 — 0.036 
3.7 HD PLCɣ2 pY1217 0.035 0.19 — 0.065 
3.7 HD PLCɣ2 pY759 0.048 0.26 — 0.088 
3.7 HD PLCɣ2 pY753 0.055 0.29 — 0.105 
3.7 HD Syk pY525/6 - - 
3.7 HD LAT pY200 - - 
3.7 HD SLP76 pY145 - - 
3.7 HD Btk pY551 - - 
3.7 HD Src pY418 2.1 1.240 — 3.700 
3.3 HD Aggregation w/o indomethacin 2.489 1.340 — 50.16 
3.3 HD Aggregation with indomethacin 4.56 3.312 — 6.447 
3.9 WT Mouse Btk pY223 0.053 0.024 — 0.111 
3.9 WT Mouse PLCɣ2 pY1217 0.177 0.43 — 0.747 
3.9 WT Mouse PLCɣ2 pY759 0.164 0.27 — 1.663 
3.9 WT Mouse PLCɣ2 pY753 - - 
3.9 WT Mouse Syk pY525/6 - - 
3.9 WT Mouse LAT pY200 - - 
3.9 WT Mouse Btk pY551 - - 
3.9 WT Mouse Src pY418 0.349 0.20 — 7.109 
3.21 XLA Aggregation 0.086 0.37 — 0.212 
3.21 XLA Src pY418 1.24 0.667 — 2.311 
3.21 XLA LAT pY200 - - 
3.21 XLA PLCɣ2 pY753 0.069 0.35 — 0.208 
3.21 XLA PLCɣ2 pY759 0.033 0.10 — 0.104 
3.21 XLA PLCɣ2 pY1217 0.035 0.014 — 0.087 
Acalabrutinib containing figures 
3.11 HD Aggregation 21.25 12.27 — 37.11 
3.11 HD Secretion 6.37 3.706 — 11.02 
3.11 HD Ca2+ Mobilisation 5.317 2.843 — 10.15 
3.12 HD Btk pY223 0.308 0.177 — 0.549 
3.12 HD PLCɣ2 pY1217 0.88 0.393 — 2.070 
3.12 HD PLCɣ2 pY759 1.211 0.479 — 3.244 
3.12 HD PLCɣ2 pY753 2.75 1.200 — 6.590 
3.12 HD Syk pY525/6 - - 
3.12 HD LAT pY200 - - 
3.12 HD SLP76 pY145 - - 
3.12 HD Btk pY551 - - 
3.12 HD Src pY418 - - 
3.21 XLA Aggregation 8.918 4.425 — 18.86 
 
Table 3.2: IC50 values for all dose response curves for experiments involving 
stimulation with CRP and inhibition with ibrutinib and acalabrutinib 
Dose-response curves from all figures in Chapter 3 are summarised in this table. 
Confidence intervals are provided to better enable comparison between curves. 
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3.3 Discussion 
The headline results of this line of enquiry into the effect of Btk inhibitors on 
GPVI-mediated platelet function are: 
i) PLCɣ2 and subsequent platelet activation can still occur in the absence 
of PLCɣ2 phosphorylation as long as Btk is present. Analogous to what 
has been shown in B-cells, this also shows a non-kinase dependent, 
adapter role of Btk. 
ii) The inhibitory effect of Btk inhibitors on GPVI-mediated platelet function 
is mediated through non-Tec family kinase off-target effects but the exact 
identify of this off-target effect is unknown. 
 
3.3.1 Btk Adapter role and its phosphorylation of PLCɣ2  
These results show clearly that Ca2+ mobilisation and platelet activation can 
occur at ibrutinib and acalabrutinib concentrations where PLCɣ2 
phosphorylation is lost.  This is apparent on the whole cell phosphorylation blots 
in Figure 3.7Ai and Figure 3.12Ai where there is loss of phosphorylation at a 
band of ~140 kDa at 70 nM ibrutinib and 2 μM acalabrutinib respectively. This is 
also seen in the blots using phosphospecific antibodies. It is definitively shown 
at pY753 and pY759. It would probably also be the case for pY1197 but for the 
poor performance of this particular antibody in all but one of the experiments. 
Loss of phosphorylation at Y1217 is seen in almost all experiments at these low 
concentrations of Btk inhibitor but there is a trace of ongoing low level 
phosphorylation at this site at higher concentrations of Btk inhibitor in some 
experiments (see Figure 3.7Aii). It could be that the semi-quantitative method of 
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measuring the relative phosphorylation intensities was not sensitive enough to 
pick up this low level phosphorylation consistently or the apparent low level 
phosphorylation that is occasionally seen could merely represent a slight 
overexposure of the western blot membrane or low-level basal activation. The 
results of the XLA patient studies also support an adapter function for Btk in 
addition to its kinase role. They show definitively that, in the absence of Btk, 
PLCɣ2 phosphorylation at pY753 and pY1217 is required for platelet activation. 
Further work showing the adapter role was performed by collaborators and 
published recently (Nicolson et al. 2018). Here, Btk deficient DT40 cells (which 
also do not contain Tec) were transfected with GPVI and the FcRɣ chain along 
with WT or kinase dead (KD) Btk. Both forms of Btk were sufficient to restore 
Ca2+ mobilisation as measured by the nuclear factor of activated T-cells (NFAT) 
assay. 
These experiments do not give any mechanistic insight into how Btk can act as 
an adapter but there is pre-existing evidence of this being the case for Btk in B-
cells. KD Btk has been shown to reconstitute BCR signalling in Btk deficient 
DT40 cells (Tomlinson et al. 2001). The same has been shown in A20 B cells 
(Salto et al. 2003) This latter, and another, study showed that the process is 
probably mediated through Btk’s association with PIP5K and its production of 
PIP2, which acts as a substrate for PLCɣ2 to produce IP3 and DAG even when it 
is not activated through phosphorylation (Sekiya et al. 1999; Salto et al. 2003). 
These studies also give some more information in platelets about which 
tyrosines on PLCɣ2 are phosphorylated by Btk and which by Syk or other Tec 
family kinases. From the work with ibrutinib and acalabrutinib in human healthy 
donor or WT mouse platelets it appears that Btk is required for phosphorylation 
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of tyrosines in both the SH2-SH3 linker as well as in the C-terminal region. The 
work with XLA patients, however, clearly shows that these can be 
phosphorylated in the absence of Btk. In this instance it is likely that Tec (and 
not Syk) is responsible for the residual phosphorylation. This hypothesis is 
supported by the reversibility of high concentration ibrutinib’s inhibition of Syk 
activation but irreversibility of the PLCɣ2 phosphorylation seen in Figure 3.8 and 
also by Figure 3.12 where Syk activation is unaffected by high concentration 
acalabrutinib, but PLCɣ2 phosphorylation at all sites is lost. 
 
3.3.2 Off-target effects 
These results show definitively that both ibrutinib and acalabrutinib block GPVI-
mediated platelet function through non-Tec family kinase off-target effects and, 
in the case of ibrutinib, this occurs at pharmacologically achieved 
concentrations. Btk inhibition alone is insufficient to inhibit any assay used to 
assess platelet function downstream of GPVI except in aggregation when very 
low concentrations of agonist are used (1 μg/ml CRP). This is consistent with 
the already published studies involving XLA patients (Quek et al. 1998) and Btk 
deficient mice (Atkinson et al. 2003) and it explains why major bleeding is seen 
with ibrutinib but not with acalabrutinib (Shatzel et al. 2015). 
Some differences between these results and some previous studies need 
further explanation and elaboration however. Levade et al. found that the 
concentration of ibrutinib required to inhibit GPVI-mediated Btk pY223 in a flow 
cytometry assay (0.5 μM) was the same as the concentration that inhibited 
platelet aggregation. In the same series of experiments, however, using western 
blotting they also show loss of whole cell phosphorylation at this same 
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concentration (Levade et al. 2014) whereas the concentration required to block 
whole cell phosphorylation in the results above (Figure 3.7) is >10 fold higher 
than that required to block Btk pY223. This probably reflects the different 
assays used to assess Btk pY223. The only thing to add here is that the results 
seen using XLA patient platelets (Figure 3.21) show definitively that Btk is not 
required for GPVI-mediated platelet activation. Taken together, these results 
imply that the conclusions of Levade et al; that ibrutinib blocks GPVI-mediated 
platelet activation via its effects on Btk, are incorrect. Rigg et al, however, also 
show that one of their ibrutinib analogues blocks GPVI-mediated platelet 
activation at concentrations that do not inhibit Src pY418. The explanation for 
this is probably that they used a different assay to measure platelet activation 
(P-selectin expression as measured by flow cytometry). Experiments performed 
in Chapter 5 below also show that P-selectin expression is lost at lower levels of 
ibrutinib than those that inhibit aggregation downstream of GPVI (see Figure 
5.1). 
The concentration of agonist in in vitro studies of platelet function that 
represents a “physiological concentration” is a controversial topic. The closest in 
vitro assay to physiological conditions is the flow adhesion assay. It is likely that 
high agonist concentrations are closest to in vivo activation levels however, 
particularly given the difference in bleeding symptoms seen between GPVI 
deficient patients and those with XLA. In support of this, the flow adhesion 
assays showed no effect with Btk-specific concentrations of ibrutinib in vitro or 
with blood ex vivo from patients with XLA. There was a trend towards a 
difference in adhesion to collagen between the patients with CLL treated with 
ibrutinib and those with XLA (see Figure 3.19). Indeed, in a more recent study 
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Bye et al. reported thrombus instability on collagen in a flow adhesion assay in 
blood from patients treated with ibrutinib. This is consistent with the findings that 
Btk kinase function is not required for platelet adhesion to collagen under flow, 
but that off-target effects of ibrutinib occurring with higher concentrations 
mediate this inhibition (Bye et al. 2017). The reason for the studies performed 
here not detecting this thrombus instability in ibrutinib treated patients probably 
lies in the design of the assay. The studies from other groups that detected a 
thrombus instability in ibrutinib treated patients or blood treated in vitro with high 
concentrations of ibrutinib/ibrutinib analogue either used higher shear rates than 
used in these experiments (2200 s-1 vs 1000 s-1) and/or studied adhesion over a 
longer time period (5-10 mins vs 3 mins) (Rigg et al. 2016; Bye et al. 2015; Bye 
et al. 2017). The lack of effect on adhesion to collagen under flow could, 
however, be explained by the results of Busygina et al. They found the assay 
was dependent on GPIb and integrin α2β1 mediated adhesion rather than GPVI 
(Busygina et al. 2018). 
The experiments above show that this off-target effect of Btk inhibitors is not 
mediated through inhibition of Tec. Tec phosphorylation is seen to be lost in a 
biphasic way when platelets are inhibited with ibrutinib or acalabrutinib (Figure 
3.7Bii and 3.12Bii) and that this occurs at lower concentrations than those that 
cause blockade of GPVI-mediated platelet function. The other piece of evidence 
in support of a non-Tec kinase off-target effect is striking in both its clarity and 
simplicity; the blockade of GPVI-mediated platelet aggregation by ibrutinib is 
reversible but the corresponding inhibition of GPVI-mediated PLCɣ2 
phosphorylation is irreversible (Figure 3.5 and Figure 3.8). The only irreversible 
part of the platelet aggregation curve is the delay seen at concentrations which 
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just inhibit Btk pY223. 
The identity of the kinase targeted by this off-target action of the Btk inhibitors is 
not known. SFKs would seem a strong possibility because the inhibition of Src 
pY418 strongly correlates with loss of aggregation and, like aggregation, this 
inhibition of phosphorylation is reversible (The antibody raised against Src 
pY418 detects phosphorylation of the active site of Src, Lyn and Fyn). In 
support of this, Src pY418 inhibition is seen at the 1 μM ibrutinib (and ibrutinib 
analogue) concentration used by Bye et al. and Rigg et al. in their experiments 
where they see loss of platelet adhesion to collagen under flow (Bye et al. 2015; 
Rigg et al. 2016). What goes against this, however, is that ibrutinib treated 
patients have normal Src pY418 and that acalabrutinib does not inhibit Src 
pY418 but, like ibrutinib, still inhibits GPVI-mediated platelet aggregation at ~50-
fold higher concentrations than those which inhibit Btk pY223 (Table 3.2). It is 
possible, however that the ibrutinib treated patients did have inhibition of Src 
pY418 but that this effect was washed out during the process of isolating 
washed platelets. The same explanation could apply for why there was no effect 
seen in the spreading assays performed on the platelets isolataed from Btk 
inhibitor treated patients. Other tyrosine kinases, present in platelets, that have 
been shown to be inhibited by ibrutinib (with no data published on acalabrutinib) 
include Csk. This would seem an unlikely kinase for causing blockade of 
aggregation when inhibited, however, as it is a negative regulator of SFK 
phosphorylation. 
These results show that, despite acalabrutinib’s more favourable selectivity to 
Btk over other Src, Syk and Tec kinases in in vitro kinase assays, the window 
between Btk inhibition and blockade of GPVI-induced aggregation in vitro is 
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similar to that of ibrutinib. Despite this, acalabrutinib, but not ibrutinib, fails to 
block GPVI-mediated platelet activation ex vivo. It is likely that this is because of 
the differential dosing and pharmacodynamics of the two Btk inhibitors. 
Acalabrutinib is used at a dose of 1.5 mg/kg twice daily (Byrd et al. 2016; Barf et 
al. 2017) and ibrutinib at a single daily dose of 6 mg/kg in CLL or 8 mg/kg in 
MCL. Pharmacokinetic studies have shown that ibrutinib achieves Btk 
occupancy of >95% at doses of 2.5 mg/kg but that doses of 6 mg/kg are 
required to maintain this over 24 hours (Advani et al. 2012). Acalabrutinib at 1.5 
mg/kg twice daily also achieves full Btk occupancy over 24 hours (Byrd et al. 
2016). The peak unbound plasma concentration of ibrutinib in patients is 0.5 μM 
(Levade et al. 2014) and that of acalabrutinib 1.3 μM (Byrd et al. 2016). The 
half-life of ibrutinib is 4-8 hours (Advani et al. 2012). The half-life of acalabrutinib 
is 1 hour (Byrd et al. 2016). Despite the peak concentration of acalabrutinib 
being approximately 2-fold higher than the concentration of ibrutinib, the 5-fold 
lower potency of acalabrutinib as an inhibitor of Btk (Barf et al. 2017) means 
that, in potency terms, it is dosed at a lower level consistent with the lack of 
inhibition of GPVI. This implies that ibrutinib could be used at a lower 
concentration to achieve Btk blockade. Indeed, there is retrospective clinical 
evidence that doses less than 6 mg/kg are as effective as 6 mg/kg at treating 
CLL (Banerjee et al. 2016) and a prospective clinical trial using doses as low as 
2.5 mg/kg has just been reported showing adequate Btk inhibition (Bose et al. 
2016; Chen et al. 2018).  
During the writing of this thesis, Bye et al. reported complete blockade of 
platelet aggregation to high concentrations of collagen in patients receiving 
ibrutinib or acalabrutinib (Bye et al. 2017), in contrast to the findings of the 
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above experiments. Bye et al. used the Optimul 96 well microtitre assay to 
measure aggregation rather than the widely used light transmission 
aggregometry (LTA). It has been shown that Optimul is a more sensitive assay 
than LTA (Lordkipanidzé et al. 2014; M. Chan et al. 2018). It is probable that the 
delay in onset of aggregation observed using LTA by concentrations of ibrutinib 
or acalabrutinib that just block Btk manifest as complete blockade in the Optimul 
assay.  
The results of this work explain the lack of major bleeding side effects 
experienced by patients taking acalabrutinib relative to ibrutinib and suggest 
that the major bleeding side effect of ibrutinib can potentially be abolished by 
reducing the dose. Further, this study also shows that the bleeding caused by 
ibrutinib is not due to an irreversible action. This predicts that the GPVI 
blockade wears off over a period of 24 hours as the drug is cleared (Advani et 
al. 2012). Logically therefore, in the event of a major bleed, there may be no 
need to use expensive and potentially harmful platelet transfusions to correct 
the signalling deficit. Each clinical scenario should be judged on its own merits, 
however, and individual clinician discretion is crucial.  
 
In conclusion; the present study shows that inhibition of Btk kinase activity 
causes only partial inhibition of GPVI signalling in platelets and provides 
evidence that Btk supports GPVI signalling by functioning as an adapter protein 
as well as a kinase. The excessive bleeding induced by ibrutinib relative to 
acalabrutinib is likely to reflect a non-Tec family kinase off-target inhibitory effect 
of ibrutinib, possibly on SFKs. 
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CHAPTER 4: THE EFFECT OF 




In the late 1990’s and early 2000’s when platelet studies using XLA patients and 
Btk/Tec knockout mice were being performed, platelet CLEC-2 had not been 
identified and thus platelets from these sources have not yet been used to study 
Btk’s role in CLEC-2 mediated platelet function. It is only since the introduction 
of the Btk inhibitors that ibrutinib has been used as a tool to try and elucidate 
the function of Btk downstream of platelet CLEC-2. Even so, there is very little 
existing literature on this topic. In fact there are only two papers, one by Manne 
et al. and one by Lee et al (Manne et al. 2015; Lee et al. 2017). The latter only 
having a single relevant experiment. What follows will describe the findings of 
these studies as far as is relevant to Btk and CLEC-2 and highlight what is still 
unknown. 
 
4.1.1 The current understanding of the role of Btk in CLEC-2 
mediated platelet function 
 In the study by Manne et al. it is shown that ibrutinib completely blocks CLEC-2 
mediated aggregation in human and mouse platelets at very low concentrations 
(10 nM). They also demonstrate the same thing for granule secretion in human 
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platelets (Manne et al. 2015). These concentrations are much lower than those 
required to block any aspect of GPVI-mediated platelet function in any 
published study. This contrasts directly with results from Lee et al. where 500-
fold higher concentrations of ibrutinib (5 μM) were required to block CLEC-2 
mediated mouse platelet aggregation (Lee et al. 2017). The nature of the 
agonist or its concentration could perhaps explain this difference; Manne et al. 
used very low concentrations of rhodocytin for their mouse studies (10 nM) and 
a wide range for their human studies (30 - 300 nM) whereas Lee et al. used a 
single concentration of podoplanin-Fc (2 μg/ml) for their experiments. 
In contrast to their results with ibrutinib, Manne et al. show that XID mouse 
platelets (i.e. those lacking the PH-domain of Btk) still have some residual 
aggregation in response to CLEC-2 ligation with low concentrations of agonist. 
Even more interestingly, they show that addition of 5 nM ibrutinib completely 
blocks this response (Manne et al. 2015). However, they do not explicitly state 
that this shows an off-target effect of ibrutinib, even at this very low 
concentration. 
 
CLEC-2 mediated signalling events in ibrutinib treated platelets have only been 
studied by Manne et al. They show in human and mouse platelets that low 
concentration ibrutinib is sufficient, downstream of CLEC-2, not only to block 
Btk Y223 and downstream PLCɣ2 phosphorylation (as is the case for GPVI-
mediated signalling events) but also to inhibit “upstream” signalling events such 
as Syk autophosphorylation such as is only seen at very high concentrations of 
ibrutinib downstream of GPVI. From this they deduce that Btk lies upstream of 
Syk when activated by CLEC-2 ligation (see Figure 1.4). 
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A potential confounder for these results, not considered in their manuscript by 
Manne et al. is CLEC-2’s reliance on secondary mediator feedback for full 
activation to occur. It was shown by Pollitt et al. that CLEC-2 signalling, unlike 
GPVI, is critically dependent on secondary mediator feedback via ADP and 
TxA2 (Pollitt et al. 2010). The platelet preparation method used by Manne et al. 
down-regulates the P2Y1 receptor, thus removing part of this secondary 
feedback.  
Further evidence of ibrutinib’s off-target effects against Tec can be deduced 
from the in vivo experiments performed by Manne et al. using Btk and Tec 
knockout mice. They show that Btk/Tec double knockout mouse embryos, but 
not mice deficient only in Btk or Tec, have evidence of blood lymphatic mixing 
analogous to that seen in CLEC-2 deficient mice (Manne et al. 2015). Therefore 
function of both Btk and Tec has to be blocked before platelet function 
downstream of CLEC-2 is affected. 
 
4.1.2 What this study adds 
Given that CLEC-2 is a potentially attractive drug target for thrombosis because 
of its critical role in venous thrombosis but lack of contribution to haemostasis, 
and the Manne et al. paper shows that very low concentrations of ibrutinib are 
required to inhibit CLEC-2 it seems plausible that Btk inhibition may be a way of 
selectively targeting platelet CLEC-2 function therapeutically. 
The aim of this set of experiments therefore is to clarify the difference seen 
between the results of the Lee et al. and Manne et al. studies as regards 
ibrutinib dosing and to explore the underlying mechanism behind ibrutinib’s 
apparent low concentration inhibition of CLEC-2 signalling. They will focus on 
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how this differs from its effects on GPVI function which mediate bleeding, with 
particular attention paid to the novel model of signalling events downstream of 
CLEC-2 as described by Manne et al. In doing so the feasibility of Btk inhibition 
as a surrogate way of blocking platelet CLEC-2 function will be evaluated for 
taking forward to more translational studies. 
 
4.2 Results 
4.2.1 Btk inhibition blocks CLEC-2 mediated 
platelet function 
4.2.1.1 Ibrutinib inhibits CLEC-2 mediated platelet aggregation in 
PRP 
GPVI and CLEC-2 share many similar features within their signalling cascades. 
Initial studies were performed to see if the concentration-response for inhibition 
of CLEC-2 function by ibrutinib was similar to that against GPVI. 
The agonist concentration that most closely matches the level of physiological 
CLEC-2 stimulus is not known. But because of the possibility that these 
experiments might comprise part of the justification for a new anti-thrombotic 
indication for Btk inhibitors and in order to match the experiments that had been 
performed looking at GPVI, maximal concentrations of CLEC-2 agonist were 
used. Unlike for the experiments investigating GPVI signalling, no agonist dose 
finding studies were performed. The concentration of 300 nM rhodocytin was 
chosen for all in vitro CLEC-2 assays as this is known to be a maximal 
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concentration in vitro (Parguina et al. 2012). 
Firstly, ibrutinib was added to healthy human donor PRP prior to performing 
LTA. The inhibitory effects are shown in Figure 4.1Ai and B and the IC50 of this 
and each subsequent dose response curve in this chapter are shown in Table 
4.1. Blockade of aggregation was achieved at 7 μM. This is a high concentration 
but of note it is 10-fold lower than the concentration required to block 
aggregation in PRP stimulated with CRP 10 μg/ml. 
 
4.2.1.2 Ibrutinib inhibits CLEC-2 mediated platelet aggregation in 
washed platelets 
Similar experiments were performed in washed platelets. Results are shown in 
Figure 4.1Aii and B with IC50 values shown in Table 4.1. As for the results for 
GPVI stimulated platelets, removal of plasma proteins resulted in ~100-fold 
increase in potency with complete inhibition at 70 nM. Strikingly however, and 
different to the results with GPVI stimulation, complete inhibition of CLEC-2 
mediated aggregation was seen at 10-fold lower concentrations of ibrutinib than 
are required to block GPVI-mediated aggregation. This is in line with the results 
of Manne et al (Manne et al. 2015). The IC50 for this assay was similar to that 
for blockade of Btk pY223 in GPVI stimulated platelets; namely 23 nM. 
 
4.2.1.3 Ibrutinib inhibits CLEC-2 mediated platelet granule release 
Functional studies were extended to include the measurement of ATP release 
from CLEC-2 stimulated platelets. As for LTA, platelets were inhibited with 
increasing concentrations of ibrutinib. These experiments were performed by a 
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medical student (Josh Hinds) undergoing an intercalated BMedSci degree who 
was under working under supervision as part of this project. The results, shown 
in Figure 4.1Aiii and B and Table 4.1, show that ibrutinib inhibits CLEC-2 




Figure 4.1: Ibrutinib dose-dependently inhibits CLEC-2 mediated platelet 
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aggregation, granule release and Ca2+ mobilisation. 
(A) (i) PRP and (ii, iii) washed platelets at 4x108/ml isolated from healthy donors were 
stimulated with rhodocytin 300 nM after incubation with ibrutinib or vehicle at the stated 
concentrations for 5 minutes. LTA and granule release measurements were then 
undertaken for 5 and 3 minutes respectively. Representative traces of three identical 
aggregation (i, ii) and granule secretion experiments (iii). (B) Dose response curves 
(n=3) for Ai-iii. (C) Human ADP-sensitive (i, iii) and WT mouse (ii) washed platelets at 
4x108/ml were incubated with vehicle or ibrutinib for 5 minutes prior to stimulation with 
rhodocytin 300 nM for 3 minutes. Representative trace of (i, ii) LTA and (iii) Ca2+ 
mobilisation from 3 identical experiments. (D) Dose response curves (n=3) for Ci-iii. All 
results are shown as mean ± SEM. 
 
4.2.1.4 Ibrutinib inhibits CLEC-2 mediated Ca2+ mobilisation and 
platelet aggregation in ADP-sensitive platelets with a lower potency 
than it inhibits aggregation in standard platelets 
Further functional studies were performed using ibrutinib to inhibit CLEC-2 
mediated Ca2+ mobilisation. As previously mentioned, the method of platelet 
preparation for the Ca2+ mobilisation assay differs from the standard method as 
it needs lower centrifugation speeds and does not require the addition PGI2. 
This protocol produces platelets which are ADP sensitive as opposed to 
standard methodology which down-regulates the P2Y1 receptor and renders 
platelets ADP insensitive (Koessler et al. 2016). Experiments attempting to use 
platelets prepared using standard methods in the Ca2+ mobilisation assay were 
unsuccessful. 
The results, shown in Figure 4.1Ciii and D and Table 4.1 show that ibrutinib is 
less potent at inhibiting Ca2+ mobilisation under these conditions than it is at 
inhibiting CLEC-2 mediated aggregation in washed platelets produced by 
standard methods. To see if the reason for this discrepancy was because of the 
different method of platelet preparation ibrutinib was also used to inhibit platelet 
aggregation as measured by LTA. The results of this experiment (Figure 4.1Ci 
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and D and Table 4.1) show ibrutinib has a similar potency for inhibition of 
CLEC-2 mediated platelet aggregation as for Ca2+ mobilisation in ADP-sensitive 
platelets. 
 
4.2.1.5 WT mouse platelets are less sensitive to blockade of CLEC-2 
mediated platelet aggregation by ibrutinib than human platelets, 
regardless of preparation method 
The function of CLEC-2 on mouse platelets is better understood than in human 
platelets and so, because future experiments were planned to use 
pharmacological Btk inhibition in in vivo mouse thrombosis assays, it was 
necessary to test whether ibrutinib blocked CLEC-2 function in mouse platelets 
as in human platelets. 
Ibrutinib was added to WT mouse washed platelets in vitro in exactly the same 
conditions as for human washed platelets. Results are shown in Figure 4.1Cii 
and D and Table 4.1. Surprisingly, the concentration of ibrutinib required to 
inhibit CLEC-2 mediated mouse platelet aggregation was over 500-fold higher 
than for human platelets. Consistent with the studies of Lee et al. this 
concentration was modestly higher than that required to inhibit GPVI-mediated 
mouse platelet aggregation (Lee et al. 2017). 
 
4.2.1.6 Platelets taken from patients on ibrutinib and acalabrutinib 
have inhibited CLEC-2 mediated platelet aggregation 
In order to see if the in vitro effects of ibrutinib on CLEC-2 function were 
applicable at physiological concentrations blood was taken patients with CLL 
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who were being treated with ibrutinib, acalabrutinib or the non-Btk inhibitor 
containing treatment regime FCR. PRP was isolated from blood samples taken 
prior to starting treatment and then at various time points during their treatment. 
Similar to the results from experiments examining GPVI-mediated platelet 
function, platelets from patients with CLL prior to starting any treatment showed 
absent or reduced/delayed CLEC-2 mediated platelet aggregation (Figure 4.2A, 
Bii-iii). This inhibition, however, was much more marked than that seen with 
GPVI-mediated platelet aggregation shown in Figure 3.15. Data in Figure 3.15 
and previous studies show that a high WCC in patients with CLL is associated 
with impaired ADP mediated platelet aggregation (Lipsky et al. 2015; Glenn et 
al. 2009). 
Figure 4.2Ai shows that as the WCC reduces, CLEC-2 mediated platelet 
responses are restored for patients treated with the non-Btk containing 
chemotherapy regimen FCR. This is consistent with the restoration of ADP 
mediated platelet function as seen in Figure 3.15 and previous studies showing 
that ADP is an essential secondary mediator in platelet activation secondary to 
CLEC-2 ligation (Pollitt et al. 2010).This restoration of CLEC-2 mediated platelet 
aggregation does not occur in patients treated with ibrutinib (Figure 4.2Aii). It is 
clear that a high WCC is a potential confounder, thus, once this was realised all 
further platelet function analysis was performed in patients with a WCC in the 
normal range (ie once the initial lymphocytosis, known to be associated with Btk 
inhibitor treatment had resolved (Rossi & Gaidano 2014)). All the subsequent 
results, with the exception of 4 patients taking ibrutinib, are shown on patients 
with a WCC in the normal range of < 11 x109/l.  
Once this initial confounder had been identified, studies were extended to 
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include more patients on different treatment regimens and also to study the 
effects of Btk inhibitor treatment on aggregation in response to different 
concentrations of the CLEC-2 agonist rhodocytin. 
Regardless of the concentration of rhodocytin, CLEC-2 mediated platelet 
aggregation was completely blocked in all patients receiving Btk inhibitor 
treatment and in none of the patients receiving the control chemotherapy 
(Figure 4.2B). 
 
Figure 4.2: CLL patients on Btk inhibitors have complete blockade of CLEC-2 
mediated platelet aggregation. 
PRP was isolated from the blood of patients with CLL immediately prior to and 
following treatment with FCR, ibrutinib or acalabrutinib based chemotherapy regimens. 
(A) Representative traces of 3 similar experiments showing PRP from patients at 
different time points in their treatment with (i) FCR or (ii) ibrutinib following stimulation 
with rhodocytin 300 nM and optical density measurement over 5 minutes. WCCs 
(x109/l, normal range: 4-11) are shown for each trace. (B) Mean ± SEM (Pre-treatment 
n=9, post-FCR n=5, post-ibrutinib n=12, post-acalabrutinib n=3) of optical density 5 
minutes after stimulation with (i) rhodocytin 10 - 100 nM or (ii) 300 nM. (iii) 
Representative trace. Statistical analysis was performed with a 2-way ANOVA with 
Tukey’s correction for multiple comparisons. (C) Mean ± SEM (healthy donor n=6, XLA 
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n=4) of optical density 5 minutes after stimulation with (i) rhodocytin 10 - 100 nM or (ii) 
300 nM. (iii) Representative trace. Statistical analysis was performed with a two-tailed 
t-test. *P<0.05, ns = non-significant. 
 
4.2.1.7 Platelets from patients with XLA have inhibited CLEC-2 
mediated platelet aggregation 
To enable the study of the effect of Btk inhibition on CLEC-2 mediated platelet 
function without any off-target effects on Tec that might be occurring (shown by 
the ibrutinib treated XID mouse studies by Manne et al. (Manne et al. 2015) and 
the results from Chapter 3 looking at the additional effect of low concentration 
ibrutinib on GPVI-mediated platelet function in XLA patients), PRP from patients 
with XLA was also used. Analogous to the results from patients taking Btk 
inhibitors, PRP from patients with XLA also failed to aggregate in response to 
low, medium or high concentrations of rhodocytin (Figure 4.2C). 
 
4.2.2 The inhibition of CLEC-2 mediated platelet 
function with ibrutinib is irreversible 
Because of the similar IC50 for ibrutinib’s inhibition of CLEC-2 mediated platelet 
activation in human washed platelets and its blockade of Btk pY223 
downstream of GPVI, it may be that CLEC-2 induced platelet function may be 
critically dependent on Btk’s kinase activity. A further piece of evidence towards 
this would be if, like ibrutinib’s actions on Btk, its inhibition of CLEC-2 mediated 




4.2.2.1 Ibrutinib induced blockade of CLEC-2 mediated platelet 
function is time-dependent 
The first indication that an interaction is irreversible is if it is time-dependent. 
Thus human washed platelets were incubated with several concentrations of 
ibrutinib for increasing time periods from 30 seconds up to 60 minutes before 
being stimulated with rhodocytin. Again, this time-dependent assay was 
performed, under supervision, as part of a BMedSci degree by Josh Hinds. 
Light transmission aggregometry and granule secretion were then measured 
and results are shown in Figure 4.3A and B as well as Table 4.1. The IC50 
values for the 30 second and 5 minute incubation dose response curves could 
not be calculated. Despite this it is clear from these results that the effect of 




Figure 4.3: Ibrutinib’s blockade of CLEC-2 mediated platelet function is both 
time-dependent and irreversible. 
Human healthy donor washed platelets at 4x108/ml were incubated with ibrutinib or 
vehicle for 30 seconds - 60 minutes before being stimulated with rhodocytin 300 nM for 
5 minutes. (A) Representative aggregation traces from one of the five identical 
experiments. (B) Mean data ± SEM showing the effect of ibrutinib incubation time on 
CLEC-2 mediated platelet (i) aggregation and (ii) granule secretion. (C) Healthy donor 
human washed platelets at 4x108/ml were incubated with ibrutinib or vehicle for 5 
minutes before being stimulated with rhodocytin 300 nM (i). Alongside, washed 
platelets at 4 x108/ml, treated identically with either ibrutinib or vehicle, were washed 
twice in modified-Tyrode’s-HEPES buffer and resuspended to 4x108/ml. Platelets were 
then stimulated with rhodocytin 300 nM (ii). Traces are representative of three identical 
experiments (D) Mean data (n=3) analysed with one-way ANOVA and shown as mean 
± SEM.Results shown are  mean ± SEM and were analysed with one-way ANOVA. ns 
= non-significant. 
 
4.2.2.2 Ibrutinib induced blockade of CLEC-2 mediated platelet 
function is irreversible 
In an identical way to the experiments performed while investigating the effect 
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of ibrutinib on GPVI-mediated platelet function; after incubation with the drug or 
vehicle platelets were either stimulated with rhodocytin or washed twice in 
modified-Tyrode’s HEPES buffer to see if the inhibitory effect of ibrutinib could 
be washed out. The results seen in Figure 4.3 clearly show that the inhibitory 
effect of ibrutinib on CLEC-2 mediated platelet aggregation is irreversible. This 
result contrasts markedly with the result from the same experiment involving 
GPVI-mediated platelet aggregation. 
 
4.2.3 Ibrutinib inhibits phosphorylation events 
downstream of the CLEC-2 receptor 
The concentration at which ibrutinib inhibits CLEC-2 mediated platelet function 
in human washed platelets is identical to that which inhibits Btk Y223 
phosphorylation downstream of GPVI activation. This raises the possibility that, 
unlike GPVI-mediated platelet function, CLEC-2 might be critically dependent 
on Btk kinase function. To study this further experiments were carried out to 
look at tyrosine phosphorylation events downstream of the CLEC-2 receptor 
and how these were affected by ibrutinib. 
 
4.2.3.1 Whole cell phosphorylation levels plateau and do not reduce 
following stimulation with rhodocytin for up to 5 minutes 
There are reports showing that phosphorylation events downstream of the 
multiple platelet receptors are time-dependent (Kralisz & Cierniewski 1998; 
Mazet et al. 2015; Gibbins et al. 1996). To ensure no phosphorylation events 
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were missed due to lysing activated platelets too long after addition of agonist 
pan-tyrosine phosphorylation downstream of the CLEC-2 receptor were 
measured at different time points following ligation of the receptor with 
rhodocytin 300 nM. Time points up to 300 seconds were sampled and it was 
found that, in the presence of eptifibatide, phosphorylation levels reached a 
maximum at 90 seconds with no reduction visible up to 300 seconds (see 
Figure 4.4A). 
 
4.2.3.2 Ibrutinib inhibits autophosphorylation of Btk Y223, PLCɣ2, 
Syk and Btk Y551 phosphorylation with the same potency as it 
inhibits aggregation 
CLEC-2 signalling utilises the same protein kinase signalling architecture as 
GPVI and so the experiment performed to examine the effects of ibrutinib on 
tyrosine phosphorylation events downstream of CLEC-2 utilised the same 
methods and antibodies as seen in Chapter 3 in Figure 3.7. The only 
differences being that, despite robust phosphorylation seen at these sites 
downstream of GPVI, blots for PLCɣ2 pY753 (not shown) and pY759 (see 
Figure 4.4Bi) did not detect any phosphorylation and so these have not been 
quantified. 
Despite the similar signalling architecture, the effect of ibrutinib on CLEC-2 
mediated tyrosine phosphorylation was markedly different to that seen on the 
phosphorylation events downstream of GPVI (see Figure 4.4B). All 
phosphorylation events studied, except Src pY418, showed complete loss of 
phosphorylation at 70 nM ibrutinib with virtually identical IC50s to the inhibition of 
CLEC-2 mediated platelet aggregation and granule secretion as well as GPVI-
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mediated Btk Y223 phosphorylation (see Table 4.1). Manne et al. had similar 
findings (but notably did not study Btk pY551) and concluded that, downstream 
of CLEC-2, Btk must lie upstream of Syk (Manne et al. 2015). Of note, Btk 
pY223 was far weaker in all the rhodocytin stimulated samples than in those 
stimulated by CRP. Attempts to examine Tec phosphorylation by 
immunoprecipitation were unsuccessful. 
The finding that Btk pY551 is lost downstream of CLEC-2 in platelets treated 
with low concentration ibrutinib suggests that the Manne et al. model of Btk 
lying upstream of Syk, but downstream of SFKs may not be correct, as, if this 
were the case, it would be predicted to be phosphorylated even in the presence 




Figure 4.4: Ibrutinib irreversibly inhibits multiple tyrosine phosphorylation 
events downstream of the CLEC-2 receptor on human platelets. 
Healthy donor washed human platelets at 4x108/ml in the presence of eptifibatide 9 μM 
were incubated with ibrutinib or vehicle for 5 minutes prior to stimulation with rhodocytin 
300 nM. Platelets were then lysed with 5X reducing sample buffer 5 minutes after 
addition of agonist unless otherwise stated. Whole cell lysates were then separated by 
SDS-PAGE and Western blots were probed for whole cell phosphorylation or kinase 
phosphorylation with the stated antibodies downstream of the platelet CLEC-2 
receptor. (A) Blot from single experiment with addition of sample buffer at stated time 
points. (B) Representative blot from 4 identical experiments (i). Mean ± SEM of 4 
identical experiments for phosphorylation events downstream (ii) and upstream (iii) of 
Btk pY223 as well as Src pY418 (iv). (C) Before lysis, platelets were either washed 
twice in modified-Tyrode’s-HEPES buffer or not. Representative blots (i) and 
quantification of phosphorylation shown as Mean ± SEM of 3 identical experiments (ii) 
are shown. Results were analysed statistically using a paired two-tailed t-test *P<0.05, 





Figure 4.5: Schematic representation of predicted and actual pattern of inhibition 
of CLEC-2 mediated tyrosine phosphorylation in the presence of ibrutinib. 
Left panel depicts predicted phosphorylation results downstream of CLEC-2 in the 
absence and presence of 70 nM ibrutinib based on Manne et al. model of Btk lying 
upstream of Syk but downstream of SFKs. Right panel depicts actual phosphorylation 
results in the same conditions. 
 
4.2.3.3 Ibrutinib’s inhibition of phosphorylation events downstream 
of the CLEC-2 receptor is irreversible 
As ibrutinib’s inhibition of CLEC-2 mediated platelet function is irreversible, it is 
important to study whether this irreversibility extends to its inhibition of tyrosine 
phosphorylation events. To this end platelets treated with ibrutinib and were 
either stimulated with rhodocytin or washed twice with modified-Tyrode’s-
HEPES buffer before being stimulated, with subsequent lysis being performed 5 
minutes afterwards. 
Like the findings for phosphorylation events downstream of GPVI, results shown 
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in Figure 4.4 indicate that ibrutinib’s effects on Btk pY223 and PLCɣ2 
phosphorylation downstream of CLEC-2 are also irreversible. Unlike the GPVI 
results however, they also show that its inhibition of global phosphorylation or 
that which is upstream of Btk pY223 is also not reversible. The apparent 
irreversibility of the upstream signalling events need some further qualification 
however. Phosphorylation of Syk Y525/6 was clearly irreversible in all 
experiments. That for Src Y418, LAT Y200 and Btk Y551 appeared irreversible 
in some blots, and reversible in others, hence the wide error bars seen at these 
phosphorylation sites in Figure 4.4Cii. It is possible that these phosphorylation 
events are reversible but that the western blotting technique used was not 
sensitive enough to detect it in all instances. 
 
4.2.3.4 Ibrutinib’s inhibition of tyrosine phosphorylation downstream 
of mouse CLEC-2 mimics human and mouse GPVI but not human 
CLEC-2. The use of human ADP-sensitive platelets corrects this 
difference 
The use of human ADP-sensitive washed platelets rather than conventionally 
prepared washed platelets in the above functional assays increased the 
concentration of ibrutinib required to block CLEC-2 mediated platelet function by 
10-fold. To investigate the effect that this method of platelet preparation has on 
ibrutinib’s inhibition on tyrosine phosphorylation; biochemical studies were 
performed to examine whole cell tyrosine phosphorylation as well as that on 
specific tyrosine residues of kinases and proteins downstream of CLEC-2. 
The results are shown in Figure 4.6 and Table 4.1. Strikingly, there is no longer 
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loss of whole cell phosphorylation at 70 nM ibrutinib as is seen in conventionally 
prepared platelets, but there is partial loss of whole cell phosphorylation at 700 
nM. The loss of Btk Y223 and downstream PLCɣ2 phosphorylation mirrors that 
of inhibition of platelet aggregation with similar IC50s for all these dose response 
curves. Unlike in conventionally prepared platelets, however, phosphorylation 
events upstream of Btk pY223 were not blocked by 70 nM ibrutinib but, in fact, 
were unaffected by all but the highest concentrations of ibrutinib (7 μM). This 
pattern of phosphorylation inhibition mirrored that which was seen when 
examining the effects of ibrutinib on phosphorylation events downstream of the 
GPVI receptor. 
Although the results from Figure 4.4B using conventionally prepared platelets 
are similar to Manne et al., the findings using ADP-sensitive platelets contrast 
significantly with their study and confirm that Btk does not lie upstream of Syk in 
the CLEC-2 signalling cascade as it does downstream of GPVI. 
WT mouse platelets were much less sensitive to ibrutinib’s inhibition of CLEC-2 
mediated platelet aggregation than human platelets. To investigate whether this 
was merely to do with a reduced potency of inhibition of Btk or whether there 
was another explanation, similar biochemistry studies were performed in mouse 
platelets. 
The results are shown in Figure 4.6B. Similar to results using ibrutinib to inhibit 
GPVI-mediated phosphorylation events in human and mouse platelets and its 
inhibition of CLEC-2-mediated phosphorylation, Btk Y223 and downstream 
PLCɣ2 phosphorylation were blocked by low concentrations of ibrutinib (IC50 65 
– 122 nM). Upstream phosphorylation events, with the exception of Src pY418, 
were unaffected by even very high concentrations of ibrutinib. 
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Both of these sets of results are consistent with the known reliance of human 
CLEC-2, but not mouse CLEC-2, on secondary mediator feedback for robust 





Figure 4.6: Ibrutinib dose-dependently inhibits platelet aggregation and tyrosine 
phosphorylation in ADP-sensitive human washed platelets and WT mouse 
platelets at higher concentrations than are required to inhibit conventionally 
prepared human washed platelets. 
Eptifibatide (9 μM) treated healthy human donor washed platelets at 4x108/ml that had 
been prepared with a method to retain their sensitivity to ADP stimulation (A) and WT 
mouse washed platelets at 4x108/ml (B) were incubated with ibrutinib or vehicle for 5 
minutes before being stimulated with rhodocytin 300 nM. Platelets were then lysed with 
5X reducing sample buffer 5 minutes after addition of agonist. Whole cell lysates were 
then separated by SDS-PAGE and Western blots were probed for whole cell 
phosphorylation or kinase phosphorylation with the stated antibodies downstream of 
the platelet CLEC-2 receptor. (i) Representative blots and (ii-iv) mean ± SEM of three 
identical experiments examining the tyrosine phosphorylation levels of the proteins 
shown.  
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Figure Name of Curve IC50 (μM) 95% C.I. 
4.1 HD PRP Aggregation 5.417 2.869 — 11.32 
4.1 HD Aggregation 0.023 0.009 — 0.053 
4.1 HD Secretion 0.072 0.043 — 0.124 
4.1 HD Ca2+ Mobilisation 1.016 0.399 — 4.582 
4.1 HD Aggregation (ADP-sensitive)  0.282 0.080 — 1.428 
4.1 WT Mouse WP Aggregation 13.28 4.650 — 129.2 
4.3 Aggregation. 30 seconds Ibru - - 
4.3 Aggregation. 5 minutes Ibru - - 
4.3 Aggregation. 30 minutes Ibru  0.086 0.027 — 0.578 
4.3 Aggregation. 60 minutes Ibru 0.038 0.007 — 0.153 
4.3 Secretion. 30 seconds Ibru - - 
4.3 Secretion. 5 minutes Ibru - - 
4.3 Secretion. 30 minutes Ibru 0.072 0.026 — 0.257 
4.3 Secretion. 60 minutes Ibru 0.016 0.001 — 0.044 
4.4 HD Btk pY223 0.024 0.002 — 0.133 
4.4 HD PLCɣ2 pY1217 0.034 0.010 — 0.119 
4.4 HD Syk pY525/6 0.052 0.020 — 0.150 
4.4 HD LAT pY200 0.036 0.028 — 0.189 
4.4 HD SLP76 pY145 0.032 0.015 — 0.066 
4.4 HD Btk pY551 0.059 0.023 — 0.179 
4.4 HD Src pY418 - - 
4.6 HD Btk pY223 (ADP-sensitive) 0.142 0.029 — 1.301 
4.6 HD PLCɣ2 pY753 (ADP-sensitive) 0.024 0.005 — 0.093 
4.6 HD PLCɣ2 pY759 (ADP-sensitive) - - 
4.6 HD PLCɣ2 pY1217 (ADP-sensitive) 0.1149 0.032 — 0.421 
4.6 HD Syk pY525/6 (ADP-sensitive) - - 
4.6 HD LAT pY200 (ADP-sensitive) - - 
4.6 HD Btk pY551 (ADP-sensitive) - - 
4.6 HD Src pY418 (ADP-sensitive) - - 
4.6 WT Mouse Btk pY223 0.076 0.011 — 0.559 
4.6 WT Mouse PLCɣ2 pY753 0.074 0.026 — 0.200 
4.6 WT Mouse PLCɣ2 pY759 0.065 0.017 — 0.232 
4.6 WT Mouse PLCɣ2 pY1217 0.122 0.044 — 0.363 
4.6 WT Mouse Syk pY525/6 - - 
4.6 WT Mouse LAT pY132 - - 
4.6 WT Mouse LAT pY200 - - 
4.6 WT Mouse Btk pY551 - - 
4.6 WT Mouse Src pY418 0.35 0.126 — 1.036 
 
Table 4.1: IC50 values for all dose response curves for experiments involving 
stimulation with rhodocytin and inhibition with ibrutinib 
Dose-response curves from all figures in Chapter 4 are summarised in this table. 




4.2.3.5 Platelets taken from patients on ibrutinib have inhibited 
tyrosine kinase phosphorylation 
In order to ascertain whether the in vitro observations occurred at 
concentrations of drug achieved in vivo, samples taken from patients with CLL 
were also examined to look at the effects of Btk inhibition on tyrosine 
phosphorylation downstream of CLEC-2 ex vivo. Consistent with the in vitro 
results where low concentrations of ibrutinib caused loss of tyrosine 
phosphorylation both up- and downstream of Btk pY223; patients on ibrutinib 
and the more Btk-specific acalabrutinib had a similar pattern of loss of 
phosphorylation (see Figure 4.7). 
 
Figure 4.7: Patients treated with Btk inhibitors have globally reduced 
phosphorylation downstream of CLEC-2. 
Eptifibatide (9 μM) treated washed platelets at 4×108/ml from patients with CLL treated 
with FCR, ibrutinib or acalabrutinib were stimulated with rhodocytin 300 nM. Samples 
were lysed with 5X SDS reducing sample buffer after 5 minutes. Whole cell lysates 
were then separated by SDS-PAGE and underwent Western blot with the stated 
antibodies for whole cell phosphorylation, kinases and proteins downstream of CLEC-
2. (A) Blots are representative of similar blots from twelve patients; three treated with 
FCR, six with ibrutinib and three with acalabrutinib. (B) Percentage tyrosine 
phosphorylation as compared to FCR treated patient platelets was measured and is 
represented as the means ± SEM (ibrutinib n=6, acalabrutinib n=3). Statistical analysis 
was performed with a two way ANOVA with Tukey’s correction for multiple 
comparisons. 
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4.2.3.6 Platelets from patients with XLA have reduced CLEC-2 
mediated tyrosine phosphorylation. 
In order to see which of the ibrutinib induced biochemical changes downstream 
of CLEC-2 were secondary to Btk inhibition, or which were due to any off-target 
effects, platelet lysates from patients with XLA were probed with whole cell 
phosphorylation and phosphospecific antibodies after stimulation with 
rhodocytin. As seen in Figure 4.8A; whole cell phosphorylation was globally 
reduced, but not to the same extent as with patients treated with ibrutinib. 
Notably, similar to ibrutinib treated patients, the band at ~140 kDa representing 
phosphorylated PLCɣ2 was absent in XLA patient platelets, but, contrary to the 
results from ibrutinib treated patients and platelets from healthy donors treated 
with 70 nM ibrutinib, the band at 80 kDa comprising a combination of Syk and 
SLP76 (among other proteins) was only marginally reduced. As seen in Figure 
4.8A and B, Syk phosphorylation is reduced but not absent like it is in ex vivo 
and in vitro ibrutinib treated platelets. Src phosphorylation was unaltered, as 
was LAT phosphorylation, though there was a trend to reduction in LAT pY200, 
though this is not statistically significant. 
PLCɣ2 pY1217 was absent, as is the case with in vitro and ex vivo ibrutinib 
treated platelets stimulated with rhodocytin. This is different to the XLA platelets 





Figure 4.8: Patients with XLA have absent PLCɣ2 phosphorylation downstream of 
the CLEC-2 receptor but Src, Syk and LAT phosphorylation are present. 
Eptifibatide (9 μM) treated washed platelets at 4 x 108/ml from patients with XLA were 
lysed with 5X reducing sample buffer 5 minutes after addition of rhodocytin 300 nM or 
PBS as shown. Whole cell lysates were then separated by SDS-PAGE and Western 
blots were probed for whole cell or kinase phosphorylation with the stated antibodies. 
(A) Blot and (B) mean ± SEM (n=3) for phosphorylation events downstream of the 
CLEC-2 receptor. Results were analysed statistically using a one way ANOVA with 




4.2.4 Ibrutinib inhibits platelet spreading but not 
clustering of CLEC-2 on podoplanin 
4.2.4.1 Btk-specific concentrations of ibrutinib reduce both number 
of platelets and the spread area of platelets when adhering to 
immobilised podoplanin 
In order to look at the effect of ibrutinib on how CLEC-2 affects adhesion and 
subsequent activation of cytoskeletal machinery, the effect on platelet spreading 
on immobilised CLEC-2 ligands was studied. rhodocytin was used initially but 
attempts to get the platelets to adhere to immobilised rhodocytin were 
unsuccessful. Human Fc-conjugated podoplanin was used as a CLEC-2 ligand. 
This has been used in previous publications involving platelet spreading that 
has been shown to be mediated by CLEC-2 without involvement of the Fc-
receptor FCɣRIIa (Navarro-Núñez et al. 2015). Adhesion and spreading was 
assessed by isolating washed platelets from healthy donors and allowing them 
to spread on podoplanin coated coverslips for 45 minutes prior to fixation, 
antibody staining and imaging. Blockade of aggregation to rhodocytin 300 nM 
with ibrutinib 170 nM was confirmed prior to commencing the spreading 
experiment (not shown). Platelets were treated with ibrutinib 170 nM or vehicle 
either for 5 minutes prior to spreading or after spreading had been ongoing for 
30 minutes. Results are shown in Figure 49. There was a statistically significant 
reduction in spread platelet area and number of adherent platelets when 
ibrutinib was added to the platelets before spreading took place. There was no 
effect on number of adherent platelets or spread area in samples where 
ibrutinib was added after the initiation of spreading. This shows that Btk is 
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important for platelet adhesion to podoplanin and also the subsequent initiation, 




Figure 4.9: Incubation of platelets with ibrutinib prior to adhesion on podoplanin 
reduces both number and area of spread platelets. 
Human healthy donor washed platelets at 2x107/ml were incubated with ibrutinib (170 
nM) or vehicle for 5 minutes before spreading on podoplanin coated coverslips at 37°C 
for 45 minutes. Simultaneously, untreated platelets were spread on podoplanin coated 
coverslips at 37°C for 30 minutes before ibrutinib (170 nM) or vehicle was added and 
incubated for 15 minutes at 37°C. Coverslips were then washed to remove non-
adherent platelets before fixation with formalin and staining with AF 488-conjugated 
phalloidin. (A) Representative images of three identical experiments. Ilastik 1.1.2 
machine learning software was used to automatically and reproducibly identify platelets 
and data on platelet number and surface area was measured using the KNIME 3.4 
analytics platform. (B) Mean data ± SEM (n=3). Statistical analysis performed using 
two-tailed Welch’s t-test. (C) Mean data ± SEM (n=3). Statistical analysis performed 




4.2.4.2 Platelets taken from patients on Btk inhibitors and those with 
XLA have normal adhesion but reduced spreading when bound to 
immobilised podoplanin 
To ensure that the effect of ibrutinib on platelet spreading on podoplanin-Fc was 
a Btk-specific effect and occurred at physiologic concentrations Btk inhibitor, 
further experiments using platelets from patients with XLA and those taking Btk 
inhibitors for CLL were performed. Patients with XLA, those taking ibrutinib 420 
mg once daily or acalabrutinib 100 mg twice daily were sampled and washed 
platelets were isolated and incubated on immobilised podoplanin for 45 minutes 
before fixing and staining. Patients on FCR were not used as the control for this 
experiment as they were unavailable at the time of performing this assay. 
Consistent with the in vitro results, the results in Figure 4.10 show that both 
congenital lack of Btk or its inhibition with both ibrutinib and acalabrutinib 
treatment resulted in a reduced spread platelet area. Platelet adhesion to 
podoplanin was, however, unchanged. This, then, confirms that Btk is involved 
in the initiation of platelet spreading after activation of CLEC-2 by podoplanin, 
but it fails to support the in vitro data which showed that Btk is important for 





Figure 4.10: Platelets from patients on Btk inhibitors or those with XLA adhere in 
normal numbers but with a reduced spread area when bound to immobilised 
podoplanin-Fc. 
Washed platelets at 2x107/ml from healthy human donors, patients taking ibrutinib or 
acalabrutinib and those with XLA were incubated on podoplanin-Fc (10 μg/ml) coated 
coverslips at 37°C for 45 minutes. Coverslips were then washed to remove non-
adherent platelets before fixation with formalin and staining with AF 488-conjugated 
phalloidin. (A) Representative images. Ilastik 1.1.2 machine learning software was 
used to automatically and reproducibly identify platelets and data on platelet number 
and surface area was measured using the KNIME 3.4 analytics platform. (B) and (C) 
Data shown as mean ± SEM for healthy donors (n=5), ibrutinib (n=4), acalabrutinib 
(n=2) and XLA patients (n=2). Statistical analysis performed using a one-way ANOVA 
with Tukey’s correction for multiple comparisons. 
 
4.2.4.3 Btk-specific concentrations of ibrutinib have no effect on 
CLEC-2 receptor clustering when binding to immobilised podoplanin 
CLEC-2 clustering upon ligand binding is an important part of the activation of 
its downstream signalling. It has previously been shown that the clustering of 
CLEC-2 in response to ligation with podoplanin is dependent on the actions of 
the tyrosine kinases Syk and SFKs (Pollitt et al. 2014).Thus it seemed 
reasonable to suspect, given the potent inhibition of CLEC-2 mediated platelet 
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function and Btk’s close interaction with both Syk and SFKs, that Btk might also 
affect CLEC-2 receptor clustering. Pilot experiments were carried out to 
establish a method that enabled visualisation of CLEC-2 clustering (or lack 
thereof) when platelets were spread on immobilised podoplanin-Fc and collagen 
respectively. They were then probed with the anti-human CLEC-2 antibody 
AYP1 and the distribution of CLEC-2 was then imaged using dSTORM super-
resolution microscopy (see Figure 4.11).From this single pilot experiment it was 
clear there was a difference in CLEC-2 distribution on the surface of the platelet 




Figure 4.11: CLEC-2 clustering is seen when platelets are spread on immobilised 
podoplanin-Fc but not on collagen. 
Washed platelets (2x107/ml) from a single healthy human donor were spread on 
immobilised collagen (10 μg/ml) or podoplanin-Fc (10 μg/ml) for 45 minutes before 
fixation and probing with the anti-human CLEC-2 antibody AYP1 and secondary 
staining with goat anti-mouse antibody conjugated to AF 647. Spread platelets were 





To examine whether Btk inhibition blocked CLEC-2 clustering, platelets were 
treated with ibrutinib or vehicle in exactly the same manner as for the spreading 
experiments and were allowed to settle on immobilised podoplanin-Fc. They 
were imaged using dSTORM super-resolution microscopy as above. The 
resultant image was reconstructed with the ThunderSTORM plugin for ImageJ 
1.5 and the size and density of the CLEC-2 clusters on it were measured using 
persistence based clustering that has been described recently (Pike et al. 
2018). Surprisingly, the results, shown in Figure 4.12 show that treatment with 
ibrutinib, either before or after the initiation of spreading, has no effect on the 





Figure 4.12: CLEC-2 clustering on immobilised podoplanin-Fc is unchanged in 
the presence of Btk inhibition with ibrutinib. 
Human healthy donor washed platelets at 2x107/ml were incubated with ibrutinib (170 
nM) or vehicle for 5 minutes before spreading on podoplanin-Fc (10 μg/ml) coated 
coverslips at 37°C for 45 minutes. Simultaneously, untreated platelets were spread on 
podoplanin-Fc (10μg/ml) coated coverslips at 37°C for 30 minutes before ibrutinib (170 
nM) or vehicle (DMSO) was added and incubated for 15 minutes at 37°C. Platelets 
were then fixed and probed with the anti-human CLEC-2 antibody AYP1. Secondary 
antibody staining was performed with goat anti-mouse antibody conjugated to AF 647 
as well as AF 488-conjugated phalloidin. Spread platelets were imaged using a Nikon 
Eclipse Ti-E N-STORM system in dSTORM mode. (A) representative images from five 
identical experiments with the microscope in Total Internal Reflection Fluorescence 
(TIRF) or dSTORM mode or reconstructed images with false colour added to individual 
clusters. (B) Cluster area (i) and density (ii) are depicted as mean ± SEM (n=5). 
Statistical analysis was with two-way ANOVA with Sidak’s correction for multiple 




4.2.4.4 Platelets taken from patients with XLA or those on ibrutinib 
have normal clustering of CLEC-2 when adhering to immobilised 
podoplanin 
Simultaneously, in order to see if any effect on clustering was Btk-specific and 
occurred at concentrations of ibrutinib achieved in patients, platelets from 
healthy donors, patients with XLA and those with CLL on ibrutinib 420 mg once 
daily were spread on immobilised podoplanin-Fc in order to examine CLEC-2 
clustering. Patients receiving FCR chemotherapy were unavailable for use as 
controls at the time of performing this assay. After fixation, the platelets were 
probed with AYP1 and then imaged using dSTORM super-resolution 
microscopy. The size and density of CLEC-2 clusters were then analysed using 
persistence based clustering as before. As for the in vitro ibrutinib treated 
platelets, there was no difference in the size and density of CLEC-2 clusters 
between platelets from healthy donors and those from patients with XLA or with 




Figure 4.13: Platelets from ibrutinib treated patients have normal CLEC-2 
clustering. 
Washed platelets at 2x107/ml from healthy donors, patients with CLL taking ibrutinib or 
patients with XLA were spread on podoplanin-Fc (10 μg/ml) coated coverslips at 37°C 
for 45 minutes. Platelets were then fixed and probed with the anti-human CLEC-2 
antibody AYP1. Secondary antibody staining was performed with goat anti-mouse 
antibody conjugated to AF 647 as well as AF 488-conjugated phalloidin. Spread 
platelets were imaged using a Nikon Eclipse Ti-E N-STORM system in dSTORM mode. 
(A) representative images from seven healthy donors, four patients taking ibrutinib and 
two patients with XLA with the microscope in Total Internal Reflection Fluorescence 
(TIRF) or dSTORM mode or reconstructed images with false colour added to individual 
clusters. (B) Cluster area (i) and density (ii) are depicted as mean ± SEM (HD n=7, 
ibrutinib n=4, XLA n=2). Statistical analysis was with one-way ANOVA with Tukey’s 




4.2.5 The effect of Btk inhibition on platelet 
adhesion to podoplanin under venous flow 
4.2.5.1 In vitro ibrutinib inhibits platelet activation after adhesion to 
podoplanin under flow at venous shear 
Given platelets adhered in lower numbers but retained the ability to cluster 
CLEC-2 on podoplanin in the presence of ibrutinib, it was important to establish, 
in a more physiological model, whether these observations meant that platelets 
in which Btk had been inhibited would still be able to bind to podoplanin under 
flow conditions, and, if so, was the stimulation powerful enough to overcome Btk 
blockade and enable aggregate formation. Thus a flow adhesion assay was 
performed by Josh Hinds and supervised as part of this project. Healthy human 
donor washed platelets were isolated and treated with low concentration 
ibrutinib (170 nM) or vehicle before being reconstituted with autologous red cells 
and PPP. Prior to adding back into whole blood, the platelets were sampled and 
it was confirmed that the ibrutinib treated platelets were no longer able to 
aggregate to 300 nM rhodocytin (not shown). Because of the lack of success 
with getting platelets to adhere to immobilised rhodocytin, reconstituted whole 
blood was then flowed over podoplanin-Fc under direct microscopic vision at 
venous shear for 5 minutes. 
As seen in Figure 4.14, treatment with ibrutinib did not prevent platelet adhesion 
to a statistically significant degree, although there was a clear trend towards a 
reduction in adhesion. It did, however, reduce the size of the platelet clusters 
that formed. This is consistent with platelets still being able to bind podoplanin, 
but not being able to activate, secrete secondary mediators, and recruit other 
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platelets to form aggregates. 
 
 
Figure 4.14: In vitro Btk inhibition has no effect on adhesion but does reduce 
aggregate size when flowed over immobilised podoplanin-Fc at venous shear. 
Human healthy donor washed platelets at 10x108/ml were incubated with ibrutinib (170 
nM) or vehicle for 5 minutes before being reconstituted with autologous red cells and 
PPP to a final platelet concentration of 400x109/l. The resultant whole blood was then 
incubated with DiOC6 dye for 5 minutes before being flowed over immobilised 
podoplanin-Fc (100 μg/ml) at 125 s-1 for 5 minutes. Images were taken every second 
using fluorescent channels on a Zeiss Axio inverted microscope at 20X magnification. 
(A) Representative images from (A) vehicle treated (n=5) and (B) ibrutinib treated 
samples (n=5) are shown. Ilastik 1.1.2 machine learning software was used to 
automatically and reproducibly identify platelets and data on platelet surface area 
coverage and cluster size was measured using the KNIME 3.4 analytics platform. 
Mean data ± SEM showing (C) increase in total platelet aggregate area over time and 
(D) increase in mean aggregate size over time. Statistical analysis was performed with 




4.2.5.2 Platelets taken from patients on ibrutinib and acalabrutinib 
and those with XLA have deficient adhesion to podoplanin under 
flow conditions at venous shear 
It was important to look at whether this reduced platelet activation on adhesion 
to podoplanin under flow was achieved at physiological concentrations of Btk 
inhibitor and whether it was a Btk-specific effect. To achieve this, flow adhesion 
studies were also extended by Josh Hinds, but supervised under this project, to 
include blood ex vivo from patients treated with Btk inhibitors and from those 
with XLA. Like with the in vitro studies, blood was flowed over podoplanin-Fc at 
venous shear for 5 minutes. As for the spreading experiments, no patients on 
FCR were available as controls for this assay. 
Figure 4.15A, C and D shows that platelets from patients taking ibrutinib almost 
completely failed to adhere to podoplanin-Fc. The effect was considerably more 
marked than in the in vitro assay. It was initially felt that this probably reflected 
the additional off-target effects of the high concentrations of ibrutinib that these 
patients take. The results shown in Figure 4.15B, E and F, however, from 
patients on acalabrutinib (n=2) and those with XLA (n=2) (which are Btk-specific 
effects) do not support this conclusion. Instead, they show that Btk appears to 
be critical for platelet adhesion to podoplanin under venous flow conditions. The 
difference in the results from the in vitro and ex vivo assays could be due to the 
lower (but still normal range) of platelet counts in the patients with XLA (see 
Figure 3.24Bi) or those on Btk inhibitors (see Figure 3.15Bi) rather than the 
400x109/l used in the in vitro assay. 
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Figure 4.15: Ex vivo Btk inhibition reduces adhesion to podoplanin under flow. 
Whole blood from healthy donors, patients treated with ibrutinib or acalabrutinib or 
those with XLA was incubated with DiOC6 dye for 5 minutes before being flowed across 
a capillary coated with podoplanin-Fc (100 μg/ml) at 125 s-1for 5 minutes. Images were 
taken every second using fluorescent channels on a Zeiss Axio inverted microscope at 
20X magnification. (A) Representative images from (i) healthy donors, patients treated 
with (ii) ibrutinib 420 mg once daily, (iii) acalabrutinib 100 mg twice daily or (iv) patients 
with XLA. Ilastik 1.1.2 machine learning software was used to automatically and 
reproducibly identify platelets. Data on platelet surface area coverage and cluster size 
was measured using the KNIME 3.4 analytics platform. Mean data ± SEM showing 
increase in total platelet aggregate area over time of (C) healthy donors (n=4) and 
ibrutinib treated patients (n=5) and (D) acalabrutinib treated patients (n=2) and those 
with XLA (n=2). Mean data ± SEM showing increase in mean aggregate size over time 
of (E) healthy donors and ibrutinib treated patients and (F) acalabrutinib treated 
patients and those with XLA, the curve from healthy donor platelets is included for 





The main findings from the above studies into the role of Btk downstream of 
CLEC-2 receptor ligation in platelets are: 
i) Btk inhibitors are highly effective at blocking almost all aspects of CLEC-
2 mediated platelet function and, in human platelets, this is likely to be a 
Btk-specific effect in which Tec does not play a role. 
ii) The role of Btk downstream of CLEC-2 in human vs mouse platelets is 
different with the function in humans being critically dependent on its 
kinase activity whereas in mice it behaves in a similar way to that 
downstream of GPVI in both human and mouse platelets where it also 
operates as an adapter.  
iii) Btk does not lie upstream of Syk in the CLEC-2 signalling cascade, as it 
does when activated by GPVI ligation. 
 
4.3.1 Btk kinase activity is critical for platelet CLEC-2 function in 
human platelets 
These results have shown that, with the exception of Ca2+ mobilisation, Btk 
inhibitors block all aspects of CLEC-2 mediated human platelet function and 
signalling at very low concentrations consistent with the effect being mediated 
through their inhibition of Btk kinase function. 
This is manifest in the in vitro experiments with ibrutinib and the ex vivo 
experiments using platelets from patients with XLA. The time-dependent and 
irreversible nature of the inhibition of CLEC-2 mediated platelet function by 
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ibrutinib points to an effect on Tec kinases. The results of the biochemical 
experiments with the IC50 for ibrutinib’s inhibition of Btk pY223 being the same 
as that for aggregation, regardless of the method of platelet preparation, points 
further towards it being a specific effect on Btk. Finally the ex vivo experiments 
performed on patients with XLA show that they have no demonstrable CLEC-2 
function or PLCɣ2 phosphorylation downstream of CLEC-2. This is despite the 
presence of Tec in these platelets. Taken together, these results show that Btk 
kinase function is critical for CLEC-2 signalling in human platelets. Further 
experiments performed by Craig Hughes at the University of Reading using 
DT40 cells transfected with CLEC-2 and WT or KD Btk show that, unlike in 
GPVI signalling, only WT but not KD Btk can restore Ca2+ mobilisation 
downstream of CLEC-2 as measured by the NFAT reporter assay (unpublished 
data). 
The higher concentrations of ibrutinib required to prevent Ca2+ mobilisation than 
in other platelet function assays can be explained simply. Rather than a 
biological effect this appears to merely be dependent on the platelet preparation 
method used for the assay. This is because aggregation studies done with this 
different platelet preparation also needed higher concentrations of ibrutinib to be 
blocked. This blockade was still critically dependent on Btk pY223 inhibition as 
shown by the biochemical studies where the IC50 for Btk pY223, Ca2+ 
mobilisation and aggregation were the same in platelets prepared with this 
ADP-sensitive method. 
With most experiments it is expected that in vitro tests will yield more clear-cut 
results than ex vivo ones because the variables of the experiment are more 
controllable. Interestingly, with the flow adhesion experiments using immobilised 
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podoplanin, the opposite was true. In vitro tests showed platelet aggregate size 
was significantly reduced but that while overall adhesion appeared lower, this 
was not statistically significant. This would imply that platelet CLEC-2 does not 
have to be activated to adhere to podoplanin. This is contrary to what is seen in 
similar flow assays performed by Navarro-Núñez et al. where blockade of 
platelet activation with the Src inhibitor dasatinib caused reduced platelet 
adhesion to podoplanin (Navarro-Núñez et al. 2015). Ex vivo blood from 
patients treated with ibrutinib, however, showed that both overall adhesion and 
aggregate size was markedly reduced. This discrepancy with the in vitro results 
could be due to off-target inhibition of SFKs or other kinases by the high doses 
of ibrutinib used in patients with CLL. But if this were so then the results using 
blood from the acalabrutinib treated patients or those with XLA would match the 
in vitro results. Even allowing for the suboptimal number of acalabrutinib treated 
and XLA patients (two in each group) the results appear to strongly suggest that 
Btk inhibition alone is sufficient to reduce platelet adhesion and activation when 
flowed across immobilised podoplanin-Fc at venous shear rates. The in vitro 
assay, therefore, was probably not sensitive enough to pick up this reduction in 
adhesion. This was probably as a result of the high-normal platelet count of 
400x109/l in the reconstituted blood used for the assay or the experiment not 
being performed over a long enough time period. Ideally these experiments 
would be repeated using a longer time course with lower platelet counts in the 
reconstituted blood in the in vitro assay and also non-Btk inhibitor treated CLL 
patients used as the controls in the ex vivo assay. 
 
4.3.2 Off-target effects of ibrutinib mediate blockade of CLEC-2 
166 
function in mouse platelets in a similar manner to its inhibition 
downstream of GPVI 
The role of Btk downstream of CLEC-2 in mouse platelets is markedly different 
to that in humans. This is shown by two main observations: 
Firstly by the >500-fold difference in IC50s for aggregation upon stimulation with 
rhodocytin between human and mouse platelets. This difference is not 
accounted for by differing levels of ADP sensitivity of the different methods of 
washed platelet preparation because a) the mouse platelets are not sensitive to 
ADP (not shown) and b) even ADP-sensitive human platelets are still ~50-fold 
more sensitive to aggregation blockade by ibrutinib than mouse platelets. 
Secondly this is manifest in the strikingly different tyrosine phosphorylation 
patterns seen downstream of CLEC-2 when human and mouse platelets are 
inhibited with low concentrations of ibrutinib. Human platelets have nothing 
except basal levels of SFK phosphorylation when treated with 70 nM ibrutinib 
whereas mouse platelets only show loss of Btk Y223 and downstream PLCɣ2 
phosphorylation. Changing the method of platelet preparation such that the 
platelets are responsive to stimulation by ADP, however, restores the 
phosphorylation upstream of Btk pY223 in human platelets. This supports the 
observations of Pollitt et al. showing that CLEC-2 signalling in human but not 
mouse platelets is dependent on positive feedback with secondary mediators 
such as ADP (Pollitt et al. 2010). It is likely that this effect is being mediated via 
P2Y1. To prove this, P2Y1 inhibitors would need to be added to ADP-sensitive 
platelets in the presence of low concentrations of ibrutinib.  
From these observations it is evident that, as with GPVI-mediated activation of 
both human and mouse platelets, CLEC-2 mediated mouse platelet function is 
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only blocked by the off-target effects of Btk inhibitors. Indeed, consistent with 
the results of Lee et al. even bigger concentrations of ibrutinib are required to 
block CLEC-2 mediated platelet function than those previously shown to block 
activation after GPVI ligation (Lee et al. 2017). These results cannot be 
reconciled with the observations of Manne et al. however where they used the 
same low concentration of ibrutinib to block human and mouse CLEC-2 
mediated signalling and aggregation (Manne et al. 2015). One potential 
explanation is that they used a very low agonist concentration (10 nM 
rhodocytin). Manne et al. themselves, however, showed that ibrutinib increases 
platelet inhibition downstream of CLEC-2 in XID mice pointing to an off-target 
action of ibrutinib that is required to block murine CLEC-2 signalling (Manne et 
al. 2015).  
Unlike ibrutinib’s blockade of GPVI signalling however, there is reduction but not 
loss of the 140 kDa band corresponding to PLCɣ2 phosphorylation when 
concentrations > 70 nM are used to inhibit mouse CLEC-2 signalling (Figure 
4.6B). The phosphorylation of Y1217 is also not completely blocked, though this 
is not borne out when this is quantified. Again, like with GPVI signalling 
blockade, this might point to the fact that PLCɣ2 phosphorylation is markedly 
reduced but not completely lost until very high concentrations of ibrutinib but 
that the assay used to measure this phosphorylation is not sensitive enough to 
reliably pick this up. Sensitive methods to measure tyrosine phosphorylation do 
exist, such as that marketed by ProteinSimple (Padhan et al. 2017), and these 
could be employed in future studies. 
 
4.3.3 Btk does not lie upstream of Syk following CLEC-2 ligation in 
168 
human and mouse platelets 
The results depicted here do not support the conclusions by Manne et al. that 
Btk lies upstream of Syk in both mouse and human platelet CLEC-2 signalling 
(Manne et al. 2015): 
Firstly, given that Syk function is required for the formation of CLEC-2 clusters, 
the fact that both in vitro and ex vivo Btk inhibition failed to inhibit this in human 
platelets could be seen as evidence that Btk lies downstream of Syk. There are 
some potential confounders with this assay however that mean its results need 
to be interpreted with caution; the assay did not measure change in clustering 
over time, a dynamic effect of Btk inhibition which delayed rather than 
prevented CLEC-2 clustering may have been missed. The primary issue, 
however, was that the experiment was performed using a fixed ligand. The 
clustering experiments performed by Pollitt et al. which identified the critical role 
of Syk and SFKs were performed using mobile podoplanin in lipid bilayers and 
cell membranes. Thus CLEC-2 clustering brought mobile podoplanin molecules 
together. This is not possible with a fixed ligand, the CLEC-2 will bind to 
podoplanin, but it cannot move after this. The lack of the use of Syk or SFK 
inhibitors as positive controls in this experiment was a significant omission. 
Secondly, despite identical methods of platelet preparation and the use of the 
same assays and reagents, these experiments could only replicate the results 
of the Manne et al. paper in human platelets but not in mice. The results shown 
in Figure 4.6B indicate clearly that Btk does not lie upstream of Syk in mouse 
platelet CLEC-2 signalling. 
Thirdly, with regards to the position of Btk in human platelet CLEC-2 signalling; 
unlike Manne et al. the experiments reported here measured Btk pY551 as well 
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as Btk pY223. The results showed that, even at the lowest concentration of 
ibrutinib that inhibited Btk pY223, Btk pY551 was also blocked. Even if Btk lay 
upstream of Syk, Y551 would still need to be phosphorylated by the SFK Lyn as 
part of its activation as illustrated in Figure 4.5. Loss of pY551 indicates an 
alternative explanation for the loss of phosphorylation events upstream of Btk; it 
is likely that some positive feedback mechanism that reinforces all the 
phosphorylation events is being blocked in the presence of Btk kinase inhibition.  
Finally, the loss of phosphorylation events upstream of Btk in ibrutinib treated 
human platelets was shown to be partly due to an off-target effect of ibrutinib 
and partly due to an artefact secondary to the method of platelet production; 
upstream phosphorylation of Syk and LAT was still present in patients with XLA, 
revealing that the loss of phosphorylation seen in ibrutinib treated platelets is 
likely to be due to an off-target effect; also when platelets were prepared by the 
ADP-sensitive method, the upstream phosphorylation was restored.  
 
In conclusion; the present study shows that Btk does not lie upstream of Syk in 
human and mouse platelets, it provides further evidence of off-target effects of 
ibrutinib and also shows that Btk inhibitors block CLEC-2 mediated platelet 
function at >10-fold lower concentrations than they block GPVI signalling. The 
mechanism underlying this selectivity is shown to be because Btk kinase activity 
is critical for human platelet CLEC-2 function, which is not the case for GPVI. 
This means that low dose Btk inhibitors could be used therapeutically to inhibit 
CLEC-2 in platelets without any off-target effects on GPVI. 
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CHAPTER 5: THE ROLE OF 
CLEC-2 IN HUMAN 
THROMBOSIS AND THE 
EFFECT OF BTK BLOCKADE 
ON HUMAN AND MOUSE VTE 
 
5.1 Introduction 
5.1.1 Problems with current drugs for VTE 
As previously mentioned, the mainstay of treatment for VTE is with 
anticoagulants. Despite the introduction of DOACs, which reduce the annual 
rate of patients experiencing major haemorrhage from 3% to 1.5-2% (Crowther 
& Warkentin 2008), these have not been adopted universally for all forms of 
VTE for several reasons:   
i) the first is because of the perceived increase in drug costs. Though the 
overall cost of anticoagulant treatment however is not just down to the 
drug costs and in fact there are savings to be made when the lack of 
international normalised ratio (INR) monitoring for DOACs are taken into 
account (Amin et al. 2015). 
ii) the second is because of a lack of proven superiority over VKAs and 
LMWH in particular settings such as in patients with metallic heart valves 
or those with cancer associated VTE (Keeling et al. 2011; H. G. Watson 
et al. 2015). 
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iii) the third is the lack of reversal agents. For VKAs major bleeding events 
can be treated with intravenous (IV) vitamin K and an infusion of clotting 
factors called prothrombin complex concentrate (PCC) (Makris et al. 
2012). These rapidly correct the INR but, in fact, may not actually confer 
a survival benefit (Sarode et al. 2013). Until recently, however, DOACs 
have not had reversal agents. But the monoclonal antibody idarucizumab 
has now been introduced into clinical practice for the immediate reversal 
of the direct thrombin inhibitor dabigatran (Pollack et al. 2017). The 
decoy Factor Xa Andexanet Alfa is likely to be licensed soon for use for 
acute reversal of the Xa inhibitors (Connolly et al. 2016). 
iv) the fourth and final reason is the rapid off-effect of the DOACs. Because 
of their short half-lives, if a dose is missed then the patient will lose their 
therapeutic anticoagulation within a few hours. This is not the case with 
warfarin which has a very long half-life and so is considered more 
forgiving for elderly patients who intermittently forget to take their 
medications (Burn & Pirmohamed 2018). 
 
There is still an unmet clinical need, therefore, for a treatment or 
primary/secondary prophylaxis for VTE that does not cause bleeding and does 
not have the rapid off-effect associated with the DOACs. An irreversible inhibitor 
of platelet CLEC-2 or its downstream signalling. might provide the answer to 
this need if it can be shown to be effective in the setting of VTE. 
 
5.1.2 CLEC-2 as a potential therapeutic target for 
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VTE 
5.1.2.1 Platelet CLEC-2 is critical for thromboinflammation in mice 
The principal studies that show a role for CLEC-2 in reduction of 
thromboinflammation are those by Hitchcock et al. and by Payne et al. 
(Hitchcock et al. 2015; Payne et al. 2017). In the former, mice were inoculated 
with an attenuated strain of mouse salmonella (S. Typhimurium). 7 days after 
infection mice were shown to have thrombi in portal vein branches that were 
surrounded by leukocytes which suggested they were not emboli but had 
formed de novo in the liver. These thrombi were rich in fibrin and had 
podoplanin upregulated in the subendothelium surrounding the vessel. The 
mechanism for thrombus development was shown, using a mixture of drug 
treatment and genetic knockout mice, to be critically dependent on 
macrophages, podoplanin and platelet CLEC-2. The pathophysiological model 
they proposed was that bacteria triggered monocyte recruitment to the liver, the 
monocytes then matured into macrophages and expressed podoplanin. The 
trigger for thrombosis then was activation of CLEC-2 on platelets at sites of 
breach in the endothelial wall with downstream processes similar to that which 
occurs in classical thrombosis. 
In the study by Payne et al. mice underwent IVC stenosis surgery whereby the 
IVC side branches were tied off and then a ligature was placed around the IVC 
and tightened around a 30-gauge spacer. Mice were then allowed to recover 
from surgery for 48 hours prior to being culled and having their IVC examined 
for the presence of thrombus. Like in the study of Hitchcock et al. the thrombi 
that developed were rich in fibrin and resembled DVTs in humans. Again, like 
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the results of Hitchcock et al. the subendothelium surrounding the thrombus 
was shown to contain upregulated podoplanin but also showed adjacent 
platelets invading into this subendothelial layer. Finally, analogous to the results 
of Hitchcock et al., the development of thrombosis was shown, through a 
mixture of genetic knock out mice and treatment with blocking antibody, to be 
critically dependent on podoplanin and platelet CLEC-2. The proposed 
mechanism here was also that podoplanin was up-regulated by leukocytes and 
it was the activation of platelet CLEC-2 by podoplanin which triggered the 
thrombosis.  
It is perhaps surprising that IVC stenosis causes an inflammatory response 
such that leukocytes are recruited to the vessel wall. It was previously thought 
that this model caused thrombosis through disruption to blood flow in the same 
way an intra-abdominal mass might press on the iliac veins in a patient 
developing proximal DVT. Whether this process of upregulated podoplanin 
triggering venous thrombosis via platelet CLEC-2 occurs in humans has not 
been shown. 
 
5.1.2.2 Platelet CLEC-2 plays minimal/no role in haemostasis 
Consistent with presence of a single endogenous ligand which is not present in 
the vasculature under normal conditions, studies examining the role of CLEC-2 
in maintaining haemostasis show only a minor contribution. Because CLEC-2 
deficient mice die before or soon after birth and display prominent blood-filled 
lymphatics and oedema (Suzuki-Inoue et al. 2010) two methods have been 
developed in order to study the effect of CLEC-2 depletion on platelet function 
in adult animals; namely restoration of radiation chimeric mice from CLEC-2 
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deficient fetal liver cells or antibody mediated reversible down regulation of the 
receptor. These methods produce conflicting results. Radiation chimeric mice 
reconstituted with CLEC-2 deficient fetal liver cells had no impairment of 
haemostasis as shown by tail bleeding time in two studies (Suzuki-Inoue et al. 
2010; Hughes et al. 2010) whereas those with antibody mediated depletion had 
a prolonged bleeding time in one study (May et al. 2009) but not in another 
which used the same antibody (Bender et al. 2013). Radiation chimeric mice 
reconstituted with fetal liver cells display either no effect or only minor 
impairment in flow adhesion assays over collagen, VWF and fibrinogen (Suzuki-
Inoue et al. 2010; Hughes et al. 2010). 
 In vivo data looking at thrombus formation after vessel wall injury shows a mild 
reduction in thrombus formation in a laser injury model of mesenteric capillaries 
in the radiation chimeric mice (Suzuki-Inoue et al. 2010) and a more marked 
effect in a ferric chloride injury model of mesenteric arterioles in antibody 
depleted mice (May et al. 2009) The same, latter, assay using CLEC-2 fl/fl PF4-
Cre mice only produced a very subtle reduction in thrombus formation but these 
mice also had a lower platelet count than their wild type counterparts (Bender et 
al. 2013). The reason for the different results could merely be an effect of the 
induced thrombocytopenia/secondary thrombocytosis which occurs in the 
antibody treated mice. There could be additional, unaccounted for, effects of 
antibody treatment such as occurred in a study of antibody-mediated depletion 
of GPVI where the antibody treatment unexpectedly lowered the ability for 
platelets to respond to thrombin mediated activation (Schulte et al. 2006). In 
further support of CLEC-2 not playing a significant role in haemostasis, mice 
treated with a Syk inhibitor have been shown not to have a prolongation of tail 
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bleeding time (Andre et al. 2011). 
It follows then that CLEC-2 is an exciting prospect as a drug target for the 
treatment of VTE because it is critical for the formation of venous thrombus in 
mouse models of thromboinflammation but has little or no role in haemostasis. 
Therefore CLEC-2 blockade may be able to treat or prevent venous thrombosis 
triggered by inflammation without causing the bleeding that is the main side 
effect of all of the current treatments for VTE. 
 
5.1.3 Btk inhibitors as means of blocking platelet 
activation by CLEC-2 ligation 
The studies in Chapter 4 have shown that Btk inhibitors are a potent and 
specific means of blocking CLEC-2 mediated platelet activation in vitro and ex 
vivo. The attraction of using Btk inhibitors for this therapeutic indication is 
lessened, however, by the reports of bleeding in the early trials of ibrutinib for 
patients with LPDs that were not dissimilar to the rates of bleeding on 
anticoagulants. The results from Chapter 3, however show that blockade of 
GPVI-mediated platelet activation by ibrutinib (which has been correlated to 
bleeding events) is due to non-Tec kinase off-target effects that occur because 
of the high doses used. Ibrutinib, and other covalent Btk inhibitors, could be 
dosed at much lower levels to specifically target Btk in platelets in a way 
analogous to the use of aspirin. 
In combination with the effects on GPVI, a contribution towards ibrutinib induced 
bleeding has been postulated to be due to the patients’ underlying LPD as most 
bleeding events on ibrutinib occur in the first 6 months of treatment before the 
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disease is in remission (Jones et al. 2017). Therefore using Btk inhibitors in 
patients who do not have underlying haematological malignancy may abrogate 
all major bleeding events. Furthermore, using them in these patients but at 
doses that do not inhibit GPVI-mediated platelet activation may abolish the 
minor bleeding events as well.  
 
The outstanding questions are: 
i) does blockade of CLEC-2 mediated platelet activation via inhibition of its 
downstream signalling prevent in vivo venous thrombosis in mice in the 
same way as blocking the interaction between CLEC-2 and podoplanin? 
ii) does podoplanin’s activation of platelet CLEC-2 play any role in the 
development of human VTE? 
What follows aims to answer these questions by looking at whether dosing of 
mice with ibrutinib prevents in vivo thrombosis and by looking for indirect and 






5.2.1 The effect of ibrutinib on mouse 
thromboinflammation 
5.2.1.1 Ibrutinib inhibits WT mouse CLEC-2 and GPVI-mediated 
platelet function ex vivo 
In order to establish if ibrutinib inhibits in vivo thromboinflammation in mice it 
was first necessary to ensure that ibrutinib blocked platelet CLEC-2 function ex 
vivo. Ibrutinib has a half-life of 4-8 hours and so it was estimated that it would 
take 20-40 hours (5 half-lives) for trough levels of drug to stabilise. Because it 
was seen in the in vitro experiments that high concentrations of ibrutinib were 
needed to block CLEC-2 mediated platelet function in mice the maximum safe 
dose of 35 mg/kg was used. Because of the large volume of blood required for 
LTA, measurement of platelet activation by flow cytometry was used in order to 
take blood serially before and after doses of ibrutinib. In order to look at the 
effect of ibrutinib on platelet function over time, mice were dosed once daily with 
35 mg/kg ibrutinib by intraperitoneal (IP) injection for three days and had 30 μl 
heparinised blood taken pre-treatment and then at two hours following the first, 
second and third (final) doses as well as 24 hours after the final dose. Platelet 
activation in response to CRP and rhodocytin was measured by flow cytometry 
at these time points. Platelet activation in response to thrombin was also 
measured in ACD anticoagulated blood at the final time point. The results are 
depicted in Figure 5.1A. Similar to the in vitro results shown in Figure 4.1Cii and 
D, these show that platelet activation in response to thrombin was unaffected by 
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ibrutinib but that activation in response to both GPVI and CLEC-2 stimulation 
was blocked. There was still some breakthrough residual platelet activation in 
response to rhodocytin stimulation following dose 2 however. It was important to 
make sure that CLEC-2 blockade was as complete as possible throughout the 
period of time when IVC was going to be ligated and so dosing was extended to 
find a 48 hours window with full CLEC-2 blockade. Platelet activation was 
measured by flow cytometry at serial time points during the experiment with 
results from this extension of the experiment shown in Figure 4.16B. Combining 
results of these two dosing experiments showed that CLEC-2 blockade 





Figure 5.1: Activation of platelets by ligation of the CLEC-2 or GPVI receptors is 
blocked in mice dosed with ibrutinib in vivo. 
WT Mice were dosed with ibrutinib (35 mg/kg) or vehicle and bled at the stated times. 
(A) Whole blood taken into ACD and incubated with the stated agonist and FITC-
conjugated anti-P-selectin and PE-conjugated anti-integrin αIIbβ3 antibodies for 30 
minutes before undergoing red cell lysis and fixation and analysis using flow cytometry. 
Mean effect on platelet activation after stimulation with (i) rhodocytin (300 nM) or CRP 
(10 μg/ml) and (ii) thrombin (1 U/ml) is shown. Statistical analysis was performed with 
(i) two-way ANOVA with a Dunnett’s post test or (ii) two-way ANOVA. (B) Heparinised 
whole blood was incubated with the stated agonist and FITC-conjugated anti-P-selectin 
and PE-conjugated anti-integrin α2bβ3 antibodies for 30 minutes before undergoing 
red cell lysis and fixation and analysis using flow cytometry. (i) Representative plots 
from vehicle and ibrutinib treated mice. (ii) Mean effect on platelet activation after 
stimulation with rhodocytin (300 nM) or PAR4 peptide (500 μM) is shown. Statistical 
analysis was performed using a two-way ANOVA with Tukey’s multiple comparison 
180 
test. (C) Washed platelets at 4x108/ml from the same mice at the end of the experiment 
(i.e. 24 hours after dose 4) were stimulated with the stated agonists. (i-iii) 
Representative traces, (iv) mean results ± SEM is shown. Statistical analysis was 
performed with a two-way ANOVA with Sidak’s multiple comparison test. *p<0.05, 
ns=non-significant. 
Alongside analysis by flow cytometry in whole blood, at the very final time point LTA 
was performed as well in washed platelets (ie 24 hours after dose 4). These were 
stimulated with PAR4 peptide, rhodocytin and CRP. The results in Figure 5.1C show 
that, while flow cytometry indicated complete blockade of CLEC-2 and GPVI-mediated 
platelet activation, LTA showed delayed and partially inhibited aggregation to the same 
agonists at the same concentrations. This illustrates different sensitivities of LTA and 
the flow cytometry assay to platelet inhibition. 
 
5.2.1.2 The effect of ibrutinib on thrombus formation in an in vivo 
model of DVT 
In order to investigate if ibrutinib reduces the incidence of DVT in an in vivo 
mouse thrombosis model mice were dosed as above with ibrutinib or vehicle. 
Two hours following the third dose they were anaesthetised and had IVC 
stenosis induced with a ligature. This time point was chosen as this is when the 
plasma concentration of ibrutinib was expected to peak. 48 hours later they 
were culled and examined for the presence and size of any thrombus that had 
formed in the IVC. The results, shown in Figure 5.2, demonstrate that only 2 of 
the 7 mice formed a thrombus in the ibrutinib treated mice, whereas 4 out of the 






Figure 5.2: The effect of ibrutinib on the incidence of mouse DVT in mice. 
8 week old WT C57/Bl6 mice were dosed with 35 mg/kg ibrutinib or vehicle via daily IP 
injection for 4 days. Two hours following the third dose surgical IVC stenosis was 
induced with a ligature. A single mouse from each group bled from the IVC intra-
operatively and had to be culled. The remaining mice were allowed to recover and 
were then culled 46 hours later and examined for the weight and length of any IVC 
thrombus. (A-B) Results shown are median values (n=7 per group). Statistical analysis 
for these was performed with Welch’s two tailed t-test. (C) Thrombus prevalence 
shown (n=7 per group). Statistical analysis on thrombus prevalence was done with 
Fisher’s exact test. ns=non-significant. 
 
5.2.2 Patients with CLL / MCL who take Btk 
inhibitors have lower VTE rates than patients 
taking control chemotherapy 
One method of addressing the issue of there being no data on the role of 
platelet CLEC-2 in humans was to look at the existing data from clinical trials 
that tested drugs known to inhibit CLEC-2 (such as Btk inhibitors). These trials 
were performed to assess the efficacy of Btk inhibitors at treating LPDs and so 
were not powered to detect differences in venous thrombosis rates but, 
nonetheless, this information was collected and has been published as Adverse 
Event (AE) and Severe Adverse Event (SAE) rates. It is a requirement of 
American Law that clinical trials register at initiation and post results upon 
completion with the public registry www.clinicaltrials.gov and so this website can 
be used as a resource to look at venous thrombosis rates in these trials. 
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On the 20/9/2018 www.clinicaltrials.gov was searched using the term “ibrutinib 
OR PCI-32675 OR imbruvica” and results were then filtered to only include trials 
with results. This yielded 16 studies of which 14 involved patients with 
lymphoproliferative disorders. Two of these 14 were not trials for patients with 
low-grade LPDs but were in patients with acute lymphoblastic leukaemia and 
diffuse large B-cell lymphoma respectively. These were excluded in order to 
keep the patient population, and thus the underlying VTE rate, as uniform as 
possible (i.e. low grade disease only). There were 12 remaining studies for 
analysis. The registry records for each study were screened for all terms listed 
in the Common Terminology Criteria for Adverse Events (CTCAE) that related 
to VTE. (such as thromboembolic event, venous thrombosis, pulmonary 
embolism) (National Cancer Institute 2010). The number of ibrutinib treated 


















NCT01217749 CLL No 71 1 
NCT01236391 MCL No 111 1 
NCT01292135 CLL No 33 - 
NCT01105247 CLL No 132 - 
NCT01578707 CLL Yes 195 - 
NCT01744691 CLL/SLL No 144 1 
NCT01722487 CLL/SLL Yes 136 - 
NCT01646021 MCL Yes 139 1 
NCT01973387 CLL/SLL Yes 106 - 
NCT01849263 FL No 40 1 
NCT01980628 MZL No 63 1 
NCT01500733 CLL No 86 1 
Total   1256 7 
 
Table 5.1: VTE rates experienced in trials of ibrutinib with results posted on 
www.clinicaltrials.gov. 
Chronic Lymphocytic Leukaemia (CLL), Mantle Cell Lymphoma (MCL), Small 
Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma 
(MZL). 
 
The VTE rate for the ibrutinib treated patients was very low (7/1256) which is 
lower than the 5.1% per year that has been reported in historic controls with 
CLL (Kroll et al. 2013). But the data in the above table does not give information 
on how long patients were studied for and the study by Kroll et al. only included 
hospitalised patients and so is likely to have a higher event rate than applies to 
most patients with CLL. To account for these limitations the four studies which 
were RCTs where treatment was compared to a non-ibrutinib containing control 
chemotherapy were examined further. Details on median duration for each 
treatment arm was looked for but was not reliably reported in the registry and so 
the publications relating to each of these studies were found and scrutinised to 
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gain this information (see Table 5.2). 
Because the time that patients were taking ibrutinib on these studies was longer 
than the time patients took the control treatments it was necessary to express 
the total number of patients treated with each drug as total exposure to drug in 
person years. This is a standard method for comparing event rates when 
exposure times to treatment and control drugs differ. These data are shown in 
Table 5.3. Of the two studies which had VTE events (NCT01578707 and 
NCT0172487), the lower rate of VTE in ibrutinib treated patients when 
compared to those treated with conventional chemotherapy was statistically 
significant for NCT01578707 but not for NCT0172487. When results from these 
trials were combined together with the results of individual studies weighted 
according to the drug exposure time for each arm of the trial using a stratified 
cohort Cox’s regression model as previously described (Giganti et al. 2015) the 
rate of VTE in patients treated with ibrutinib was lower than patients treated with 
a control chemotherapy. This result was statistically significant.
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NCT01578707 Montillo et al. CLL Ofatumumab 195 44 0 196 8.1 2 
NCT01722487 Barr et al. CLL/SLL Chlorambucil 136 28.5 0 133 18.9 0 
NCT01646021 Dreyling et 
al. MCL Temsirolimus 139 15.6 1 141 6.2 2 
NCT01973387 Huang et al. CLL/SLL Rituximab 106 16.4 0 54 8.4 0 
Table 5.2: Ibrutinib containing RCTs with reported VTE SAEs and AEs. 
 
 











VTEs in control 
group 
Relative VTE rate 
reduction (95% CI) 
P-value 
NCT01578707 715 0 132.3 2 0 0.024a 
NCT01722487 323 0 209.5 0   
NCT01646021 139 1 72.9 2 0.263 0.22a 
NCT01973387 144.9 0 37.8 0   
Total 1363.6 1 452.5 4 0.071 (0.003-0.584) 0.012b 
Table 5.3: Ibrutinib RCTs with VTEs expressed as drug exposure in person years. 





The same search was performed using the search term “acalabrutinib OR ACP-
196 OR calquence”. This yielded 34 studies but none of these had any results 
reported. As well as Btk inhibitors, Src inhibitors have also been shown to inhibit 
platelet CLEC-2 signalling and adhesion under flow (Navarro-Núñez et al. 
2015). A search was also performed using the search term “dasatinib OR BMS-
254825 OR sprycel” to look for trials that included patients treated with the Src 
inhibitor dasatinib (trade name sprycel). This drug has been in clinical use (for 
treatment of CML and other haematological and solid organ cancers) for much 
longer than Btk inhibitors and so a search yielded 98 interventional studies with 
published results. Only two of these, however, were RCTs where there was a 
non-dasatinib treatment arm. One was a trial of dasatinib vs imatinib in patients 
with CML (NCT0048124, the DASISION trial) (Cortes et al. 2016) and the other 
was a trial of docetaxel and prednisolone plus dasatinib or placebo for patients 
with prostate cancer (NCT0074449, the READY trial) (Araujo et al. 2017). The 
number of VTE events and the lengths of treatment for each study are shown in 
Table 5.4. The number of person years of drug exposure in each trial along with 
number of VTEs and statistical analysis is shown in Table 5.5. Like the results 
with ibrutinib containing RCTs, one trial showed statistically significant reduction 
in the VTE rate in patients treated with dasatinib whereas the other trial  showed 
no significant difference. When the results were combined there was a 
statistically significant reduction in VTE events in patients treated with dasatinib 
when compared to those patients treated with a control chemotherapy. 
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NCT0048124 Cortes et al. CML Imatinib 259 60 2 260 60 1 
NCT0074449 Araujo et al. Prostate Cancer Placebo 762 11.8 8 760 11.7 28 
Table 5.4: Dasatinib containing RCTs with reported VTE SAEs and AEs. 
 
 









VTEs in control 
group 
Relative VTE rate 
reduction (95% CI) 
P-value 
NCT0048124 1295 2 1300 1 1.005 0.623a 
NCT0074449 850.9 8 703 28 0.346 0<0.001a 
Total 2145.9 10 2003 29 0.289 (0.134-0.582) <0.001b 
Table 5.5: Dasatinib RCTs with VTEs expressed as drug exposure in person years. 




5.2.3 Podoplanin is not upregulated in human 
renal vein thrombosis following kidney transplant 
Studies were undertaken to see if podoplanin is upregulated in the 
subendothelial layer in human venous thrombosis, like it is in mice. Ethical 
permission was granted through the Birmingham Human Biomaterials Resource 
Centre (HBRC) to harvest venous thrombosis along with surrounding venous 
wall from patients at post-mortem (PM) and surgery as well as already existing 
tissue in tissue banks. Between March 2016 and July 2018 no material was 
able to be sourced from PM examinations and tissue banks across the United 
Kingdom were searched for samples that contained appropriate material. This 
latter search yielded five paraffin embedded tissue blocks from renal transplants 
which had been excised within only a few days of transplantation because of 
acute renal vein thrombosis. 
The renal vein thrombosis tissue was stained with an antipodoplanin antibody 
and an IgG isotype control and counterstained with haematoxylin. 
Representative slides are shown in Figure 5.3. Podoplanin was seen 
surrounding lymphatic vessels but there was no up-regulation of it seen in the 
vein wall. This implies that podoplanin and CLEC-2 do not play a role in this 





Figure 5.3: Podoplanin is not upregulated in the venous wall surrounding acute 
renal vein thrombosis. 
Tissue blocks from five patients with acute renal transplant vein thrombosis were 
mounted onto slides and stained with anti-podoplanin antibody or isotype control before 
counterstaining with haematoxylin. (A) Kidney parenchyma showing podoplanin 
staining (arrows) on lymphatic endothelial cells surrounding lymphatic vessels (LV). (B) 
Representative slides showing equal with on podoplanin antibody and isotype control. 





The results from this chapter can be summarised thus: 
i) Ibrutinib inhibits CLEC-2 signalling ex vivo in mice and shows a trend 
towards inhibition of in vivo thrombosis but without statistical significance 
ii) Patients taking ibrutinib and dasatinib have reduced rates of VTE. 
iii) Patients with acute renal vein thrombosis following renal transplant do 
not have upregulated podoplanin in the vessel wall surrounding the clot 
 
5.3.1 Ibrutinib inhibits ex vivo CLEC-2 mediated platelet activation 
but not in vivo thrombosis in mice 
As would be expected from the in vitro and the ex vivo human experiments, 
ibrutinib dosed to mice also caused inhibition of CLEC-2 mediated platelet 
function ex vivo. Similar to the in vitro results from mouse platelets, the dose 
required to block signalling downstream of CLEC-2 was slightly higher than for 
GPVI. Indeed, Figure 5.1Ai shows that GPVI was completely blocked after a 
single dose of ibrutinib, whereas it took three daily doses to inhibit CLEC-2. 
This blockade of CLEC-2 mediated platelet function did not translate into a 
statistically significant reduction in thrombus formation in the IVC stenosis 
model although there was a clear trend. The study, however, was 
underpowered as two animals had to be culled and the incidence of thrombosis 
in the controls was lower than anticipated. The experiment was powered to take 
into account the normal rate of thrombosis in uninhibited mice of 60% and an 
expected thrombosis rate of 18% in the ibrutinib treated mice. The results, 
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however, were a 57% and 28% thrombosis rate in the vehicle and ibrutinib 
treated mice respectively. The same results, but with 22 mice in each group 
rather than 7, would have yielded a statistically significant result. It is possible, 
therefore, that the experiment was underpowered because the thrombosis rate 
in the ibrutinib treated mice was 10% higher than expected. 
It could also be because the degree of CLEC-2 inhibition was not adequate to 
inhibit the signalling cascade that results from podoplanin ligation. This assay 
used expression of activated integrin αIIbβ3 and P-selectin as measured by flow 
cytometry as a means of assessing platelet activation. The flow cytometry 
assay showed complete blockade of CLEC-2 and GPVI-mediated platelet 
activation for the duration of the IVC stenosis unlike LTA, which showed delay 
and incomplete blockade of aggregation upon activation of GPVI and delay but 
no reduction in overall aggregation following CLEC-2 ligation. 
Another reason for there being no statistically significant reduction in thrombosis 
rates could be that podoplanin can still recruit platelets to the site of vessel wall 
inflammation even if signalling downstream of CLEC-2 is blocked. It is possible 
that podoplanin-recruited platelets could be activated by other means such as 
ADP present on damaged endothelial cells. The previous in vivo studies looking 
at thrombosis reduction by inhibiting the CLEC-2 axis have only utilised genetic 
CLEC-2 depletion, pharmacological depletion of podoplanin, or antibody 
mediated blockade of the CLEC-2:podoplanin interaction, not inhibition of 
signalling downstream of CLEC-2. What goes against this latter explanation 
however is the results of the flow adhesion assays performed on platelets from 
patients treated with ibrutinib or acalabrutinib, or those with XLA (Figure 4.15). 
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Similar to the results from Pollitt et al. using Syk and Src inhibitors, here 
platelets fail to adhere to podoplanin indicating that activation downstream of 
CLEC-2 is required for this interaction to result in stable adhesion of platelets 
(Pollitt et al. 2014). 
 
5.3.2 Patients taking ibrutinib have reduced rates of VTE 
The fact that patients treated with ibrutinib have lower VTE rates than control 
patients from the same clinical trials is a potential signal that CLEC-2 plays a 
role in at least some forms of human VTE. Given the high doses of ibrutinib 
used in these trials (420-560 mg once daily) the reduction in VTE rates could be 
due to off-target effects of ibrutinib inhibiting signalling downstream of other 
receptors in platelets and immune cells such as GPVI. 
The same reduction in VTE rates was also seen in RCTs comparing dasatinib 
to control treatments. It might be considered surprising that a drug so well 
established as dasatinib only has two RCTs where it is compared to a control 
treatment but, for trials of treatment for cancer, where often patients have 
relapsed and are left with no remaining treatment options, even a single arm 
trial where a small degree of disease response is seen is useful as an indicator 
that the drug can be used. If this is all that is required for a drug to be licensed 
in cancer therapy, it would in fact make very little economic sense for 
pharmaceutical companies to compare their drugs directly with existing 
treatments where their drug might be shown to be inferior.  
This reduction in VTE rates was statistically significant whether a Cox’s 
regression analysis with a stratified cohort approach or a meta-analysis 
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approach was used (not shown). In a stratified analysis it is assumed that the 
coefficient of treatment/control is the same for each study and this is estimated 
from all the data. In a meta-analysis different coefficients are estimated for each 
study and these are then combined to produce a single estimate. 
A potential confounder for both sets of results with ibrutinib and dasatinib is that 
risk of VTE in haematological or solid organ malignancy correlates with the 
burden of disease. Thus patients who are treated with a drug that produces 
deeper and longer remissions are likely to have lower VTE rates. In all of these 
trials, the overall survival (OS) and progression free survival (PFS) of patients 
treated with ibrutinib and dasatinib was longer than control patients (not shown). 
This means that in order to truly know whether patients on these tyrosine kinase 
inhibitors (TKIs) have lower VTE rates an appropriately powered study in 
patients without underlying malignancy is necessary.  
Another potential problem with comparing results across different trials as has 
been done here is that the control groups in each trial are different but for the 
purposes of the analysis they are being treated as if they are the same. But 
when the VTE rates in the treatment and control arms of individual trials are 
compared half of them showed a statistically significant reduction in VTEs in 
patients treated with ibrutinib an dasatinib. The trials that showed a statistically 
significant difference were the ones that were better powered to do so, either by 
having the longest drug exposure times (Montillo et al. 2017), or by studying a 
condition (prostate cancer) with a high rate of VTE (Araujo:2017cb}. The trials 




5.3.3 Patients with acute renal vein thrombosis following renal 
transplant do not have upregulated podoplanin in the vessel wall 
surrounding the clot 
Unlike the observations in mice, the fact that podoplanin was not seen to be 
upregulated in human venous thrombosis tissue was surprising, particularly 
given the reduction in VTE seen in patients taking ibrutinib. The likely 
explanation for this finding was that the pathophysiology of acute renal vein 
thrombosis in a transplanted kidney is mediated through reduced blood flow and 
not through inflammation. Renal vein thrombosis in this setting occurs either 
because of hypovolaemia secondary to inadequate peri-operative fluid 
resuscitation or because of technical problems occurring during surgery such as 
a kinked renal vein, or a stenosis at the point the transplanted renal vein 
anastomoses to the native vasculature (Hogan et al. 2015). 
Ideally a variety of different types of venous thrombosis tissue would have been 
collected and tested for the presence of podoplanin. The aim was to collect 
samples from those that had already been collected for other reasons and 
stored in hospital pathology departments or tissue banks or collect new samples 
from hospital PMs where patients were found to have died from or with VTE. 
There are a number of reasons why these samples proved to be very difficult to 
obtain. First was the paucity of hospital PMs and second was the lack of any 
surgical procedure that is currently performed for treatment of VTE which 
removes both clot and surrounding vessel wall.  
The frequency of hospital PMs is diminishing and thus the incidence of 
219 
discovering a VTE at PM is very low. As a result, despite efforts to the contrary, 
the pathologists had a lack of familiarity with this particular research project and, 
even if they did identify VTE during a PM, this information was not passed onto 
the HBRC. Because of this an additional strategy employed in this project was 
to ask for hospital bereavement office staff to screen death certificates and 
report if a patient was found to have a term relating to VTE written as having 
contributed to or caused death. Patients’ relatives would then be approached 
and consented to carry out a limited PM. Unfortunately, due to staff turnover 
and the pressured workload in the bereavement office, no patients were 
identified through this route. 
There are surgical procedures such as thrombectomy which are performed 
rarely in acute life- or limb threatening venous thrombosis or thrombosis in the 
arteriovenous (AV) fistulae used for intravenous haemodialysis access. The 
latter was not pursued because it was felt that the high shear rates in AV 
fistulae were not representative of VTE. The former was not suitable because 
the retrieved thrombus does not have vein wall along with it. 
It was, therefore, necessary to rely on venous thrombus that had been detected 
incidentally in histological samples. This is how the renal transplant samples 
were sourced. There is, however, a collaborating group at the University of 
Pennsylvania in Philadelphia led by Mark Kahn that has managed to obtain 
DVT and PE with surrounding vein from PMs of two patients. Their preliminary 
results are very exciting as they appear to show podoplanin expressing cells 
infiltrating the venous valve leaflets in the area where there is a DVT, but not on 
the valves where there is no DVT (see Appendix 1, Supplementary Figure.1). 
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In conclusion: there is only indirect or preliminary evidence that CLEC-2 and 
podoplanin play a role in human VTE, with direct evidence only very preliminary 
at the time of writing this thesis. The results from the mouse in vivo thrombosis 
assay do not conclusively show that ibrutinib is effective for targeting CLEC-2 in 
venous thrombosis but there is enough uncertainty about whether this particular 
experiment was underpowered to warrant further work in this area. 
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CHAPTER 6: GENERAL 
DISCUSSION 
 
6.1 Summary of Results 
This study has investigated the effect of Btk inhibitors on platelet function and 
signalling downstream of GPVI, which is correlated with the bleeding side effect 
seen with ibrutinib, and the effect downstream of CLEC-2, which has an 
uncertain role in haemostasis in mouse and no known role in man. It has also 
examined the role that the CLEC-2/podoplanin axis plays in human VTE and 
whether Btk inhibitors may provide a means of targeting CLEC-2 clinically in 
VTE while preserving activation by GPVI and other platelet receptors. 
The headline results of this study are: 
i) Btk inhibitors block GPVI-mediated platelet function reversibly at 
concentrations that are greater than those required to block Tec kinases 
demonstrating that this is an off-target action. 
ii) The kinase function of Btk is not critical for PLCɣ2 activation downstream 
of GPVI in platelets (as judged by abrogation of Btk autophosphorylation 
and complete loss of phosphorylation of PLCɣ2) but it also plays a role 
which is unveiled when the results of ibrutinib-inhibited healthy donor 
platelets are compared with those from ibrutinib-inhibited platelets from 
patients with XLA. 
iii) In direct contrast to the studies downstream of GPVI, the kinase function 
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of Btk (but not Tec) is critical for platelet signalling downstream of CLEC-
2 and this manifests in Btk inhibitors blocking CLEC-2-mediated platelet 
function at 50-fold lower concentrations than those required to block 
GPVI-mediated platelet function at maximal agonist concentrations. This 
difference is due to the feedback role of secondary mediators and actin 
in supporting platelet activation by CLEC-2. 
iv) Btk does not lie upstream of Syk in human and mouse CLEC-2 induced 
signalling, and not upstream as proposed by Manne et al. If this was the 
case, phosphorylation of Btk on the SFK activation site would not be 
altered. 
v) Ibrutinib has off-target effects on an unknown kinase at very low 
concentrations which were unmasked when it was added to platelets 
from patients with XLA. This occurs downstream of both GPVI and 
CLEC-2 but downstream of the former it manifests as loss of the residual 
PLCɣ2 phosphorylation whereas downstream of the latter it manifests as 
loss of Syk and LAT phosphorylation. 
vi) Ibrutinib reduces the incidence of VTE in a meta-analysis of studies 





6.1.1 Patients on Btk inhibitors have platelet dysfunction, mediated 
by an off-target drug effect, which only manifests as bleeding when 
it is combined with the patients’ underlying haematological 
malignancy 
As previously discussed, in the first trials for ibrutinib as a treatment of LPDs, 
patients experienced a major haemorrhage rate of up to 5%. This rate is higher 
than occurs even with patients treated with anticoagulants and resulted in safety 
concerns about the combination of ibrutinib with anticoagulants/antiplatelets and 
the subsequent decision not to co-administer ibrutinib with VKAs. Whether due 
to regression to the mean or due to the contraindication of ibrutinib for patients 
on VKAs, the rate of major haemorrhage for patients on ibrutinib decreased to 
2-4% in the subsequent trials (Wang et al. 2015; Pavlik A et al. 2016; Jones et 
al. 2017). The rate of minor haemorrhage was also high at 28% (Wang et al. 
2015). A systematic review was performed on the four RCTs that compared 
ibrutinib to a control treatment. This concluded that ibrutinib treatment was 
associated with an increased rate of bleeding of any grade, but that the 
increase in major haemorrhage was not statistically significant (albeit there was 
a clear trend). It was acknowledged as part of the review, however, that the 
number of patients was not sufficient to adequately power the study for major 
haemorrhage (Caron et al. 2017). 
The bleeding seen with ibrutinib treatment has been correlated with impaired 
LTA in response to collagen and reduced adhesion to VWF under flow (Levade 
et al. 2014). This, however, is out of keeping with reports of mild bleeding in 
patients who are homozygous for a truncation in GPVI that prevents expression 
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(Matus et al. 2013) and the absence of bleeding in patients who lack Btk and it 
seems likely that the major bleeding seen in patients taking ibrutinib is due to a 
combination of functional impairment of GPVI and GPIb signalling (and other 
receptors e.g. integrin αIIbβ3) and their underlying haematological malignancy. 
This theory is supported by reports that the bleeding seen with ibrutinib occurs 
in the first six months of treatment and then tails off as the disease is brought 
into remission (Jones et al. 2017), that baboons treated with ibrutinib analogues 
do not have an increased bleeding time (Rigg et al. 2016) and mice treated with 
ibrutinib only develop haemostatic defects if they also have deficiency of P2Y12 
(Lee et al. 2017). 
What this study adds to this is to show that it is non-Tec family kinase off-target 
effects of ibrutinib that result in loss of platelet activation by GPVI (and probably 
also by GPIb and integrin αIIbβ3) and that this inhibition is reversible. It also 
shows that the on-target action of ibrutinib to inhibit Btk kinase function, and 
even its additional off-target inhibition of Tec kinase, is not sufficient to block 
GPVI-mediated platelet signalling most likely because Tec kinases can act as 
adapter proteins and support PLCɣ2 activation in the absence of 
phosphorylation. 
 
From this information I conclude that bleeding in patients taking ibrutinib occurs 
because: 
i) The clinical dose is supra-maximal for blockade of Btk and causes GPVI 
inhibition due to off-target effects. 
ii) The fact that patients have an underlying haematological malignancy 
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contributes to the bleeding. 
 
6.1.2 Btk inhibitors block CLEC-2 mediated platelet function at much 
lower concentrations than those that block platelet activation by 
GPVI 
Unlike the effects of Btk inhibitors on GPVI-mediated platelet function, which 
occur at supra-maximal concentrations and are due to reversible, off-target 
effects, they irreversibly abrogate CLEC-2 mediated platelet function at 
concentrations which are 50-fold lower and are due to on-target, specific 
inhibition of Btk kinase activity. Even though it has been shown as part of this 
study that low concentration ibrutinib has an off-target effect on one or more 
other tyrosine kinases, the dependence of CLEC-2 on Btk inhibition is clear 
from the results in XLA patients despite the presence of Tec. Unlike its role 
downstream of GPVI, the adapter function of Btk is not able to activate PLCɣ2 
downstream of CLEC-2 and nor is Tec kinase in platelets able to substitute 
possibly because it is expressed at a lower level or because it cannot function 
as an adapter. One difference between Btk and Tec is that Tec’s 
autophosphorylation site does not lie in a YxxM motif, which binds selectively to 
the SH2 domains of PI3K. It would be interesting to study whether this 
difference prevents it serving as an adapter with PLCɣ2 downstream of CLEC-2.  
These studies have shown that Btk inhibitors can block CLEC-2 function in in 
vitro and ex vivo models of platelet activation. They are not as convincing when 
considering blockade of the podoplanin-CLEC-2 axis in vivo however. Despite 
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adequate blockade of CLEC-2 mediated platelet activation as measured by flow 
cytometry, ibrutinib did not prevent mouse venous thrombosis in vivo to a 
statistically significant degree. It is possible that this is because CLEC-2 ligation 
by podoplanin is sufficient to recruit platelets and lead to thrombosis in the 
absence of platelet activation downstream of CLEC-2, but this is unlikely as the 
results from the ex vivo flow adhesion assay show that the platelets from 
patients taking Btk inhibitors and those with XLA do not adhere to podoplanin in 
venous flow conditions. It is more likely, instead, that this the negative result of 
this experiment was due to it being under powered, or due to inadequate CLEC-
2 blockade and further experiments are required fully answer this question. The 
results from the RCTs of ibrutinib in LPD are encouraging in this regard 
however, as there is a statistically significant reduction in VTE in the patients 
treated with ibrutinib when compared to controls. 
 
6.1.3 Podoplanin induced platelet CLEC-2 activation is involved in 
human VTE 
The methods that I have employed to look for evidence that platelet CLEC-2 
plays a role in human VTE/thromboinflammation were two-fold; firstly I looked 
for indirect evidence using VTE rates from clinical trials using drugs that have 
been shown to block CLEC-2; the second looked directly for podoplanin 
expression in the subendothelium of veins surrounding a thrombus. 
The rates of VTE in trials of ibrutinib and dasatinib treated patients were 
reduced compared to controls. This gives some indirect evidence that CLEC-2 
is involved in human VTE but, of course, this reduction could be due to 
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inhibition of other platelet receptor signalling pathways.  
Direct evidence of podoplanin expression in human VTE was not found as part 
of this study. This was because of the difficulty in obtaining such tissue and also 
because the only tissue that was obtained (i.e. Transplanted kidney) has a fairly 
unique pathophysiology which is not representative of VTE. During the write up 
phase of this project, however, a histological sample of “classic” DVT has been 
obtained by collaborators and this does show evidence of podoplanin 
expression in the diseased but not control valve of the patient (see 
Supplementary Figure.1 in Appendix 1). This is particularly exciting as this also 
indirectly supports the validity of the mouse stenosis model of DVT. 
 
Overall, therefore, I have obtained promising indirect and direct evidence that 
podoplanin and CLEC-2 play a role in human VTE similar to the more 
established role in mouse thromboinflammation. 
 
6.2 Final conclusions 
Given that CLEC-2 is critical in mouse thromboinflammation but not 
haemostasis, that it may have a similar role in human VTE but also not 
haemostasis, and that Btk inhibitors block all aspects of human platelet CLEC-2 
function at a > 10 fold lower concentration than is currently achieved in their 
treatment of LPD, it would seem that Btk inhibitors are an attractive way of 
targeting platelet CLEC-2 in vivo. The bleeding side effect that occurs in 
patients treated with Btk inhibitors could be perceived as a barrier to this, but, 
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for reasons detailed above, bleeding is unlikely if patients without underlying 
haematological malignancy are treated with low doses of Btk inhibitor that lack 
off-target effects. Significantly, I have shown that XLA patients, who have no 
known bleeding phenotype, lack any demonstrable platelet CLEC-2 function. 
Further evidence that supports the view that Btk inhibitors can be used outside 
of the haematological malignancy disease setting without a bleeding side effect 
comes from the fact that the inhibitor PRN-1008 is undergoing phase II trials for 
ITP (Principia Biopharma 2018). Moreover, the Syk inhibitor fostamatinib, which 
has also been shown to block CLEC-2 mediated platelet activation (Spalton et 
al. 2009), has just been licensed as a treatment for ITP (Bussel et al. 2018). If 
there was any hint of extra bleeding due to platelet dysfunction in these, already 
thrombocytopenic, patients then they would be readily apparent. 
 
In order to translate these findings into the clinical use of Btk inhibitors as a 
treatment for or prophylaxis against VTE there are several further studies and 
considerations that are needed. Firstly the mouse IVC stenosis experiment 
needs to be extended with adequate numbers of mice to ensure it is properly 
powered; secondly the finding that podoplanin is in the vessel wall in a single 
patient with VTE needs to be repeated on more patients; thirdly it is important to 
investigate further whether patients with XLA do not have a bleeding phenotype, 
for example by undertaking a bleeding assessment tool (BAT) as published by 
the International Society for Thrombosis and Haemostasis (ISTH) to assess 
their bleeding symptoms (Rodeghiero et al. 2010); fourthly it would be 
interesting to see if there is any evidence of blood lymphatic mixing in patients 
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with XLA as occurs in CLEC-2 deficient mice and can be detected in patients 
using ultrasound based clinical imaging techniques (Seeger et al. 2009) (albeit 
these are due to defects during but not post-development); fifthly ex vivo 
platelet function analysis needs to be studied in healthy volunteers taking very 
low doses of ibrutinib in order to look for effects on platelet CLEC-2, and indeed 
this line of enquiry was considered as part of the above study, but the time-
frame and costs involved in order to perform these experiments as part of a 
clinical research training fellowship were prohibitive. Indeed, in a study that is 
unlikely to have received ethical approval in the UK due to concerns over self-
experimentation, Busygina et al. showed that inhibitory effects on GPIb 
signalling were still detectable in two of the investigators who took daily or 
alternate day doses of 120 mg ibrutinib (i.e. 1/6 of the current daily dose used 
for treating CLL); and sixthly a phase II trial using low dose Btk inhibitors in 
addition to/instead of conventional VTE prophylaxis for patients undergoing 
surgery for high risk of VTE (e.g. for total knee replacement surgery) could 
provide direct evidence of the hypothesis and pave the way for a future phase 
III trial. 
APPENDIX 
Podoplanin is upregulated on the valve leaflets surrounding venous 
thrombosis in human veins in vivo 
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Supplementary Figure.1. Podoplanin is upregulated on venous valve 
surrounding thrombus in human veins in vivo. 
Femoral vein from a patient with deep vein thrombosis (DVT) identified at post mortem 
was sectioned, fixed and stained with the anti-human podoplanin (hPDPN) antibody 
NZ-1. (A) Venous valve with no surrounding DVT stained with hPDPN (red) and 4,6-
diamidino-2-phenylindole (DAPI, blue). Arrows show locations of lymphatic vessels in 
the vein wall. (B). Venous valve with no surrounding DVT stained with hPDPN. (C) 
Venous valve with surrounding DVT stained with hPDPN. Arrows show infiltrating cells 
staining positive for human podoplanin. Vein Lumen (L), Vein Wall (W), Venous Valve 
(Va). Images courtesy of John Welsh (University of Pennsylvania, Philadelphia, PA) 
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